日本臨牀　別冊　血液症候群（第3版）I

出版社： 日本臨牀社
発行日： 2023-09-30
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 血液症候群（第3版）I―その他の血液疾患を含めて―
電子書籍版： 2023-09-30 （第3版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

24,200 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

24,200 円(税込)

購入する

目次

  • 特集　血液症候群（第3版）I
    　　　―その他の血液疾患を含めて―

    序　文

    I．造血幹細胞異常
    　１．再生不良性貧血
    　　（１）テロメア制御遺伝子とその構造
    　　（２）遺伝性骨髄不全症候群
    　　　　１）Fanconi 貧血
    　　　　２）先天性角化不全症
    　　　　３）Shwachman-Diamond 症候群
    　　（３）後天性再生不良性貧血
    　　（４）二次性再生不良性貧血
    　　　　１）薬剤性再生不良性貧血
    　　　　２）肝炎後再生不良性貧血
    　　　　３）再生不良性貧血-発作性夜間ヘモグロビン尿症症候群
    　　（５）再生不良性貧血診療の参照ガイド

    II．赤血球の異常
    　１．貧　血
    　　（１）赤芽球癆
    　　　　１）先天性赤芽球癆(Diamond-Blackfan症候群)
    　　　　２）後天性赤芽球癆
    　　　　　(1)薬剤誘発性赤芽球癆
    　　　　　(2)T細胞大型顆粒リンパ球性白血病に伴う後天性赤芽球癆
    　　　　　(3)胸腺腫を合併する慢性赤芽球癆
    　　　　　(4)ヒトパルボウイルスB19感染による急性赤芽球癆
    　　（２）先天性赤血球異形成貧血
    　　（３）巨赤芽球性貧血
    　　　　１）悪性貧血
    　　　　２）若年性悪性貧血
    　　　　３）Imerslund-Gräsbeck症候群
    　　　　４）チアミン反応性巨赤芽球性貧血症候群
    　　　　５）先天性オロト酸尿症
    　　　　６）ホルムイミノトランスフェラーゼ欠損症
    　　　　７）胃切除後巨赤芽球性貧血
    　　　　８）薬剤起因性巨赤芽球性貧血
    　　　　９） ビタミンB12依存性メチルマロン酸尿症
    　　　　10）ホモシスチン尿症
    　　　　11）葉酸欠乏性巨赤芽球性貧血
    　　　　12）5-メチルテトラヒドロ葉酸ーホモシステインメチル転換酵素欠損症
    　　　　13）ジヒドロ葉酸還元酵素欠損症
    　　　　14）ビタミンC欠乏性巨赤芽球性貧血
    　　　　15）Hunter舌炎
    　　　　16）亜急性連合性脊髄変性症
    　　（４）鉄欠乏性貧血と類似疾患
    　　　　１）鉄欠乏性貧血
    　　　　２）鉄剤不応の鉄欠乏性貧血
    　　　　３）先天性無トランスフェリン血症
    　　　　４）後天性無トランスフェリン血症
    　　　　５）Hayem-Faber症候群（慢性鉄欠乏性貧血）
    　　（５）鉄芽球性貧血
    　　　　１）遺伝性鉄芽球性貧血
    　　　　２）後天性鉄芽球性貧血
    　　　　３）ピリドキシン反応性鉄芽球性貧血
    　　（６）銅欠乏性貧血(Menkes症候群，kinky hair syndrome)
    　　（７）溶血性貧血
    　　　　１）先天性溶血性貧血
    　　　　２）後天性溶血性貧血
    　　（８）その他の貧血
    　　　　１）肝疾患に伴う貧血
    　　　　２）内分泌疾患に伴う貧血
    　　　　３）腎性貧血
    　　　　４）未熟児貧血
    　　　　５）老人性貧血
    　　　　６）薬剤起因性貧血
    　　　　７）放射線による造血障害
    　　　　８）寄生虫や微生物による赤血球損傷
    　　　　９）アルコールによる造血障害
    　２．ヘモグロビン異常
    　　（１）先天性メトヘモグロビン血症
    　　　　１）NADH-シトクロムb5還元酵素異常による遺伝性メトヘモグロビン血症
    　　　　２）ヘモグロビンM 症
    　　（３）後天性メトヘモグロビン血症
    　　（４）スルフヘモグロビン血症
    　　（５）カルボキシヘモグロビン(COHb)血症
    　３．ポルフィリン代謝異常
    　　（１）先天性ポルフィリン代謝異常
    　　　　１）骨髄性ポルフィリン代謝異常
    　　　　２）肝性ポルフィリン代謝異常
    　　（２）後天性ポルフィリン代謝異常
    　　　　１）鉛中毒によるポルフィリン症
    　４．鉄過剰症
    　　（１）ヘモクロマトーシス
    　　（２）二次性ヘモクロマトーシス
    　　（３）新生児鉄過剰症
    　　（４）腎ヘモジデローシス
    　５．二次性赤血球増加症
    　　（１）相対的赤血球増加症
    　　　　１）脱水症
    　　　　２）ストレス多血症
    　　（２）絶対的赤血球増加症
    　　　　１）心疾患に伴う二次性多血症
    　　　　２）腎疾患に伴う赤血球増加症
    　　　　３）Pickwick症候群に伴う赤血球増加症
    　　　　４）エリスロポエチン産生腫瘍
    　　　　５）劣性遺伝性家族性赤血球増加症
    　６．一次性赤血球増加症
    　　（１）ジホスホグリセリン酸ムターゼ異常症

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 造血幹細胞異常

P.8 掲載の参考文献
1) Blackburn EH, Epel ES, Lin J : Human telomere biology : A contributory and interactive factor in aging, disease risks, and protection. Science 350 : 1193-1198, 2015.
PubMed
2) de Lange T : Shelterin-Mediated Telomere Protection. Annu Rev Genet 52 : 223-247, 2018.
PubMed
3) Seimiya H : Crossroads of telomere biology and anticancer drug discovery. Cancer Sci 111 : 3089-3099, 2020.
PubMed
4) Bell RJ, Rube HT, Xavier-Magalhaes A, et al : Understanding TERT Promoter Mutations : A Common Path to Immortality. Mol Cancer Res 14 : 315-323, 2016.
PubMed
5) Revy P, Kannengiesser C, Bertuch AA : Genetics of human telomere biology disorders. Nat Rev Genet 24 : 86-108, 2023.
PubMed
6) Garus A, Autexier C : Dyskerin : an essential pseudouridine synthase with multifaceted roles in ribosome biogenesis, splicing, and telomere maintenance. RNA 27 : 1441-1458, 2021.
PubMed
7) Vulliamy T, Marrone A, Goldman F, et al : The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413 : 432-435, 2001.
PubMed
8) Yamaguchi H, Baerlocher GM, Lansdorp PM, et al : Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 102 : 916-918, 2003.
PubMed
9) Savage SA, Giri N, Baerlocher GM, et al : TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 82 : 501-509, 2008.
PubMed
10) Walne AJ, Vulliamy T, Beswick R, et al : TINF2 mutations result in very short telomeres : analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 112 : 3594-3600, 2008.
PubMed
11) Yamaguchi H, Calado RT, Ly H, et al : Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 352 : 1413-1424, 2005.
PubMed
12) Marrone A, Walne A, Tamary H, et al : Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood 110 : 4198-4205, 2007.
PubMed
13) Du HY, Pumbo E, Ivanovich J, et al : TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood 113 : 309-316, 2009.
PubMed
14) Sharma R, Sahoo SS, Honda M, et al : Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue. Blood 139 : 1039-1051, 2022.
 
15) Townsley DM, Dumitriu B, Liu D, et al : Danazol Treatment for Telomere Diseases. N Engl J Med 374 : 1922-1931, 2016.
PubMed
P.14 掲載の参考文献
1) Fanconi G : Familiare infantile perniziosa-artige anamie pernizioses blutbild und konstitution Jahrb Kinderh 117 : 257-280, 1927.
 
2) Fanconi G : Familial constitutional panmyelocytopathy, Fanconi's anemia (F.A.). I. Clinical aspects. Semin Hematol 4 : 233-240, 1967.
 
3) Schroeder TM, Anschutz F, Knopp A : [Spontaneous chromosome aberrations in familial panmyelopathy]. Humangenetik 1 : 194-196, 1964. [PMID : 5869479]
 
4) Sasaki MS, Tonomura A : A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents. Cancer Res 33 : 1829-1836, 1973.
PubMed
5) 小原明 : 日本における小児再生不良性貧血など造血障害性疾患の現状-日本小児血液学会再生不良性貧血委員会疫学調査 1988～2005年-. 日本小児血液学会雑誌 22 : 53-62, 2008.
Medical*Online
6) Mori M, Hira A, Yoshida K, et al : Pathogenic mutations identified by a multimodality approach in 117 Japanese Fanconi anemia patients. Haematologica 104 : 1962-1973, 2019.
PubMed
7) Kottemann MC, Smogorzewska A : Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 493 : 356-363, 2013.
PubMed
8) Ceccaldi R, Sarangi P, D'Andrea AD : The Fanconi anaemia pathway : new players and new functions. Nat Rev Mol Cell Biol 17 : 337-349, 2016.
PubMed
9) Neveling K, Endt D, Hoehn H, et al : Genotype-phenotype correlations in Fanconi anemia. Mutat Res 668 : 73-91, 2009.
PubMed
10) Malric A, Defachelles AS, Leblanc T, et al : Fanconi anemia and solid malignancies in childhood : A national retrospective study. Pediatr Blood Cancer 62 : 463-70, 2015.
PubMed
11) Langevin F, Crossan GP, Rosado IV, et al : Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 475 : 53-58, 2011.
PubMed
12) Hira A, Yabe H, Yoshida K, et al : Variant ALDH2 is associated with accelerated progression of bone marrow failure in Japanese Fanconi anemia patients. Blood 122 : 3206-3209, 2013.
PubMed
13) 矢部普正, 高田穣, 村松秀城 : Fanconi貧血. 遺伝性骨髄不全症診療ガイドライン 2023 (日本小児血液・がん学会編), p16-28, 診断と治療社, 2023.
 
14) Kutler DI, Singh B, Satagopan J, et al : A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101 : 1249-1256, 2003.
PubMed
15) Yabe H, Inoue H, Matsumoto M, et al : Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia. Br J Haematol 134 : 208-212, 2006.
PubMed
P.20 掲載の参考文献
1) 山口博樹, 小島勢二, 高橋義行, ほか : 先天性角化不全症. 遺伝性骨髄不全症診療ガイドライン 2023 (日本小児血液・がん学会編), P44-52, 診断と治療社, 2023.
 
2) Calado RT, Young NS : Telomere diseases. N Engl J Med 361 : 2353-2365, 2009.
PubMed
3) Walne AJ, Marrone A, Dokal I : Dyskeratosis congenita : a disorder of defective telomere maintenance? Int J Hematol 82 : 184-189, 2005.
PubMed
4) Walne AJ, Dokal I : Advances in the understanding of dyskeratosis congenita. Br J Haematol 145 : 164-172, 2009.
PubMed
5) Yamaguchi H, Sakaguchi H, Yoshida K, et al : Clinical and genetic features of dyskeratosis congenita, cryptic dyskeratosis congenita, and Hoyeraal-Hreidarsson syndrome in Japan. Int J Hematol 102 : 544-552, 2015.
PubMed
6) Niewisch MR, Giri N, McReynolds LJ, et al : Disease progression and clinical outcomes in telomere biology disorders. Blood 139 : 1807-1819, 2022.
PubMed
7) 山口博樹, 檀和夫 : テロメア関連遺伝子異常による骨髄不全症. 臨床血液 51 : 646-653, 2010.
 
8) Nachmani D, Bothmer AH, Grisendi S, et al : Germline NPM1 mutations lead to altered rRNA 2'-O-methylation and cause dyskeratosis congenita. Nat Genet 51 : 1518-1529, 2019.
PubMed
9) Toufektchan E, Lejour V, Durand R, et al : Germline mutation of MDM4, a major p53 regulator, in a familial syndrome of defective telomere maintenance. Sci Adv 6 : eaay3511, 2020.
 
10) Marrone A, Dokal I : Dyskeratosis congenita : molecular insights into telomerase function, ageing and cancer. Expert Rev Mol Med 6 : 1-23, 2004.
PubMed
11) Yamaguchi H, Baerlocher GM, Lansdorp PM, et al : Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 102 : 916-918, 2003.
PubMed
12) Yamaguchi H, Calado RT, Ly H, et al : Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 352 : 1413-1424, 2005.
PubMed
13) Junko T, Ly H, Yamaguchi H, et al : Identification and functional characterization of novel telomerase variant alleles in Japanese patients with bone-marrow failure syndromes. Blood Cells Mol Dis 40 : 185-191, 2008.
PubMed
14) Vulliamy T, Marrone A, Szydlo R, et al : Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 36 : 447-449, 2004.
PubMed
15) Calado RT, Yewdell WT, Wilkerson KL, et al : Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood 114 : 2236-2243, 2009.
PubMed
16) Townsley DM, Dumitriu B, Liu D, et al : Danazol Treatment for Telomere Diseases. N Engl J Med 374 : 1922-1931, 2016.
PubMed
17) Gadalla SM, Sales-Bonfim C, Carreras J, et al : Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant 19 : 1238-1243, 2013.
 
18) Barbaro P, Vedi A : Survival after Hematopoietic Stem Cell Transplant in Patients with Dyskeratosis Congenita : Systematic Review of the Literature. Biol Blood Marrow Transplant 22 : 1152-1158, 2016.
PubMed
19) Fioredda F, Iacobelli S, Korthof ET, et al : Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. Br J Haematol 183 : 110-118, 2018.
PubMed
20) Fogarty PF, Yamaguchi H, Wiestner A, et al : Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 362 : 1628-1630, 2003.
PubMed
P.25 掲載の参考文献
1) Shwachman H, Diamond LK, Oski FA, et al : The syndrome of pancreatic insufficiency and bone marrow dysfunction. J Pediatr 65 : 645-663, 1964.
PubMed
2) Dror Y, Donadieu J, Koglmeier J, et al : Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome. Ann N Y Acad Sci 1242 : 40-55, 2011.
PubMed
3) Boocock GR, Morrison JA, Popovic M, et al : Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet 33 : 97-101, 2003.
PubMed
4) Hashmi SK, Allen C, Klaassen R, et al : Comparative analysis of Shwachman-Diamond syndrome to other inherited bone marrow failure syndromes and genotype-phenotype correlation. Clin Genet 79 : 448-458, 2011.
PubMed
5) Zhang S, Shi M, Hui CC, et al : Loss of the mouse ortholog of the shwachman-diamond syndrome gene (Sbds) results in early embryonic lethality. Mol Cell Biol 26 : 6656-6663, 2006.
 
6) Menne TF, Goyenechea B, Sanchez-Puig N, et al : The Shwachman-Bodian-Diamond syndrome protein mediates translational activation of ribosomes in yeast. Nat Genet 39 : 486-495, 2007.
PubMed
7) Ganapathi KA, Austin KM, Lee CS, et al : The human Shwachman-Diamond syndrome protein, SBDS, associates with ribosomal RNA. Blood 110 : 1458-1465, 2007.
PubMed
8) Kennedy AL, Myers KC, Bowman J, et al : Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun 12 : 1334, 2021.
PubMed
9) Minelli A, Maserati E, Nicolis E, et al : The isochromosome i (7) (q10) carrying c.258+2t>c mutation of the SBDS gene does not promote development of myeloid malignancies in patients with Shwachman syndrome. Leukemia 23 : 708-711, 2009.
 
10) Valli R, Pressato B, Marletta C, et al : Different loss of material in recurrent chromosome 20 interstitial deletions in Shwachman-Diamond syndrome and in myeloid neoplasms. Mol Cytogenet 6 : 56, 2013.
PubMed
11) Watanabe K, Ambekar C, Wang H, et al : SBDS-deficiency results in specific hypersensitivity to Fas stimulation and accumulation of Fas at the plasma membrane. Apoptosis 14 : 77-89, 2009.
PubMed
12) Austin KM, Gupta ML Jr, Coats SA, et al : Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome. J Clin Invest 118 : 1511-1518, 2008.
PubMed
13) Furutani E, Liu S, Galvin A, et al : Hematologic complications with age in Shwachman-Diamond syndrome. Blood Adv 6 : 297-306, 2022.
PubMed
14) Lindsley RC, Saber W, Mar BG, et al : Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376 : 536-547, 2017.
PubMed
15) 遺伝性骨髄不全症診療ガイドライン 2023 (一般社団法人日本小児血液・がん学会編) VII Shwachman-Diamond症候群. 診断と治療社, 2023.
 
P.32 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患政策研究事業, 特発性造血障害に関する調査研究班 : 再生不良性貧血診療の参照ガイド, 令和4年度改訂版, 2023.
 
2) 太田晶子, 島田直樹 : 再生不良性貧血の罹患率の推計-臨床調査個人票の解析-. 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究 平成28年度総括・分担研究報告書, p50-54, 2017.
 
3) Young NS, Calado RT, Scheinberg P : Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108 : 2509-2519, 2006.
PubMed
4) Yoshizato T, Dumitriu B, Hosokawa K, et al : Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med 373 : 35-47, 2015.
PubMed
5) Teramura M, Kimura A, Iwase S, et al : Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults : a multicenter randomized study in Japan. Blood 110 : 1756-1761, 2007.
PubMed
6) Nakao S, Takami A, Takamatsu H, et al : Isolation of a T-cell clone showing HLA-DRB1*0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood 89 : 3691-3699, 1997.
 
7) Risitano AM, Maciejewski JP, Green S, et al : In-vivo dominant immune responses in aplastic anaemia : molecular tracking of putatively pathogenetic T-cell clones by TCR β--CDR3 sequencing. Lancet 364 : 355-364, 2004.
 
8) Katagiri T, Sato-Otsubo A, Kashiwase K, et al : Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 118 : 6601-6609, 2011.
PubMed
9) Hosokawa K, Mizumaki H, Yoroidaka T, et al : HLA class I allele-lacking leukocytes predict rare clonal evolution to MDS/AML in patients with acquired aplastic anemia. Blood 137 : 3576-3580, 2021.
 
10) Locasciulli A, Bacigalupo A, Bruno B, et al : Hepatitis-associated aplastic anaemia : epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party. Br J Haematol 149 : 890-895, 2010.
PubMed
11) Killick SB, Bown N, Cavenagh J, et al : Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172 : 187-207, 2016.
PubMed
12) Seiki Y, Sasaki Y, Hosokawa K, et al : Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome : a reliable marker for a benign subset of bone marrow failure. Haematologica 98 : 901-907, 2013.
PubMed
13) 米村雄士, 松本雅則, 稲田英一, ほか : 科学的根拠に基づいた赤血球製剤の使用ガイドライン (改訂第2版). 日本輸血細胞治療学会誌 64 : 688-699, 2018.
Medical*Online
14) 高見昭良, 松下正, 緒方正男, ほか : 科学的根拠に基づいた血小板製剤の使用ガイドライン : 2019年改訂版. 日本輸血細胞治療学会誌 65 : 544-561, 2019.
Medical*Online
15) Gurion R, Gafter-Gvili A, Paul M, et al : Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica 94 : 712-719, 2009.
PubMed
16) Lee JW, Yoon SS, Shen ZX, et al : Iron chelation therapy with deferasirox in patients with aplastic anemia : a subgroup analysis of 116 patients from the EPIC trial. Blood 116 : 2448-2454, 2010.
PubMed
P.37 掲載の参考文献
1) 再生不良性貧血診療の参照ガイド 令和4年度改訂版, 2023. [http://zoketsushogaihan.umin.jp/file/2022/AA_final20230801.pdf]
 
2) Bronfin ID, Singerman I : Acute aplastic anemia complicating arsphenamine therapy : Report of a case treated for syphilis coincident with tuberculosis. JAMA 98 : 1725-1728, 1932.
 
3) Rheingold JJ, Spurling CL : Chloramphenicol and aplastic anemia. JAMA 149 : 1301-1304, 1952.
 
4) Marsh JC, Ball SE, Cavenagh J, et al : Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 147 : 43-70, 2009.
PubMed
5) Nagao T, Mauer AM : Concordance for drug-induced aplastic anemia in identical twins. N Engl J Med 281 : 7-11, 1969.
PubMed
P.41 掲載の参考文献
1) 再生不良性貧血診療の参照ガイド (令和4年度改訂版) (研究代表者三谷絹子). 厚生労働科学研究費補助金難治性疾患政策研究事業特発性造血障害に関する調査研究. [http://zoketsushogaihan.umin.jp/file/2022/Aplastic_Anemia.pdf]
 
2) Brown KE, Tisdale J, Barrett AJ, et al : Hepatitis-associated aplastic anemia. N Engl J Med 336 : 1059-1064, 1997.
PubMed
3) Locasciulli A, Bacigalupo A, Bruno B, et al : Hepatitis-associated aplastic anaemia : epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party. Br J Haematol 149 : 890-895, 2010.
PubMed
4) Young NS, Issaragrasil S, Chieh CW, et al : Aplastic anaemia in the Orient. Br J Haematol 62 : 1-6, 1986.
PubMed
5) Wang H, Tu M, Fu R, et al : The clinical and immune characteristics of patients with hepatitis-associated aplastic anemia in China. PLoS One 9 : e98142, 2014.
 
6) 小原明 : 日本における小児再生不良性貧血など造血障害性疾患の現状-日本小児血液学会再生不良性貧血委員会疫学調査 1988～2005年-. 日本小児血液学会雑誌 22 : 53-62, 2008.
Medical*Online
7) Bottiger LE, Westerholm B : Aplastic anaemia. 3. Aplastic anaemia and infectious hepatitis. Acta Med Scand 192 : 323-326, 1972.
PubMed
8) Alshaibani A, Dufour C, Risitano A, et al : Hepatitis-Associated Aplastic Anemia. Hematol Oncol Stem Cell Ther 15 : 8-12, 2022.
PubMed
9) Babushok DV, Grignon AL, Li Y, et al : Disrupted lymphocyte homeostasis in hepatitis-associated acquired aplastic anemia is associated with short telomeres. Am J Hematol 91 : 243-247, 2016.
PubMed
10) 工藤寿子, 小島勢二 : 肝炎後再生不良性貧血. 日本小児血液学会雑誌 17 : 557-561, 2003.
 
11) Osugi Y, Yagasaki H, Sako M, et al : Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia. Haematologica 92 : 1687-1690, 2007.
PubMed
12) Townsley DM, Scheinberg P, Winkler T, et al : Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med 376 : 1540-1550, 2017.
PubMed
13) Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al : Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med 386 : 11-23, 2022.
PubMed
14) Mori T, Onishi Y, Ozawa Y, et al : Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia. Int J Hematol 109 : 711-717, 2019.
PubMed
15) DeZern AE, Zahurak M, Symons HJ, et al : Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia. Blood 141 : 3031-3038, 2023.
PubMed
P.46 掲載の参考文献
1) 厚生労働科学研究費補助金 (難治性疾患政策研究事業), 特発性造血障害に関する調査研究班 : 発作性夜間ヘモグロビン尿症診療の参照ガイド, 令和4年度改訂版, 2023.
 
2) Lewis SM, Dacie JV : The aplastic anaemia--paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol 13 : 236-251, 1967.
PubMed
3) Nishimura JI, Kanakura Y, Ware RE, et al : Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 83 : 193-207, 2004.
PubMed
4) Takeda J, Miyata T, Kawagoe K, et al : Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73 : 703-711, 1993.
PubMed
5) Dunn DE, Tanawattanacharoen P, Boccuni P, et al : Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 131 : 401-408, 1999.
PubMed
6) Katagiri T, Kawamoto H, Nakakuki T, et al : Individual hematopoietic stem cells in human bone marrow of patients with aplastic anemia or myelodysplastic syndrome stably give rise to limited cell lineages. Stem Cells 31 : 536-546, 2013.
PubMed
7) Hosokawa K, Sugimori C, Ishiyama K, et al : Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria-type cells specific to patients with bone marrow failure. Ann Hematol 97 : 2289-2297, 2018.
PubMed
8) Borowitz MJ, Craig FE, Digiuseppe JA, et al : Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 78 : 211-230, 2010.
PubMed
9) Hosokawa K, Ishiyama K, Ikemoto T, et al : The clinical significance of PNH-phenotype cells accounting for < 0.01% of total granulocytes detected by the Clinical and Laboratory Standards Institute methods in patients with bone marrow failure. Ann Hematol 100 : 1975-1982, 2021.
 
10) Araten DJ, Nafa K, Pakdeesuwan K, et al : Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A 96 : 5209-5214, 1999.
PubMed
11) Hu R, Mukhina GL, Piantadosi S, et al : PIG-A mutations in normal hematopoiesis. Blood 105 : 3848-3854, 2005.
PubMed
12) Fattizzo B, Ireland R, Dunlop A, et al : Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia. Leukemia 35 : 3223-3231, 2021.
PubMed
13) Sugimori C, Mochizuki K, Qi Z, et al : Origin and fate of blood cells deficient in glycosyl-phosphatidylinositol-anchored protein among patients with bone marrow failure. Br J Haematol 147 : 102-112, 2009.
PubMed
14) Hillmen P, Young NS, Schubert J, et al : The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355 : 1233-1243, 2006.
PubMed
15) Nishimura J, Yamamoto M, Hayashi S, et al : Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370 : 632-639, 2014.
PubMed
16) Kelly RJ, Hill A, Arnold LM, et al : Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria : sustained efficacy and improved survival. Blood 117 : 6786-6792, 2011.
PubMed
P.53 掲載の参考文献
1) 再生不良性貧血診療の参照ガイド 令和4年度改訂版 (再生不良性貧血の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ), 2023年3月. [http://zoketsushogaihan.umin.jp/file/2022/Aplastic_Anemia.pdf]
 
2) Townsley DM, Scheinberg P, Winkler T, et al : Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med 376 : 1540-1550, 2017.
PubMed
3) Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al : Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med 386 : 11-23, 2022.
PubMed
4) Patel BA, Groarke EM, Lotter J, et al : Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag : a phase 2 study. Blood 139 : 34-43, 2022.
PubMed
5) Assi R, Garcia-Manero G, Ravandi F, et al : Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124 : 4192-4201, 2018.
PubMed
6) Hosokawa K, Yamazaki H, Tanabe M, et al : High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag. Leukemia 35 : 906-909, 2021.
PubMed
7) Ise M, Iizuka H, Kamoda Y, et al : Romiplostim is effective for eltrombopag-refractory aplastic anemia : results of a retrospective study. Int J Hematol 112 : 787-794, 2020.
PubMed
8) Kanda Y, Usuki K, Inagaki M, et al : Decision analysis of allogeneic bone marrow transplantation versus immunosuppressive therapy for young adult patients with aplastic anemia. Int J Hematol 117 : 660-668, 2023.
PubMed
9) Huang LF, Li L, Jia JS, et al : Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia : Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation? Transplant Cell Ther 28 : 586.e1-586.e7, 2022.
PubMed
10) Kako S, Nakasone H, Endo H, et al : Clinical course of patients with aplastic anemia or myelodysplastic syndrome associated with persistent neutropenia. Hematol Oncol 30 : 82-88, 2012.
PubMed
11) Scheinberg P, Fischer SH, Li L, et al : Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 109 : 3219-3224, 2007.
PubMed
12) Killick SB, Bown N, Cavenagh J, et al : Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172 : 187-207, 2016.
PubMed
13) Fan X, Desmond R, Winkler T, et al : Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias. Blood Adv 4 : 1700-1710, 2020.
PubMed

II 赤血球の異常

P.60 掲載の参考文献
1) Vlachos A, Ball S, Dahl N, et al : Diagnosing and treating Diamond Blackfan anaemia : results of an international clinical consensus conference. Br J Haematol 142 : 859-876, 2008.
PubMed
2) Da Costa L, Leblanc T, Mohandas N : Diamond-Blackfan anemia. Blood 136 : 1262-1273, 2020.
PubMed
3) 小原明 : 日本における小児再生不良性貧血など造血障害性疾患の現状-日本小児血液学会再生不良性貧血委員会疫学調査 1988～2005年-. 日小血会誌 22 : 53-62, 2008.
 
4) Draptchinskaia N, Gustavsson P, Andersson B, et al : The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet 21 : 169-175, 1999.
PubMed
5) Gazda HT, Sheen MR, Vlachos A, et al : Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet 83 : 769-780, 2008.
PubMed
6) Doherty L, Sheen MR, Vlachos A, et al : Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. Am J Hum Genet 86 : 222-228, 2010.
PubMed
7) Wang R, Yoshida K, Toki T, et al : Loss of function mutations in RPL27 and RPS27 identified by whole-exome sequencing in Diamond-Blackfan anaemia. Br J Haematol 168 : 854-864, 2015.
PubMed
8) Ikeda F, Yoshida K, Toki T, et al : Exome sequencing identified RPS15A as a novel causative gene for Diamond-Blackfan anemia. Haematologica 102 : e93-e96, 2017.
PubMed
9) Ulirsch JC, Verboon JM, Kazerounian S, et al : The Genetic Landscape of Diamond-Blackfan Anemia. Am J Hum Genet 103 : 930-947, 2018.
PubMed
10) Kuramitsu M, Sato-Otsubo A, Morio T, et al : Extensive gene deletions in Japanese patients with Diamond-Blackfan anemia. Blood 119 : 2376-2384, 2012.
PubMed
11) Gripp KW, Curry C, Olney AH, et al : Diamond-Blackfan anemia with mandibulofacial dystostosis is heterogeneous, including the novel DBA genes TSR2 and RPS28. Am J Med Genet A 164A : 2240-2249, 2014.
PubMed
12) Sankaran VG, Ghazvinian R, Do R, et al : Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest 122 : 2439-2443, 2012.
PubMed
13) 伊藤悦朗, 小島勢二, 大賀正一, ほか : Diamond-Blackfan貧血. 遺伝性骨髄不全症診療ガイドライン 2023 (一般社団法人日本小児血液・がん学会編), p4-15, 診断と治療社, 2023.
 
14) Vlachos A, Atsidaftos E, Lababidi ML, et al : L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia : Results from a multicenter pilot phase I/II study from the Diamond-Blackfan Anemia Registry. Pediatr Blood Cancer 67 : e28748, 2020.
PubMed
15) Koyamaishi S, Kamio T, Kobayashi A, et al : Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond-Blackfan anemia. Bone Marrow Transplant 56 : 1013-1020, 2021.
PubMed
P.63 掲載の参考文献
1) 石田文宏 : 後天性赤芽球癆の病態と治療研究の進歩. 臨床血液 61 : 1098-1104,, 2020.
 
2) Sawada K, Hirokawa M, Fujishima N, et al : Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 92 : 1021-1028, 2007.
 
3) Smalling R, Foote M, Molineux G, et al : Drug-induced and antibody-mediated pure red cell aplasia : a review of literature and current knowledge. Biotechnol Annu Rev 10 : 237-250, 2004.
PubMed
4) 赤芽球癆診療の参照ガイド改訂版作成のためのワーキンググループ : 赤芽球癆診療の参照ガイド 令和4年度改訂版 (第7版), 2023年.
 
5) Guo Q, Gao J, Guo H, et al : Immune checkpoint inhibitor-induced pure red cell aplasia : Case series and large-scale pharmacovigilance analysis. Int Immunopharmacol 114 : 109490, 2023.
 
6) 山口優太, 三田和広, 村上賢, ほか : 薬剤中止のみで自然軽快した, フルダラビンによる赤芽球癆の1例. 臨床血液 62 : 209, 2021.
 
P.67 掲載の参考文献
1) Means RT Jr : Pure red cell aplasia. Blood 128 : 2504-2509, 2016.
PubMed
2) Sawada K, Fujishima N, Hirokawa M : Acquired pure red cell aplasia : updated review of treatment. Br J Haematol 142 : 505-514, 2008.
PubMed
3) Nakazawa H, Sakai K, Ohta A, et al : Incidence of acquired pure red cell aplasia : a nationwide epidemiologic analysis with 2 registry databases in Japan. Blood Adv 6 : 6282-6290, 2022.
PubMed
4) Kwong YL, Au WY, Leung AY, et al : T-cell large granular lymphocyte leukemia : an Asian perspective. Ann Hematol 89 : 331-339, 2010.
 
5) Oshimi K : Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias. Intern Med 56 : 1759-1769, 2017.
PubMed
6) Handgretinger R, Geiselhart A, Moris A, et al : Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med 340 : 278-284, 1999.
PubMed
7) Masuda M, Teramura M, Matsuda A, et al : Clonal T cells of pure red-cell aplasia. Am J Hematol 79 : 332-333, 2005.
PubMed
8) Ishida F, Matsuda K, Sekiguchi N, et al : STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci 105 : 342-346, 2014.
PubMed
9) Kawakami T, Sekiguchi N, Kobayashi J, et al : Frequent STAT3 mutations in CD8+ T cells from patients with pure red cell aplasia. Blood Adv 2 : 2704-2712, 2018.
PubMed
10) Andersson EI, Tanahashi T, Sekiguchi N, et al : High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood 128 : 2465-2468, 2016.
PubMed
11) Yamane T, Kawakami T, Sekiguchi N, et al : High frequency of STAT3 gene mutations in T-cell receptor (TCR) γδ-type T-cell large granular lymphocytic leukaemia : implications for molecular diagnostics. Br J Haematol 190 : e301-e304, 2020.
 
12) Bareau B, Rey J, Hamidou M, et al : Analysis of a French cohort of patients with large granular lymphocyte leukemia : a report on 229 cases. Haematologica 95 : 1534-1541, 2010.
PubMed
13) Chan WC FK, Morice WG, Matutes E : T-cell large granular lymphocytic leukaemia. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, revised ed (ed by Swerdlow SH, Campo E, Harris NL, et al), International Agency for Research on Cancer, p348-350, 2017.
 
14) Fujishima N, Sawada K, Hirokawa M, et al : Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia : a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 93 : 1555-1559, 2008.
 
15) Hirokawa M, Sawada K, Fujishima N, et al : Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia : a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 93 : 27-33, 2008.
 
16) Hirokawa M, Fukuda T, Ohashi K, et al : Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant 19 : 1026-1032, 2013.
 
17) 厚生労働省 : 「輸血療法の実施に関する指針」及び「血液製剤の使用指針」の一部改正について 2023. [Available from : https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000065580.html.]
 
18) Balasubramanian SK, Sadaps M, Thota S, et al : Rational management approach to pure red cell aplasia. Haematologica 103 : 221-230, 2018.
PubMed
19) Gurnari C, Maciejewski JP : How I manage acquired pure red cell aplasia in adults. Blood 137 : 2001-2009, 2021.
 
20) Halkes C, de Wreede LC, Knol C, et al : Allogeneic stem cell transplantation for acquired pure red cell aplasia. Am J Hematol 94 : E294-E296, 2019.
PubMed
21) Hirokawa M, Sawada K, Fujishima N, et al : Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy : a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol 169 : 879-886, 2015.
 
22) Clark DA, Dessypris EN, Krantz SB : Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood 63 : 277-286, 1984.
PubMed
23) 廣川誠, 藤島直仁, 澤田賢一, ほか : 赤芽球癆診療の参照ガイド 令和1年改訂版 (第6版). 2020.
 
24) 石田文宏, 中澤英之, 張替秀郎, ほか : 赤芽球癆診療の参照ガイド 令和4年改訂版 (第7版) 2023. [Available from : http://zoketsushogaihan.umin.jp/resources.html.]
 
P.72 掲載の参考文献
1) Means RT Jr : Pure red cell aplasia. Blood 128 : 2504-2509, 2016.
PubMed
2) 厚生労働省科学研究費補助金難治性疾患政策研究事業特発性造血障害に関する調査研究班. 赤芽球癆診療の参照ガイド 令和4年度改訂版 (第7版) (研究代表者三谷絹子), 2023. [http://zoketsushogaihan.umin.jp/file/2022/Erythroblastic_locomotor_ataxia.pdf]
 
3) 藤島直仁 : 赤芽球癆の診断と治療. 臨床血液 62 : 931-937, 2021.
 
4) Nakazawa H, Sakai K, Ohta A, et al : Incidence of acquired pure red cell aplasia : a nationwide epidemiologic analysis with 2 registry databases in Japan. Blood Adv 6 : 6282-6290, 2022.
PubMed
5) Yen CC, Huang WL, Li SS, et al : Pure Red Cell Aplasia and Other Haematological Diseases Associated With Thymoma : A Case Series and Systematic Review. Front Med (Lausanne) 8 : 759914, 2021.
PubMed
6) Gurnari C, Maciejewski JP : How I manage acquired pure red cell aplasia in adults. Blood 137 : 2001-2009, 2021.
 
7) Sawada K, Hirokawa M, Fujishima N, et al : Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 92 : 1021-1028, 2007.
 
8) Fujishima N, Hirokawa M, Fujishima M, et al : Oligoclonal T cell expansion in blood but not in the thymus from a patient with thymoma-associated pure red cell aplasia. Haematologica 91 (12 Suppl) : ECR47, 2006.
 
9) Michishita Y, Hirokawa M, Fujishima N, et al : CDR3-independent expansion of Vδ1 T lymphocytes in acquired chronic pure red cell aplasia. Immunol Lett 150 : 23-29, 2013.
 
10) Handgretinger R, Geiselhart A, Moris A, et al : Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med 340 : 278-284, 1999.
PubMed
11) Hirokawa M, Sawada K, Fujishima N, et al : Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia : a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 93 : 27-33, 2008.
 
12) Fujishima N, Kohmaru J, Koyota S, et al : Clonal hematopoiesis in adult pure red cell aplasia. Sci Rep 11 : 2253, 2021.
PubMed
13) Kawakami T, Sekiguchi N, Kobayashi J, et al : Frequent STAT3 mutations in CD8+ T cells from patients with pure red cell aplasia. Blood Adv 2 : 2704-2712, 2018.
PubMed
14) Hirokawa M, Sawada K, Fujishima N, et al : Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy : a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol 169 : 879-886, 2015.
 
15) Chen Z, Liu X, Chen M, et al : Successful sirolimus treatment of patients with pure red cell aplasia complicated with renal insufficiency. Ann Hematol 99 : 737-741, 2020.
PubMed
16) Yang Y, Tang Z, Huang Y, et al : Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia : a prospective cohort study. Blood Cancer J 13 : 74, 2023.
 
P.75 掲載の参考文献
1) 赤芽球癆診療の参照ガイド改訂版作成のためのワーキンググループ : 赤芽球癆診療の参照ガイド 令和4年度改訂版. 2023. [http://zoketsushogaihan.umin.jp/file/2022/pure_red_cell_aplasia.pdf]
 
2) Saarinen UM, Chorba TL, Tattersall P, et al : Human parvovirus B19-induced epidemic acute red cell aplasia in patients with hereditary hemolytic anemia. Blood 67 : 1411-1417, 1986.
PubMed
3) Koduri PR : Parvovirus B19-related anemia in HIV-infected patients. AIDS Patient Care STDS 14 : 7-11, 2000.
PubMed
4) Eid AJ, Ardura MI, et al : Human parvovirus B19 in solid organ transplantation : Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant 33 : e13535, 2019.
PubMed
5) Young NS, Brown KE : Parvovirus B19. N Engl J Med 350 : 586-597, 2004.
PubMed
6) 松倉晴道 : 本邦におけるヒトパルボウイルスB19の輸血副作用発生状況と安全対策. 日本輸血細胞治療学会誌 60 : 561-564, 2014.
Medical*Online
7) Cossart YE, Field AM, Cant B, et al : Parvovirus-like particles in human sera. Lancet 1 : 72-73, 1975.
PubMed
8) Brown KE, Anderson SM, Young NS : Erythrocyte P antigen : cellular receptor for B19 parvovirus. Science 262 : 114-117, 1993.
PubMed
9) Mortimer PP, Humphries RK, Moore JG, et al : A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature 302 : 426-429, 1983.
PubMed
10) Brown KE, Hibbs JR, Gallinella G, et al : Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 330 : 1192-1196, 1994.
PubMed
11) Anderson MJ, Higgins PG, Davis LR, et al : Experimental parvoviral infection in humans. J Infect Dis 152 : 257-265, 1985.
PubMed
12) 根上利宏, 太田正之, 奥田洽爾, ほか : 鉄欠乏性貧血患者に発症したparvovirus B19感染症による急性赤芽球癆の1例. 臨床血液 35 : 670-675, 1994.
 
13) Frickhofen N, Chen ZJ, Young NS, et al : Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 87 : 818-824, 1994.
PubMed
14) 牧野茂義, 福田隆浩, 上田章 : 健康成人に発症したヒトパルボウイルスB19の持続感染による赤芽球癆の1例. 日本内科学会誌 90 : 323-325, 2001.
 
15) Crabol Y, Terrier B, Rozenberg F, et al : Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection : a retrospective study of 10 patients and review of the literature. Clin Infect Dis 56 : 968-977, 2013.
PubMed
P.81 掲載の参考文献
1) Crookston JH, Godwin TF, Wightman KJR, et al : Congenital Dyserythropoietic Anemia. Abstracts from XIth Congress of the International Society of Haematology. pp18, Sydney, 1966.
 
2) Roy NBA, Babbs C : The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I. Br J Haematol 185 : 436-449, 2019.
PubMed
3) Iolascon A, Esposito MR, Russo R : Clinical aspects and pathogenesis of congenital dyserythropoietic anemias : from morphology to molecular approach. Haematologica 97 : 1786-1794, 2012.
PubMed
4) Iolascon A, Andolfo I, Russo R : Congenital dyserythropoietic anemias. Blood 136 : 1274-1283, 2020.
PubMed
5) 多賀崇, 伊藤剛, 浅見恵子, ほか : Congenital Dyserythropoietic Anemia の全国調査. 日本小児血液学会雑誌 22 : 233-238, 2008.
Medical*Online
6) Hamada M, Doisaki S, Okuno Y, et al : Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia. Int J Hematol 108 : 306-311, 2018.
PubMed
7) Arnaud L, Saison C, Helias V, et al : A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet 87 : 721-727, 2010.
PubMed
8) Russo R, Andolfo I, Manna F, et al : Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias. Am J Hematol 93 : 672-682, 2018.
PubMed
9) Muramatsu H, Okuno Y, Yoshida K, et al : Clinical utility of next-generation sequencing for inherited bone marrow failure syndromes. Genet Med 19 : 796-802, 2017.
 
10) Rangarajan HG, Stanek JR, Abdel-Azim H, et al : Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia : A Report from the Pediatric Transplant and Cellular Therapy Consortium. Transplant Cell Ther 28 : 329.e1-329.e9, 2022.
 
11) Fattizzo B, Motta I : Rise of the planet of rare anemias : An update on emerging treatment strategies. Front Med (Lausanne) 9 : 1097426, 2022.
PubMed
12) Dessy-Rodriguez M, Fananas-Baquero S, Venturi V, et al : Lentiviral Gene Therapy for the Correction of Congenital Dyserythropoietic Anemia Type II. Blood 138 (Suppl 1) : 1994, 2021.
 
P.84 掲載の参考文献
1) Esposito G, Dottori L, Pivetta G, et al : Pernicious anemia ; The hematological presentation of a multifaceted disorder caused by cobalamin deficiency. Nutrients 14 : 1672, 2022.
PubMed
2) Toh BH, van Driel IR, Gleeson PA : Pernicious anemia. N Engl J Med 337 : 1441-1448, 1997.
PubMed
3) Carmel R, Agrawal YP : Failures of cobalamin assays in pernicious anemia. N Engl J Med 367 : 385-386, 2012.
PubMed
4) 宍戸努, 廣島由紀, 植松望武, ほか : 血清ビタミンB12が正常値を呈しmecobalamin投与によって改善した悪性貧血. 臨床血液 59 : 675-681, 2018.
 
5) Hershko C, Camaschella C : How I treat unexplained refractory iron deficiency anemia. Blood 123 : 326-333, 2014.
 
6) Green R, Kuhl W, Jacobson R, et al : Masking of macrocytosis by alpha-thalassemia in black with pernicious anemia. N Engl J Med 307 : 1322-1325, 1982.
PubMed
7) Wang H, Li L, Qin LL, et al : Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev 3 : CD004655, 2018.
 
8) Vannella L, Lahner E, Osborn J, et al : Systematic review : gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther 37 : 375-382, 2013.
PubMed
P.87 掲載の参考文献
1) Watkins D, Rosenblatt DS : Inborn Errors of Cobalamin Absorption and Metabolism. Am J Med Genet C Semin Med Genet 157 : 33-44, 2011.
 
2) McIntyre OR, Sullivan LW, Jeffries GH, et al : Pernicious anemia in childhood. N Engl J Med 272 : 981-986, 1965.
 
3) Tanner SM, Sturm AC, Baack EC, et al : Inherited cobalamin malabsorption. Mutations in three genes reveal functional and ethnic patterns. Orphanet J Rare Dis 7 : 56, 2012.
PubMed
4) Ruan J, Han B, Zhuang J, et al : Hereditary intrinsic factor deficiency in China caused by a novel mutation in the intrinsic factor gene-a case report. BMC Med Genet 21 : 221, 2020.
 
5) Gordon MM, Brada N, Remacha A, et al : A Genetic Polymorphism in the Coding Region of the Gastric Intrinsic Factor Gene (GIF) Is Associated With Congenital Intrinsic Factor Deficiency. Hum Mutat Mutation 23 : 85-91, 2004.
PubMed
6) Tanner SM, Li Z, Perko JD, et al : Hereditary juvenile cobalamin deficiency caused by mutations in the intrinsic factor gene. Proc Natl Acad Sci USA 102 : 4130-4133, 2005.
PubMed
7) Katz M, Lee SK, Cooper BA : Vitamin B12 malabsorption due to a biologically inert intrinsic factor. N Engl J Med 287 : 425-429, 1972.
PubMed
8) Katz M, Mehlman CS, Allen RH : Isolation and characterization of an abnormal human intrinsic factor. J Clin Invest 53 : 1274-1283, 1974.
PubMed
9) Lambert HP, Prankerd TA, Smellie JM : Pernicious anemia in childhood. A report of two cases in one family and their relationship to the etiology of pernicious anemia. Q J Med 30 : 71-90, 1961.
 
10) Chanarin I, James D : Humoral and cell-mediated intrinsic-factor antibody in pernicious anemia. Lancet 303 : 1078-1080, 1974.
 
11) Parry TE : The diagnosis of megaloblastic anaemia. Clin Lab Haematol 2 : 89-109, 1980.
PubMed
12) Bolaman Z, Kadikoylu G, Yukselen V, et al : Oral versus intramuscular cobalamin treatment in megaloblastic anemia : a single-center, prospective, randomized, open-label study. Clin Ther 25 : 3124-3134, 2003.
PubMed
P.89 掲載の参考文献
1) Imersland O : Idiopathic chronic megaloblastic anemia in children. Acta Paediatr Suppl (Upps) 49 (Suppl 119) : 1-115, 1960.
 
2) Grasbeck R, Gordin R, Kantero I, et al : Selective vitamin B12 malabsorption and proteinuria in young people. A syndrome. Acta Med Scand 167 : 289-296, 1960.
PubMed
3) Grasbeck R : Imerslund-Grasbeck syndrome (selective vitamin B12 malabsorption with proteinuria). Orphanet J Rare Dis 1 : 17, 2006.
PubMed
4) Tanner SM, Li Z, Bisson R, et al : Genetically heterogenous selective intestinal malabsorption of vitamin B12 : Founder effects, consanguinity, and high clinical awareness explain aggregations in Scandinavia and the Mddle East. Hum Mutat 23 : 327-333, 2004.
PubMed
5) Beech CM, Liyanarachchi S, Shah NP, et al : Ancient founder mutation is responsible for Imerslund-Grasbeck Syndrome among diverse ethnicities. Orphanet J Rare Dis 6 : 74, 2011.
PubMed
6) Namour F, Dobrovoljski G, Chery C, et al : Luminal expression of cubilin is impaired in Imerslund-Grasbeck syndrome with compound AMN mutations in intron 3 and exon 7. Haematologica 96 : 1715-1719, 2011.
PubMed
7) Elshinawy M, Gao HH, AI-Nabhani DM, et al : Clinical and Molecular characteristics of Imerslund-Grasbeck syndrome : First report of Novel Frameshift variant Exon 11 of AMN gene. Int J Lab Hematol 43 : 1009-1015, 2021.
 
8) Grasbeck R, Kvist G : Congenital specific vitamin B 12 malabsorption syndrome with proteinuria. Munch Med Wochenschr 109 : 1936-1944, 1967.
PubMed
9) Bor MV, Cetin M, Aytac S, et al : Nonradioactive vitamin B12 absorption test evaluated in controls and in patients with inherited malabsorption of vitamin B12. Clin Chem 51 : 2151-2155, 2005.
PubMed
10) Gangarossa S, Romano V, Schiliro G : Efficacy of oral administration of high-dose cobamamide in a patient with Imerslund-Grasbeck syndrome. Pediatr Hematol Oncol 13 : 387-389, 1996.
 
11) Boina Abdallah A, Ogier de Baulny H, Kozyraki R, et al : How can cobalamin injections be spaced in long-term therapy for inborn errors of vitamin B (12) absorption? Mol Genet Metab 107 : 66-71, 2012.
PubMed
P.94 掲載の参考文献
1) Labay V, Raz T, Baron D, et al : Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet 22 : 300-304, 1999.
PubMed
2) Porter FS, Rogers LE, Sidbury JB Jr : Thiamine-responsive megaloblastic anemia. J Pediatr 74 : 494-504, 1969.
PubMed
3) Fleming JC, Tartaglini E, Steinkamp MP, et al : The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nat Genet 22 : 305-308, 1999.
PubMed
4) Diaz GA, Banikazemi M, Oishi K, et al : Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nat Genet 22 : 309-312, 1999.
 
5) Dutta B, Huang W, Molero M, et al : Cloning of the human thiamine transporter, a member of the folate transporter family. J Biol Chem 274 : 31925-31929, 1999.
PubMed
6) Zhang S, Qiao Y, Wang Z, et al : Identification of novel compound heterozygous variants in SLC19A2 and the genotype-phenotype associations in thiamine-responsive megaloblastic anemia. Clin Chim Acta 516 : 157-168, 2021.
 
7) Reidling JC, Lambrecht N, Kassir M, et al : Impaired intestinal vitamin B1 (thiamin) uptake in thiamin transporter-2-deficient mice. Gastroenterology 138 : 1802-1809, 2010.
PubMed
8) Ozand PT, Gascon GG, Al Essa M, et al : Biotin-responsive basal ganglia disease : a novel entity. Brain 121 (Pt 7) : 1267-1279, 1998.
 
9) Boros LG, Steinkamp MP, Fleming JC, et al : Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood 102 : 3556-3561, 2003.
PubMed
10) Bergmann AK, Sahai I, Falcone JF, et al : Thiamine-responsive megaloblastic anemia : identification of novel compound heterozygotes and mutation update. J Pediatr 155 : 888-892.e1, 2009.
 
11) Akin L, Kurtoglu S, Kendirci M, et al : Does early treatment prevent deafness in thiamine-responsive megaloblastic anaemia syndrome? J Clin Res Pediatr Endocrinol 3 : 36-39, 2011.
PubMed
12) Warncke K, Prinz N, Iotova V, et al : Thiamine-Responsive Megaloblastic Anemia-Related Diabetes : Long-Term Clinical Outcomes in 23 Pediatric Patients From the DPV and SWEET Registries. Can J Diabetes 45 : 539-545, 2021.
PubMed
P.98 掲載の参考文献
1) AI Absi HS, Sacharow S, AI Zein N, et al : Hereditary orotic aciduria (HOA) : A novel uridine-5-monophosphate synthase (UMPS) mutation. Mol Genet Metab Rep 26 : 100703, 2021.
 
2) Huguley CM Jr, Bain JA, Rivers SL, et al : Refractory megaloblastic anemia associated with excretion of orotic acid. Blood 14 : 615-634, 1959.
PubMed
3) Sumi S, Suchi M, Kidouchi K, et al : Pyrimidine metabolism in hereditary orotic aciduria. J Inherit, Metab Dis 20 : 104-105, 1997.
PubMed
4) Imaeda M, Sumi S, Imaeda H, et al : Hereditary orotic aciduria heterozygotes accompanied with neurological symptoms. Tohoku J Exp Med 185 : 67-70, 1998.
PubMed
5) Salerno C, Crifo C : Diagnostic value of urinary orotic acid levels : applicable separation methods. J Chromatogr B Analyt Technol Biomed Life Sci 781 : 57-71, 2002.
PubMed
6) Suchi M, Mizuno H, Kawai Y, et al : Molecular Cloning of the Human UMP synthase Gene and Characterization of point Mutations in two Hereditary Orotic Aciduria Families. Am J Hum Genet 60 : 525-539, 1997.
PubMed
7) Brosnan ME, Brosnan JT : Orotic acid excretion and arginine metabolism. J Nutr 137 (6 Suppl 2) : 1656S-1661S, 2007.
 
8) Becroft DMO, Phillips LI : Hereditary Orotic Aciduria and Megaloblastic Anaemia : A Second Case, with Response to Uridine. Br Med J 1 : 547-552, 1965.
 
9) Grohmann K, Lauffer H, Lauenstein P, et al : Hereditary orotic aciduria with epilepsy and without megaloblastic anemia. Neuropediatrics 46 : 123-125, 2015.
PubMed
10) Ohba Y, Takasu M, Nishii N, et al : Japanese black cattle with orotic aciduria detected by gaschromatography/mass-spectrometry. J Vet Med Sci 69 : 313-316, 2007.
 
11) Staretz-Chacham O, Damseh NS, Daas S, et al : Hereditary orotic aciduria identified by newborn screening. Front Genet 14 : 1135267, 2023.
PubMed
12) Weinberg ME, Roman MC, Jacob P, et al : Enhanced uridine bioavailability following administration of a triacetyluridine-rich nutritional supplement. PLoS One 6 : e14709, 2011.
PubMed
P.101 掲載の参考文献
1) Arakawa T, Ohara K, Takahashi Y, et al : Formiminotransferase-deficiency syndrome : a new inborn error of folic acid metabolism. Ann Pediatr 205 : 1-11, 1965.
 
2) Arakawa T, Tamura T, Ohara K, et al : Familial occurrence of formiminotransferase deficiency of syndrome. Tohoku J Exp Med 96 : 211-217, 1968.
PubMed
3) Arakawa T, Ohara K, Kudo Z, et al : "Hyperfolic-acidemia with formiminoglutamic-aciduria following histidine loading". Suggfsted for a case of congenital deficiency in formiminotransferase. Tohoku J Exp Med 80 : 370-382, 1963.
PubMed
4) Majumdar R, Yori A, Rush PW, et al : Allelic spectrum of formiminotransferase-cyclodeaminase gene variants in individuals with formiminoglutamic aciduria. Mo Gene Genomic Med 5 : 795-799, 2017.
 
5) Rowe PB : Inherited disorders of folate metabolism. In : The Metabolic Basis of Inherited Disease. (ed by Stanbury JB, Wyngaarden JB, Fredrickson DS, et al), p498, McGraw-Hill, New York, 1983.
 
6) Hilton JF, Christensen KE, Watkins D, et al : The molecular basis of glutamate formiminotransferase deficiency. Hum Mutat 22 : 67-73, 2003.
PubMed
7) Solans A, Estivill X, de la Luna S : Cloning and characterization of human FTCD on 21q22.3, a candidate gene for glutamate formiminotransferase deficiency. Cytogenet Cell Genet 88 : 43-49, 2000.
PubMed
8) Perry TL, Applegarth DA, Evans ME, et al : Metabolic studies of a family with massive formiminoglutamic aciduria. Pediatr Res 9 : 117-122, 1975.
PubMed
9) Rosenblatt DS, et al : Inherited disorders of folate transport and metabolism. In : The Metabolic and Molecular Bases of Inherited Disease, 7th ed (ed by Sciver CR, et al), p3111-3128, McGraw-Hill, New York, 1995.
 
10) Russell A, Statter M, Abzug-Horowitz S : Methionine dependent glutamic acid formiminotransferase deficiency : human and experimental studies in its therapy. Monogr Hum Genet 9 : 65-74, 1978.
PubMed
11) Duran M, Ketting D, de Bree PK, et al : A case of formiminoglutamic aciduria. Clinical and biochemical studies. Eur J Pediatr 136 : 319-323, 1981.
PubMed
P.106 掲載の参考文献
1) 松田晃 : 巨赤芽球性貧血, 日本内科学会雑誌 95 : 2010-2015, 2006.
 
2) 寺島雅史 : 胃全摘後長期生存患者の栄養評価, 日本消化器外科学会雑誌 27 : 1737-1746, 1994.
 
3) Omine M : Megaloblastic anemia-questions left unanswered in the 20th century. Int J Hematology (Suppl 1) : 8, 2000. (video)
 
4) 友田正信 : 胃全摘出後の物質代謝 XIV. 胃全摘後の貧血. 日本外科全書 19 巻, p313-320, 金原出版, 南江堂, 1957.
 
5) Beyan C, Beyan E, Kaptan K, et al : Post-gastrectomy anemia : evaluation of 72 cases with post-gastrectomy anemia. Hematology 12 : 81-84, 2007.
PubMed
6) Heinrich HC : Metabolic Basis of the Diagnosis and Therapy of Vitamin B12 Deficiency, Semin Hematol 1 : 199-249, 1964.
PubMed
7) Jun JH, Yoo JE, Lee JA, et al : Anemia after gastrectomy in long-term survivors of gastric cancer : A retrospective cohort study, Int J Surg 28 : 162-168, 2016.
PubMed
8) Hu Y, Kim HI, Hyung WJ, et al : Vitamin B (12) deficiency after gastrectomy for gastric cancer : an analysis of clinical patterns and risk factors. Ann Surg 258 : 970-975, 2013.
PubMed
9) 大口純人, 井上文央, 丹羽秀夫, ほか : 口腔内異常を伴う胃全摘術後の巨赤芽球性貧血, 日大口腔科学 44 : 165-169, 2018.
Medical*Online
10) Butler CC, Vidal-Alaball J, Cannings-John R, et al : Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency : a systematic review of randomized controlled trials. Fam Pract 23 : 279-285, 2006.
PubMed
P.110 掲載の参考文献
1) Green R, Datta Mitra A : Folate, Cobalamin, and Megaloblastic Anemias. In : Williams' Hematology, 10th ed (ed by Kaushansky K, Lichtman MA, Prchal JT, et al), p639-672, McGraw-Hill, New York, 2021.
 
2) Carmel R : Megaloblastic Anemias : Disorders of Impaired DNA Synthesis. In : Wintrobe's Clinical Hematology, 14th ed (ed by Geer JP, Rodger GM, Glader B, et al), p927-958, Wolters Kluwer, Philadelphia, 2019.
 
3) Scott JM, Weir DG : Drug-induced megaloblastic change. Clin Haematol 9 : 587-606, 1980.
PubMed
4) Hesdorffer CS, Longo DL : Drug-Induced Megaloblastic Anemia. N Engl J Med 373 : 1649-1658, 2015.
PubMed
5) 小峰光博 : DNA合成障害による貧血. 三輪血液病学 第3版 (浅野茂隆, 池田康夫, 内山卓編), p974-1000, 文光堂, 2006.
 
6) Shander A, Javidroozi M, Ashton ME : Drug-induced anemia and other red cell disorders : a guide in the age of polypharmacy. Curr Clin Pharmacol 6 : 295-303, 2011.
PubMed
7) 金丸昭久 : 副作用各論重大な副作用血液巨赤芽球性貧血. 日本臨牀 65 (増刊 8 : 医薬品副作用学) : 482-486, 2007.
 
8) Bellou A, Aimone-Gastin I, De Korwin JD, et al : Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy. J Intern Med 240 : 161-164, 1996.
PubMed
9) Ruscin JM, Page RL 2nd, Valuck RJ : Vitamin B12 deficiency associated with histamine 2-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 36 : 812-816, 2002.
 
10) Vogelzang NJ, Rusthoven JJ, Symanowski J, et al : Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 : 2636-2644, 2003.
PubMed
11) Hoffbrand AV, Necheles TF : Mechanism of folate deficiency in patients receiving phenytoin. Lancet 2 : 528-530, 1968.
PubMed
12) Kelly D, Weir D, Reed B, et al : Effect of anticonvulsant drugs on the rate of folate catabolism in mice. J Clin Invest 64 : 1089-1096, 1979.
PubMed
13) Reid C, Chanarin I : Effect of phenytoin on DNA synthesis by human bone marrow. Scand J Haematol 20 : 237-240, 1978.
PubMed
14) Halsted CH, Gandhi G, Tamura T : Sulfasalazine inhibits the absorption of folates in ulcerative colitis. N Engl J Med 305 : 1513-1517, 1981.
PubMed
15) Dali-Youcef N, Andres E : An update on cobalamin deficiency in adults. QJM 102 : 17-28, 2009.
PubMed
P.112 掲載の参考文献
1) 厚生労働科学研究費補助金子ども家庭総合研究事業 : タンデムマス等の新技術を導入した新しい新生児マススクリーニング体制の確立に関する研究 平成23年度報告書 (主任研究者山口清次), 2012.
 
2) Wiedemann A, Oussalah A, Lamireau N, et al : Clinical, phenotypic and genetic landscape of case reports with genetically proven inherited disorders of vitamin B (12) metabolism : A meta-analysis. Cell Rep Med 3 : 100670, 2022.
PubMed
P.118 掲載の参考文献
1) 楢崎秀彦, 浅野健 : ホモシスチン尿症. 別冊日本臨牀血液症候群 (第2版) p102-106, 日本臨牀社, 2013.
 
2) 長尾雅悦 : 指定難病最前線 (Volume 132) ホモシスチン尿症. 新薬と臨床 71 : 746-749, 2022.
 
3) 大澤好充, 山田健治 : 診断・治療可能な遺伝性疾患を見逃さないために先天代謝異常症ホモシスチン尿症. 小児科臨床 73 : 672-677, 2020.
 
4) 坂本修 : 知っておくべき治療可能な胎児・新生児希少疾患先天代謝異常ホモシスチン尿症. 周産期医学 48 : 1347-1351, 2018.
 
5) 東京都予防医学協会 : 新生児マススクリーニング検査の実績. [https://www.yobouigaku-tokyo.or.jp/baby/public_index.html] (2023年6月閲覧)
 
6) Morris AA, Kozich V, Santra S, et al : Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis 40 : 49-74, 2017.
PubMed
7) 新生児マススクリーニング対象疾患等診療ガイドライン 2019 (日本先天代謝異常学会編), 診断と治療社, 2019.
 
8) Huemer M, Diodato D, Schwahn B, et al : Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis 40 : 21-48, 2017.
PubMed
9) 浅野茂隆, 池田康夫, 内山卓 (監) : 三輪血液病学. p7, p2070, 図版p2044, 文光堂, 2006.
 
10) Green R : Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood 129 : 2603-2611, 2017.
PubMed
P.122 掲載の参考文献
1) 宮内潤, ほか : 巨赤芽球性貧血と悪性貧血. 骨髄疾患診断アトラス-血液形態と骨髄病理, 第2版 (宮内潤, 泉二登志子編), p33-36, 中外医学社, 2010.
 
2) 生田克也, ほか : 巨赤芽球性貧血. 血液診療エキスパート-貧血, (金倉譲, 中尾眞二, 伊藤悦郎, ほか編), p91-99, 中外医学社, 2010.
 
3) 小峰光博 : II. 赤血球, B. 赤血球の生化学と機能, 4. ビタミンB12と葉酸の代謝. 三輪血液病学, (浅野茂隆, 池田康夫, 内山卓監), p184-213, 文光堂, 2006.
 
4) 小峰光博 : III. 赤血球の疾患, 3. DNA 合成障害による貧血, c. 葉酸欠乏性巨赤芽球性貧血. 三輪血液病学, (浅野茂隆, 池田康夫, 内山卓監), p992-1000, 文光堂, 2006.
 
5) 田中勝, ほか : I章 赤血球系・骨髄増殖性疾患. D. 巨赤芽球性貧血. 専門医のための薬物療法 Q&A-血液, (富野康日己監, 押味和夫, 小松則夫, 長澤俊郎編), p36-42, 中外医学社, 2007.
 
6) 厚生省報道発表資料 : 「神経管閉鎖障害の発症リスク低減のための妊娠可能な年齢の女性等に対する葉酸の摂取に係る適切な情報提供の推進について」, 2000.
 
P.124 掲載の参考文献
1) Wiedemann A, Oussalah A, Lamireau N, et al : Clinical, phenotypic and genetic landscape of case reports with genetically proven inherited disorders of vitamin B (12) metabolism : A meta-analysis. Cell Rep Med 3 : 100670, 2022.
PubMed
2) Schuh S, Rosenblatt DS, Cooper BA, et al : Homocystinuria and megaloblastic anemia responsive to vitamin B12 therapy. An inborn error of metabolism due to a defect in cobalamin metabolism. N Engl J Med 310 : 686-690, 1984.
PubMed
3) Watkins D, Rosenblatt DS : Genetic heterogeneity among patients with methylcobalamin deficiency. Definition of two complementation groups, cblE and cblG. J Clin Invest 81 : 1690-1694, 1988.
PubMed
4) Huemer M, Burer C, Jesina P, et al : Clinical onset and course, response to treatment and outcome in 24 patients with the cblE or cblG remethylation defect complemented by genetic and in vitro enzyme study data. J Inherit Metab Dis 38 : 957-967, 2015.
PubMed
5) Watkins D, Ru M, Hwang HY, et al : Hyperhomocysteinemia due to methionine synthase deficiency, cblG : structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173 L. Am J Hum Genet 71 : 143-153, 2002.
 
P.128 掲載の参考文献
1) Banka S, Blom HJ, Walter J, et al : Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency. Am J Hum Genet 88 : 216-225, 2011.
PubMed
2) Cario H, Smith DE, Blom H, et al : Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease. Am J Hum Genet 88 : 226-231, 2011.
PubMed
3) Walters TR : Congenital megaloblastic anemia responsive to N5-formyl tetrafolic acid administration. J Pediatr 70 : 686-687, 1967.
 
4) Tauro GP, Danks DM, Rowe PB, et al : Dihydrofolate reductase deficiency causing megaloblastic anemia in two families. N Engl J Med 294 : 466-470, 1976.
PubMed
5) 片山直之 : 巨赤芽球性貧血. 血液診療エキスパート-貧血, (金倉譲監, 中尾眞二, 伊藤悦郎, ほか編), p91-99, 中外医学社, 2010.
 
6) 濱崎浩之, 金丸昭久 : ジヒドロ葉酸還元酵素欠損症. 赤血球の異常. 巨赤芽球性貧血, 別冊日本臨牀領域別症候群 20, 血液症候群 I p139-141, 日本臨床社, 1998.
 
7) 小峰光博 : II. 赤血球, B. 赤血球の生化学と機能, 4. ビタミンB12と葉酸の代謝. 三輪血液病学, (浅野茂隆, 池田康夫, 内山卓監), p184-213, 文光堂, 2006.
 
8) 小峰光博 : III. 赤血球の疾患, 3. DNA合成障害による貧血, c. 葉酸欠乏性巨赤芽球性貧血. 三輪血液病学, (浅野茂隆, 池田康夫, 内山卓監), p992-1000, 文光堂, 2006.
 
9) 加納康彦, ほか : VII. 葉酸ならびにビタミンB12代謝とその異常. 最新内科学大系 I, 第18巻 貧血・多血症, p137-151, 中山書店, 1992.
 
P.131 掲載の参考文献
1) Suter PM : Vitamin and Trace Mineral Deficiency and Excess. In : Harrison's Principles of Internal Medicine, 21th Edition (ed by Loscalzo J, Fauci A, Kasper D, et al), p2565-2566, McGraw-Hill Education, New York, 2022.
 
2) 小峰光博 : 巨赤芽球性貧血. 三輪血液病学第3版 (浅野茂隆, 池田康夫, 内山卓編), p974-996, 文光堂, 2006.
 
3) Green R, Datta Mitra A : Anemia due to Other Nutritional Deficiencies. In : Williams Hematology, Tenth Edition (ed by Kaushansky K, Lichtman MA, Prchal JT, et al), p731-732, McGraw-Hill Education, New York, 2021.
 
4) 「日本人の食事摂取基準」策定委員会 : 日本人の食事摂取基準 (2020年版), 令和元年12月, [https://www.mhlw.go.jp/content/10904750/000586553.pdf]
 
5) Gitlin SD : Nutritional Anemias. In : Hematology for the Medical Student (ed by Schmaier AH, Petuzzill LM), p35-48 Lippincott Williams & Wilkins, Philadelphia, 2003.
 
6) Hoffbrand AV, Weir DG : The history of folic acid. Br J Haematol 113 : 579-589, 2001.
PubMed
7) Clark NG, Sheard NF, Kelleher JF : Treatment of iron-deficiency anemia complicated by scurvy and folic acid deficiency. Nutr Rev 50 : 134-137, 1992.
PubMed
8) 佐久間長彦 : ビタミンCの臨床. Modern Physician (福澤健治, 渡邊敏編) : 1251-1253, 2007.
 
9) 石神昭人 : 実際の健康食品・サプリメントビタミンC. 診断と治療 109 : 1057-1060, 2021.
 
P.134 掲載の参考文献
1) Moller JOL : Klinische Bemerkungen uber einige weniger bekannte Krankheiten der Zunge. Dtsch Klinik. 3 : 273-275, 1851.
 
2) Hunter W : Further observations on pernicious anemia (seven cases) : a chronic infective disease ; its relation to infection from the mouth and stomach ; suggested serum treatment. Lancet 1 : 221-224, 1900.
 
3) Graells J, Ojeda RM, Muniesa C, et al : Glossitis with linear lesions : an early sign of vitamin B12 deficiency. J Am Acad Dermatol 60 : 498-500, 2009.
PubMed
4) Ishizuka K, Katayama K, Ohira Y : Moeller-Hunter glossitis. BMJ Case Rep 15 : e251810, 2022.
PubMed
5) 任智美 : 診断に苦慮されたHunter舌炎の1例. 耳鼻咽喉科免疫アレルギー 38 : 9-12, 2020.
Medical*Online
6) Stabler SP : Clinical practice. Vitamin B12 deficiency. N Engl J Med 368 : 149-160, 2013.
PubMed
7) Kaptan K, Beyan C, Ural AU, et al : Helicobacter pylori-is it a novel causative agent in Vitamin B12 deficiency? Arch Intern Med 160 : 1349-1353, 2000.
PubMed
8) Vannella L, Lahner E, Osborn J, et al : Systematic review : gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther 37 : 375-382, 2013.
PubMed
9) Takahashi N, Kameoka J, Takahashi N, et al : Causes of macrocytic anemia among 628 patients : mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. Int J Hematol 104 : 344-357, 2016.
PubMed
10) Pruthi RK, Tefferi A : Pernicious anemia revisited. Mayo Clin Proc 69 : 144-150, 1994.
PubMed
11) Carmel R, Agrawal YP : Failures of cobalamin assays in pernicious anemia. N Engl J Med 367 : 385-386, 2012.
PubMed
12) Oberley MJ, Yang DT : Laboratory testing for cobalamin deficiency in megaloblastic anemia. Am J Hematol 88 : 522-526, 2013.
PubMed
13) Lindenbaum J, Savage DG, Stabler SP, et al : Diagnosis of cobalamin deficiency : II. Relative sensitivities of serum cobalamin, methylmalonic acid, and total homocysteine concentrations. Am J Hematol 34 : 99-107, 1990.
PubMed
14) Carmel R : Reassessment of the relative prevalences of antibodies to gastric parietal cell and to intrinsic factor in patients with pernicious anaemia : influence of patient age and race. Clin Exp Immunol 89 : 74-77, 1992.
PubMed
P.139 掲載の参考文献
1) Qudsiya Z, De Jesus O : Subacute Combined Degeneration of the Spinal Cord. In : StatPearls [Internet]. Treasure Island (FL) : StatPearls Publishing ; 2023.
 
2) 永石彰子, 黒田康夫 : ビタミンB12の吸収・代謝・利用と神経障害. 神経内科 61 : 319-323, 2004.
 
3) Bauman WA, Shaw S, Jayatilleke E, et al : Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 23 : 1227-1231, 2000.
PubMed
4) Lindenbaum J, Rosenberg IH, Wilson PW, et al : Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 60 : 2-11, 1994.
PubMed
5) Jain KK, Malhotra HS, Garg RK, et al : Prevalence of MR imaging abnormalities in vitamin B12 deficiency patients presenting with clinical features of subacute combined degeneration of the spinal cord. J Neurol Sci 342 : 162-166, 2014.
PubMed
6) 唐沢正光, 谷田部寛, 山内博正 : ビタミンB12欠乏による巨赤芽球性貧血51 症例の臨床病態. 臨床血液 25 : 1746-1753, 1984.
 
7) Lindenbaum J, Healton EB, Savage DG, et al : Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 318 : 1720-1728, 1988.
 
8) Healton EB, Savage DG, Brust JC, et al : Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 70 : 229-245, 1991.
PubMed
9) Scott JM, Dinn JJ, Wilson P, et al : Pathogenesis of subacute combined degeneration : a result of methyl group deficiency. Lancet 2 : 334-337, 1981.
PubMed
10) Scalabrino G : Cobalamin (vitamin B (12)) in subacute combined degeneration and beyond : traditional interpretations and novel theories. Exp Neurol 192 : 463-479, 2005.
PubMed
11) Chatterjee A, Yapundich R, Palmer CA, et al : Leukoencephalopathy associated with cobalamin deficiency. Neurology 46 : 832-834, 1996.
PubMed
12) Cao J, Xu S, Liu C : Is serum vitamin B12 decrease a necessity for the diagnosis of subacute combined degeneration? : A meta-analysis. Medicine (Baltimore) 99 : e19700, 2020.
PubMed
13) Jaiser SR, Winston GP : Copper deficiency myelopathy. J Neurol 257 : 869-881, 2010.
PubMed
14) Kuzminski AM, Del Giacco EJ, Allen RH, et al : Effective treatment of cobalamin deficiency with oral cobalamin. Blood 92 : 1191-1198, 1998.
PubMed
15) Cao J, Su ZY, Xu SB, et al : Subacute Combined Degeneration : A Retrospective Study of 68 Cases with Short-Term Follow-Up. Eur Neurol 79 : 247-255, 2018.
PubMed
P.142 掲載の参考文献
1) Novacek G : Plummer-Vinson syndrome. Orphanet J Rare Dis 1 : 36, 2006.
PubMed
2) Plummer S : Diffuse dilatation of the esophagus without anatomic stenosis (cardiospasm). A report of ninety-one cases. J Am Med Assoc 58 : 2013-2015, 1912.
 
3) Vinson PP : A case of cardiospasm with dilatation and angulation of the esophagus. Med Clin North Am 3 : 623-627, 1919.
 
4) Vinson PP : Hysterical dysphagia. Minnesota Med 5 : 107-108, 1922.
 
5) Paterson DR : A clinical type of dysphagia. J Laryngol Otol 34 : 289-291, 1919.
 
6) Kelly AB : Spasm at the entrance of the esophagus. J Laryngol Otol 34 : 285-289, 1919.
 
7) Wynder EL, Hultberg S, Jacobsson F, et al : Environmental factors in cancer of the upper alimentary tract ; a Swedish study with special reference to Plummer-Vinson (Paterson-Kelly) syndrome. Cancer 10 : 470-487, 1957.
PubMed
8) Nosher JL, Campbel WL, Seaman WB : The clinical significance of cervical esophageal and hypopharyngeal webs. Radiology 117 : 45-47, 1975.
PubMed
9) Chen TS, Chen PS : Rise and fall of the Plummer-Vinson syndrome. J Gastroenterol Hepatol 9 : 654-658, 1994.
PubMed
10) Dantas RO, Villanova MG : Esophageal motility impairment in Plummer-Vinson syndrome. Correction by iron treatment. Dig Dis Sci 38 : 968-971, 1993.
PubMed
11) Miranda AL, Dantas RO : Esophageal contractions and oropharyngeal and esophageal transits in patients with iron deficiency anemia. Am J Gastroenterol 98 : 1000-1004, 2003.
PubMed
12) Dickey W, McConnell B : Celiac disease presenting as the Paterson-Brown Kelly (Plummer-Vinson) syndrome. Am J Gastroenterol 94 : 527-529, 1999.
 
13) Hoffman RM, Jaffe PE : Plummer-Vinson syndrome. A case report and literature review. Arch Intern Med 155 : 2008-2011, 1995.
PubMed
14) Chisholm M : The association between webs, iron and post-cricoid carcinoma. Postgrad Med J 50 : 215-219, 1974.
PubMed
15) Larsson LG, Sandstrom A, Westling P : Relationship of Plummer-Vinson disease to cancer of the upper alimentary tract in Sweden. Cancer Res 35 : 3308-3316, 1975.
PubMed
P.146 掲載の参考文献
1) Danford DE : Pica and nutrition. Annu Rev Nutr 2 : 303-322, 1982.
PubMed
2) Moore DFJr, Sears DA : Pica, iron deficiency, and the medical history. Am J Med 97 : 290-393, 1994.
 
3) Harries JM, Hughes TF : Enumeration of the cravings of some pregnant women. Br Med J 2 : 39-40, 1958.
PubMed
4) Keith LG, Rosenberg CD, Brown E : Pica, pagophagia, and anemia. JAMA 208 : 535, 1969.
PubMed
5) Homer RD, Lackey CI, Kolasa K, et al : Pica practices of pregnant women. J Am Diet Assoc 91 : 34-38, 1991.
 
6) Mohan M, Agarwal KN, Bhutt I, et al : Iron therapy in pica. J Indian Med Assoc 51 : 16-18, 1968.
 
7) Halsted JA : Geophagia in man : its nature and nutritional effects. Am J Clin Nutr 21 : 1384-1393, 1968.
PubMed
8) Jacobziner H, Raybin HW : Gluthethimide (doriden) poisoning. Arch Pediatr (NY) 79 : 302-305, 1962.
 
9) Reynolds RD, Binder HJ, Miller MB, et al : Pagophagia and iron deficiency anemia. Ann Intern Med 69 : 435-440, 1968.
PubMed
10) Kluver H, Bucy PC : Preliminary analysis of functions of the temporal lobes in monkeys. 1939. J Neuropsychiatry Clin Neurosci 9 : 606-620, 1997.
PubMed
11) Danford DE, Huber AM : Pica among mentally retarded adults. Am J Ment Defic 87 : 141-146, 1982.
PubMed
12) Mahaffey KR : Predicting blood lead concentrations from lead in environmental media. Environ Health Perspect 106 (Suppl 6) : 1485-1493, 1998.
 
13) Haley TJ : Saturnism, pediatric and adult lead poisoning. Clin Toxicol 4 : 11-29, 1971.
PubMed
14) Rector WG Jr : Pica : its frequency and significance in patients with iron-deficiency anemia due to chronic gastrointestinal blood loss. J Gen Intern Med 4 : 512-513, 1989.
PubMed
15) Gardner JE, Tevetoglu F : The roentgenographic diagnosis of geophagia (dirt-eating) in children : a report of sixty cases. J Pediatr 51 : 667-671, 1957.
 
P.150 掲載の参考文献
1) Hershko C, Camaschella C : How I treat unexplained refractory iron deficiency anemia. Blood 123 : 326-333, 2014.
 
2) De Amicis MM, Rimondi A, Elli L, et al : Acquired Refractory Iron Deficiency Anemia. Mediterr J Hematol Infect Dis 13 : e2021028, 2021.
 
3) Cardenas VM, Mulla ZD, Ortiz M, et al : Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol 163 : 127-134, 2006.
PubMed
4) Malfertheiner P, Megraud F, O'Morain CA, et al : Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66 : 6-30, 2017.
PubMed
5) Chey WD, Leontiadis GI, Howden CW, et al : ACG Clinical Guideline : Treatment of Helicobacter pylori Infection. Am J Gastroenterol 112 : 212-239, 2017.
PubMed
6) Finberg KE, Heeney MM, Campagna DR, et al : Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 40 : 569-571, 2008.
PubMed
7) Hershko C, Hoffbrand AV, Keret D, et al : Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica 90 : 585-595, 2005.
PubMed
8) Hershko C, Skikne B : Pathogenesis and management of iron deficiency anemia : emerging role of celiac disease, helicobacter pylori, and autoimmune gastritis. Semin Hematol 46 : 339-350, 2009.
PubMed
9) Mims MP, Guan Y, Pospisilova D, et al : Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload. Blood 105 : 1337-1342, 2005.
 
10) Beutler E, Gelbart T, Lee P, et al : Molecular characterization of a case of atransferrinemia. Blood 96 : 4071-4074, 2000.
PubMed
11) Annibale B, Capurso G, Lahner E, et al : Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia. Gut 52 : 496-501, 2003.
PubMed
12) Yip R, Limburg PJ, Ahlquist DA, et al : Pervasive occult gastrointestinal bleeding in an Alaska native population with prevalent iron deficiency. Role of Helicobacter pylori gastritis. JAMA 277 : 1135-1139, 1997.
 
13) Perez-Perez GI, Israel DA : Role of iron in Helicobacter pylori : its influence in outer membrane protein expression and in pathogenicity. Eur J Gastroenterol Hepatol 12 : 1263-1265, 2000.
PubMed
14) Yokota S, Konno M, Mino E, et al : Enhanced Fe ion-uptake activity in Helicobacter pylori strains isolated from patients with iron-deficiency anemia. Clin Infect Dis 46 : e31-33, 2008.
PubMed
15) Dhaenens L, Szczebara F, Husson MO : Identification, characterization, and immunogenicity of the lactoferrin-binding protein from Helicobacter pylori. Infect Immun 65 : 514-518, 1997.
PubMed
16) Choe YH, Oh YJ, Lee NG, et al : Lactoferrin sequestration and its contribution to iron-deficiency anemia in Helicobacter pylori-infected gastric mucosa. J Gastroenterol Hepatol 18 : 980-985, 2003.
PubMed
17) Finberg KE, Whittlesey RL, Fleming MD, et al : Down-regulation of Bmp/Smad signaling by Tmprss 6 is required for maintenance of systemic iron homeostasis. Blood 115 : 3817-3826, 2010.
 
18) Ramsay AJ, Hooper JD, Folgueras AR, et al : Matriptase-2 (TMPRSS6) : a proteolytic regulator of iron homeostasis. Haematologica 94 : 840-849, 2009.
PubMed
19) Ganz T : Hepcidin and iron regulation, 10 years later. Blood 117 : 4425-4433, 2011.
PubMed
20) Sato T, Iyama S, Murase K, et al : Novel missense mutation in the TMPRSS6 gene in a Japanese female with iron-refractory iron deficiency anemia. Int J Hematol 94 : 101-103, 2011.
 
21) Kodama K, Noguchi A, Adachi H, et al : Novel mutation in the TMPRSS6 gene with iron-refractory iron deficiency anemia. Pediatr Int 56 : e41-e44, 2014.
PubMed
P.155 掲載の参考文献
1) Heilmeyer L, Keller W, Vivell O, et al : Congenital atransferrinemia in a 7-year-old girl. Dtsch Med Wochenschr 86 : 1745-1751, 1961.
 
2) Cap J, Lehotska V, Mayerova A : Congenital atransferrinemia in a 11-month-old child. Cesk Pediatr 23 : 1020-1025, 1968.
 
3) Shamsian BS, Rezaei N, Arzanian MT, et al : Severe hypochromic microcytic anemia in a patient with congenital atransferrinemia. Pediatr Hematol Oncol 26 : 356-362, 2009.
 
4) Dabboubi R, Amri Y, Yahyaoui S, et al : A new case of congenital atransferrinemia with a novel splice site mutation : c.293-63del. Eur J Med Genet 63 : 103874, 2020.
PubMed
5) Hamill RL, Woods JC, Cook BA : Congenital atransferrinemia. A case report and review of th litrature. Am J Clin Pathol 96 : 215-218, 1991.
 
6) 坂田堯 : 先天性トランスフェリン欠乏症の1例. 小児科診療 32 : 1523-1528, 1969.
 
7) Goya N, Miyazaki S, Kodate S, et al : A family of congenital atransferrinemia. Blood 40 : 239-245, 1972.
PubMed
8) Beutler E, Gelbart T, Lee P, et al : Molecular characterization of a case of atransferrinemia. Blood 96 : 4071-4074, 2000.
PubMed
9) Athiyarath R, Arora N, Fuster F, et al : Two novel missense mutations in iron transport protein transferrin causing hypochromic microcytic anaemia and haemosiderosis : molecular characterization and structural implications. Br J Haematol 163 : 404-407, 2013.
PubMed
10) Asada-Senju M, Maeda T, Sakata T, et al : Molecular analysis of the transferrin gene in a patient with hereditary hypotransferrinemia. J Hum Genet 47 : 355-359, 2002.
 
11) 山口俊一朗, ほか : 先天性無トランスフェリン血症. 別冊日本臨牀血液症候群 (第2版) I, p139-142, 2013.
 
12) Camaschella C, Pagani A, Silvestri L, et al : The mutual crosstalk between iron and erythropoiesis. Int J Hematol 116 : 182-191, 2022.
PubMed
13) Cappellini MD, Russo R, Andolfo I, et al : Inherited microcytic anemias. Hematology Am Soc Hematol Educ Program 2020 : 465-470, 2020.
PubMed
14) Piperno A, Pelucchi S, Mariani R : Inherited iron overload disorders. Transl Gastorenterol Hepatol 5 : 25, 2020.
PubMed
15) Chandra D, Dhingra B, Seth T, et al : Congenital Hypotransferrinemia, an Unusual Cause of Iron Deficiency Anemia : Report of Two Cases. Indian J Hematol Blood Transfus 33 : 402-404, 2017.
PubMed
16) Boshuizen M, van der Ploeg K, von Bonsdorff L, et al : Therapeutic use of transferrin to modulate anemia and conditions of iron toxicity. Blood Rev 31 : 400-405, 2017.
PubMed
17) Aslan D : Addition of oral iron to plasma transfusion in human congenital hypotransferrinemia : A 10-year observational follow-up with the effects on hematological parameters and growth. Pediatr Blood Cancer 65 : e26789, 2018.
 
P.157 掲載の参考文献
1) Boshuizen M, van der Ploeg K, von Bonsdorff L, et al : Therapeutic use of transferrin to modulate anemia and conditions of iron toxicity. Blood Rev 31 : 400-405, 2017.
PubMed
2) Idzerda RL, Huebers H, Finch CA, et al : Rat transferrin gene expression : tissue-specific regulation by iron deficiency. Proc Natl Acad Sci USA 83 : 3723-3727, 1986.
PubMed
3) Rolfs A, Kvietikova I, Gassmann M, et al : Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 272 : 20055-20062, 1997.
PubMed
4) Nakata K, Saitoh R, Amano J, et al : Alteration of intracellular secretory acute phase response proteins expressed in human hepatocyte induced by exposure with interleukin-6. Cytokine 59 : 317-323, 2012.
PubMed
5) Bartnikas TB : Known and potential roles of transferrin in iron biology. Biometals 25 : 677-686, 2012.
PubMed
6) Ritchie RF, Palomaki GE, Neveux LM, et al : Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin : a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 13 : 273-279, 1999.
 
7) Borini P, Guimaraes RC : Liver synthesis function in chronic asymptomatic or oligosymptomatic alcoholics : correlation with other liver tests. Rev Hosp Clin Fac Med Sao Paulo 54 : 97-102, 1999.
 
8) Descombes E, Fellay G : Hypotransferrinemia in chronic hemodialyzed (HD) patients. Artif Organs 24 : 988-989, 2000.
PubMed
9) Prinsen BHCMT, Velden MGMS, Kaysen GA, et al : Transferrin synthesis is increased in nephrotic patients insufficiently to replace urinary losses. J Am Soc Nephrol 12 : 1017-1025, 2001.
PubMed
10) Aman J, van der Heijden M, van Lingen A, et al : Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome. Crit Care Med 39 : 89-97, 2011.
PubMed
11) Raynor A, Stefanescu C, Bruneel A, et al : Reversible atransferrinemia in a patient with chronic enteropathy : is transferrin mandatory for iron transport? Biochem Med (Zagreb) 33 : 010801, 2023.
 
12) Finch CA, Huebers H : Perspectives in iron metabolism. N Engl J Med 306 : 1520-1528, 1982.
PubMed
13) Gottschalk R, Wigand R, Dietrich CF, et al : Total iron-binding capacity and serum transferrin determination under the influence of several clinical conditions. Clin Chim Acta 293 : 127-138, 2000.
PubMed
14) Beutler E, Gelbart T, Lee P, et al : Molecular characterization of a case of atransferrinemia. Blood 96 : 4071-4074, 2000.
PubMed
P.161 掲載の参考文献
1) 寺田秀夫 : Hayem-Faber 症候群. 別冊日本臨牀血液症候群 (第2版) I, p146-149, 日本臨牀社, 2013.
 
2) 小松則夫 : 鉄欠乏性貧血. 診断と治療 110 : 1029-1034, 2022.
Medical*Online
3) Hashimoto R, Matsuda T, Chonan A : Iron-deficiency anemia caused by a proton pump inhibitor. Intern Med 53 : 2297-2299, 2014.
PubMed
P.165 掲載の参考文献
1) Ducamp S, Fleming MD : The molecular genetics of sideroblastic anemia. Blood 133 : 59-69, 2019.
PubMed
2) Guernsey DL, Jiang H, Campagna DR, et al : Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet 41 : 651-653, 2009.
PubMed
3) Grandchamp B, Hetet G, Kannengiesser C, et al : A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene. Blood 118 : 6660-6666, 2011.
PubMed
4) Rademakers LH, Koningsberger JC, Sorber CW, et al : Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur J Clin Invest 23 : 130-138, 1993.
PubMed
5) Camaschella C, Campanella A, De Falco L, et al : The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 110 : 1353-1358, 2007.
PubMed
6) Schmitz-Abe K, Ciesielski SJ, Schmidt PJ, et al : Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood 126 : 2734-2738, 2015.
PubMed
7) Crispin A, Guo C, Chen C, et al : Mutations in the iron-sulfur cluster biogenesis protein HSCB cause congenital sideroblastic anemia. J Clin Invest 130 : 5245-5256, 2020.
 
8) Bykhovskaya Y, Casas K, Mengesha E, et al : Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am J Hum Genet 74 : 1303-1308, 2004.
PubMed
9) Riley LG, Cooper S, Hickey P, et al : Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia-MLASA syndrome. Am J Hum Genet 87 : 52-59, 2010.
PubMed
10) Riley LG, Rudinger-Thirion J, Schmitz-Abe K, et al : LARS2 Variants Associated with Hydrops, Lactic Acidosis, Sideroblastic Anemia, and Multisystem Failure. JIMD Rep 28 : 49-57, 2016.
PubMed
11) Neufeld EJ, Fleming JC, Tartaglini E, et al : Thiamine-responsive megaloblastic anemia syndrome : a disorder of high-affinity thiamine transport. Blood Cells Mol Dis 27 : 135-138, 2001.
PubMed
12) Chakraborty PK, Schmitz-Abe K, Kennedy EK, et al : Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood 124 : 2867-2871, 2014.
PubMed
13) Bergmann AK, Campagna DR, McLoughlin EM, et al : Systematic molecular genetic analysis of congenital sideroblastic anemia : evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 54 : 273-278, 2010.
PubMed
14) Ohba R, Furuyama K, Yoshida K, et al : Clinical and genetic characteristics of congenital sideroblastic anemia : comparison with myelodysplastic syndrome with ring sideroblast (MDSRS). Ann Hematol 92 : 1-9, 2013.
PubMed
15) 遺伝性鉄芽球性貧血の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ : 遺伝性鉄芽球性貧血診療の参照ガイド 令和1年改訂版, 2020.
 
P.169 掲載の参考文献
1) Cooley TB : A severe type of hereditary anemia with elliptocytosis : interesting sequence of splenectomy. Am J Med Sci 209 : 561-568, 1945.
 
2) Rundles RW, Falls HF : Hereditary (sex-linked?) anemia. Am J Med Sci 211 : 641-658, 1946.
PubMed
3) Cotter PD, Rucknagel DL, Bishop DF : X-linked sideroblastic anemia : identification of the mutation in the erythroid-specific δ-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley. Blood 84 : 3915-3924, 1994.
 
4) Lichtenstein DA, Crispin AW, Sendamarai AK, et al : A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia. Blood 128 : 1913-1917, 2016.
PubMed
5) Allikmets R, Raskind WH, Hutchinson A, et al : Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 8 : 743-749, 1999.
 
6) Fujiwara T, Harigae H : Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia. Free Radic Biol Med 133 : 179-185, 2019.
PubMed
7) Ducamp S, Kannengiesser C, Touati M, et al : Sideroblastic anemia : molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat 32 : 590-597, 2011.
 
8) Aivado M, Gattermann N, Rong A, et al : X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood Cells Mol Dis 37 : 40-45, 2006.
PubMed
9) Pagon RA, Bird TD, Detter JC, et al : Hereditary sideroblastic anaemia and ataxia : an X linked recessive disorder. J Med Genet 22 : 267-273, 1985.
 
10) Raskind WH, Wijsman E, Pagon RA, et al : X-linked sideroblastic anemia and ataxia : linkage to phosphoglycerate kinase at Xq13. Am J Hum Genet 48 : 335-341, 1991.
PubMed
11) Bergmann AK, Campagna DR, McLoughlin EM, et al : Systematic molecular genetic analysis of congenital sideroblastic anemia : evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer 54 : 273-278, 2010.
PubMed
12) Ohba R, Furuyama K, Yoshida K, et al : Clinical and genetic characteristics of congenital sideroblastic anemia : comparison with myelodysplastic syndrome with ring sideroblast (MDSRS). Ann Hematol 92 : 1-9, 2013.
PubMed
13) 遺伝性鉄芽球性貧血の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ : 遺伝性鉄芽球性貧血診療の参照ガイド 令和1年改訂版, 2020.
 
14) Medeiros BC, Kolhouse JF, Cagnoni PJ, et al : Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia. Bone Marrow Transplant 31 : 1053-1055, 2003.
PubMed
15) Van Dijck R, Goncalves Silva AM, Rijneveld AW : Luspatercept as Potential Treatment for Congenital Sideroblastic Anemia. N Engl J Med 388 : 1435-1436, 2023.
PubMed
P.173 掲載の参考文献
1) Arber DA, Orazi A, Hasserjian R, et al : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127 : 2391-2405, 2016.
 
2) Yoshida K, Sanada M, Shiraishi Y, et al : Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478 : 64-69, 2011.
PubMed
3) Ducamp S, Fleming MD : The molecular genetics of sideroblastic anemia. Blood 133 : 59-69, 2019.
PubMed
4) Dolatshad H, Pellagatti A, Liberante FG, et al : Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. Leukemia 30 : 2322-2331, 2016.
PubMed
5) Fujiwara T, Harigae H : Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia. Free Radic Biol Med 133 : 179-185, 2019.
PubMed
6) Kispal G, Csere P, Prohl C, et al : The mitochondrial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins. EMBO J 18 : 3981-3989, 1999.
 
7) Bhasker CR, Burgiel G, Neupert B, et al : The putative iron-responsive element in the human erythroid 5-aminolevulinate synthase mRNA mediates translational control. J Biol Chem 268 : 12699-12705, 1993.
PubMed
8) Ochi T, Fujiwara T, Ono K, et al : Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome. Sci Rep 12 : 14562, 2022.
PubMed
9) Greenberg PL, Tuechler H, Schanz J, et al : Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120 : 2454-2465, 2012.
PubMed
10) Fenaux P, Platzbecker U, Mufti GJ, et al : Luspatercept in patients with lower-risk myelodysplastic syndromes. New Engl J Med 382 : 140-151, 2020.
PubMed
11) Yoshimi A, Abdel-Wahab O : Splicing factor mutations in MDS RARS and MDS/MPN-RS-T. Int J Hematol 105 : 720-731, 2017.
 
P.176 掲載の参考文献
1) Lichtman MA, Beutler E, Kipps TJ (ed) : Williams Hematology, 7th Edition, p823-828, McGraw-Hill Medical, New York, 2005.
 
2) Willekens C, Dumezy F, Boyer T, et al : Linezolid induces ring sideroblasts. Haematologica 98 : e138-e140, 2013.
PubMed
3) Bottomley SS : Sideroblastic anemia. In : Iron in Biochemistry and Medicine II (ed by Jacobs A, Worwood M). p363-392, Academic Press, London, 1981.
 
4) 新津洋司郎, 瀧本理修, ほか : 三輪血液病学 第3版 (浅野茂隆, 池田康夫, 内山卓監), p1018-1023, 文光堂, 2006.
 
5) Savage D, Lindenbaum J : Anemia in alcoholics. Medicine (Baltimore) 65 : 322-338, 1986.
PubMed
6) Pierce HI, McGuffin RG, Hillman RS : Clinical studies in alcoholic sideroblastosis. Arch Intern Med 136 : 283-289, 1976.
PubMed
7) Bottomley SS. Sideroblastic anemias. In : Wintrobe's Clinical Hematology, 12th ed (ed by Greer JP, Foerster J, Rodgers GM, et al), p835, Lippincott Williams and Wilkins, Philadelphia, 2008.
 
8) Lumeng L, Li TK : Vitamin B6 metabolism in chronic alcohol abuse. Pyridoxal phosphate levels in plasma and the effects of acetaldehyde on pyridoxal phosphate synthesis and degradation in human erythrocytes. J Clin Invest 53 : 693-704, 1974.
PubMed
9) Beck EA, Ziegler G, Schmid R, et al : Reversible sideroblastic anemia caused by chloramphenicol. Acta Haematol 38 : 1-10, 1967.
PubMed
10) Firkin FC : Mitochondrial lesions in reversible erythropoietic depression due to chloramphenicol. J Clin Invest 51 : 2085-2092, 1972.
PubMed
11) Hines JD, Love DS : Determination of serum and blood pyridoxal phosphate concentrations with purified rabbit skeletal muscle apophosphorylase b. J Lab Clin Med 73 : 343-349, 1969.
 
P.179 掲載の参考文献
1) Sassa S : Toxic effects of lead, with particular reference to porphyrin and heme metabolism. In : Heme and Hemoproteins (ed by DeMatties F, Aldridge WN). p333-371, Springer, New York, 1978.
 
2) Valentine WN, Paglia DE, Fink K, et al : Lead poisoning : association with hemolytic anemia, basophilic stippling, erythrocyte pyrimidine 5'-nucleotidase deficiency, and intraerythrocytic accumulation of pyrimidines. J Clin Invest 58 : 926-932, 1976.
PubMed
3) Dagg JH, Goldberg A, Lochhead A, et al : The relationship of lead poisoning to acute intermittent porphyria. Q J Med 34 : 163-175, 1965.
PubMed
4) 田中健, 坂本昭彦, 白石香, ほか : 慢性鉛中毒による貧血. 臨床血液 37 : 1325-1327, 1996.
 
5) Cullen MR, Robins JM, Eskenazi B : Adult inorganic lead intoxication : presentation of 31 new cases and a review of recent advances in the literature. Medicine (Baltimore) 62 : 221-247, 1983.
 
6) Labbe RF, Rettmer RL : Zinc protoporphyrin : a product of iron-deficient erythropoiesis. Semin Hematol 26 : 40-46, 1989.
PubMed
P.182 掲載の参考文献
1) Fujiwara T, Harigae H : Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia. Free Radic Biol Med 133 : 179-185, 2019.
PubMed
2) Ducamp S, Fleming MD : The molecular genetics of sideroblastic anemia. Blood 133 : 59-69, 2019.
PubMed
3) Harris JW, Whittington RM, Weisman R Jr, et al : Pyridoxine responsive anemia in the human adult. Proc Soc Exp Biol Med 91 : 427-432, 1956.
PubMed
4) Raab SO, Haut A, Cartwright GE, et al : Pyridoxine-responsive anemia. Blood 18 : 285-302, 1961.
PubMed
5) Horrigan DL, Harris JW : Pyridoxine-responsive anemias in man. Vitam Horm 26 : 549-571, 1968.
PubMed
6) 通山薫, ほか : 不応性貧血症例の新規登録の報告. 厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究班 平成15年度総括・分担研究報告書, p102-103, 2004.
 
7) Haferlach T, Nagata Y, Grossmann V, et al : Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28 : 241-247, 2014.
PubMed
8) Fuller SJ, Wiley JS : Chapter 39. In : Hematology : Basic Principles and Practice, Eighth Edition, p507-523, Elsevier, Philadelphia, 2023.
 
9) Van Gameren II, Wijnja L, Louwes H, et al : Pyridoxin-responsive anaemia in a patient with a history of polycythaemia vera. J Intern Med 242 : 79-81, 1997.
 
10) Furuyama K, Harigae H, Kinoshita C, et al : Late-onset X-linked sideroblastic anemia following hemodialysis. Blood 101 : 4623-4624, 2003.
PubMed
11) Baumann Kreuziger LM, Wolanskyj AP, Hanson CA, et al : Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts. Eur J Haematol 86 : 512-516, 2011.
PubMed
12) French SW : Alcohol-induced vitamin-B6-responsive anemia. N Engl J Med 283 : 1173, 1970.
PubMed
13) 藤原亨, 張替秀郎 : 二次性鉄芽球性貧血. 別冊日本臨牀血液症候群 (第2版), p212-214, 日本臨牀社, 2013.
 
14) Sharp RA, Lowe JG, Johnston RN : Anti-tuberculous drugs and sideroblastic anaemia. Br J Clin Pract 44 : 706-707, 1990.
PubMed
P.186 掲載の参考文献
1) 西美和, 波多野修一, 相原克昭, ほか : 銅Copper. 日本臨床 47 : 771-774, 1989.
 
2) Turnlund JR : Copper. In : Modern Nutrition in Health and Disease, ed (ed by 10th, Shils ME, Shike M, Ross AC, et al), p286, Lippincott Williams and Wilkins, Philadelphia, 2006.
 
3) Hayashi H, Suzuki R, Wakusawa S : Wilson's disease and its pharmacological treatment. Yakugaku Zasshi 124 : 711-724, 2004.
PubMed
4) Kodama H, Murata Y, Kobayashi M : Clinical manifestations and treatment of Menkes disease and its variants. Pediatr Int 41 : 423-429, 1999.
PubMed
5) Danks DM : Copper deficiency in humans. Annu Rev Nutr 8 : 235-257, 1988.
PubMed
6) Williams DM : Copper deficiency in humans. Semin Hematol 20 : 118-128, 1983.
PubMed
7) 三木浩和, 桑山泰治, 原朋子, ほか : 汎血球減少症, 徐脈, 神経症状を呈した銅欠乏症. 臨床血液 48 : 212-216, 2007.
 
8) Jaiser SR, Winston GP : Copper deficiency myelopathy. J Neurol 257 : 869-881, 2010.
PubMed
9) 武田英二, ほか : その他の代謝異常 内科学 第九版, (杉本恒明, 矢崎義雄編), p1540, 朝倉書店, 2007.
 
10) Fiske DN, McCoy HE 3rd, Kitchens CS : Zinc-induced sideroblastic anemia : report of a case, review of the literature, and description of the hematologic syndrome. Am J Hematol 46 : 147-150, 1994.
PubMed
P.190 掲載の参考文献
1) 菅野仁 : 先天性溶血性貧血. 血液専門医テキスト 改訂第3版 (日本血液学会編), 南江堂, p174-178, 2019.
 
2) 自己免疫性溶血性貧血診療の参照ガイド 令和4年度改訂版 (厚生労働科学研究費補助金難治性疾患政策研究事業特発性造血障害に関する調査研究班自己免疫性溶血性貧血の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ編), 2023. [http://zoketsushogaihan.umin.jp/]
 
3) Bolton-Maggs PH, Langer JC, Iolascon A, et al : Guidelines for the diagnosis and management of hereditary spherocytosis-2011 update. Br J Haematol 156 : 37-49, 2012.
PubMed
4) 中西秀和 : 遺伝性溶血性貧血. 今日の治療指針 2023 (福井次矢, 高木誠, 小室一成編), 医学書院, p659, 2023.
 
5) 遺伝性球状赤血球症. [https://www.shouman.jp/disease/details/09_08_011/]
 
P.194 掲載の参考文献
1) Wallensky LD, Narla M, Lux SEIV : Disorders of the red blood cell membrane. In : Blood : Principles and Practice of Hematology (ed by Handin RI, Lux SE, Stossel TP), 2nd ed, p1789-1809, Lippincott Williams & Wilkins, Philadelphia, 2003.
 
2) Kalfa TA : Diagnosis and clinical management of red cell membrane disorders. Hematology Am Soc Hematol Educ Program 2021 : 331-340, 2021.
PubMed
3) Risinger M, Kalfa TA : Red cell membrane disorders : structure meets function. Blood 136 : 1250-1261, 2020.
PubMed
4) Yawata Y : Hereditary elliptocytosis (HE). In : Cell Membrane : The Red Blood Cell as a Model, p213-237, Wiley Blackwell, Weinheim, 2003.
 
5) Yawata Y, Kanzaki A, Yawata A, et al : Hereditary Red Cell Membrane Disorders in Japan : Their Genotypic and Phenotypic Features in 1014 Cases Studied. Hematology 6 : 399-422, 2001.
PubMed
6) Kanzaki A, Ikeda A, Yawata Y : Membrane studies on rod-shaped red cells in hereditary elliptocytosis : least haemolysis and normal sodium influx with decreased membrane lipids. Br J Haematol 70 : 105-112, 1988.
PubMed
7) Reid ME, Mohandas N : Red blood cell blood group antigens : structure and function. Semin Hematol 41 : 93-117, 2004.
PubMed
8) Suemori S, Wada H, Nakanishi H, et al : Analysis of Hereditary Elliptocytosis with Decreased Binding of Eosin-5-maleimide to Red Blood Cells. Biomed Res Int 2015 : ID 451861, 2015.
 
9) King MJ, Behrens J, Rogers C, et al : Rapid flow cytometric test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia. Br J Haematol 111 : 924-933, 2000.
PubMed
10) King MJ, Jepson MA, Guest A, et al : Detection of hereditary pyropoikilocytosis by the eosin-5-maleimide (EMA) -binding test is attributable to a marked reduction in EMA-reactive transmembrane proteins. Int J Lab Hem atol 33 : 205-211, 2011.
 
11) King MJ, et al : Using the eosin-5-maleimide binding test in the differential diagnosis of hereditary spherocytosis and hereditary pyropoikilocytosis. Cytometry B Clin Cytom 74 : 244-250, 2008.
PubMed
12) Bruce LJ : Hereditary stomatocytosis and cation-leaky red cells--recent developments. Blood Cells Mol Dis 42 : 216-222, 2009.
PubMed
13) King MJ, Bruce L, Whiteway A : The mutant erythrocyte band 3 protein in Southeast Asian ovalocytosis does not bind eosin-5-maleimide. Int J Lab Hem atol 31 : 116-117, 2009.
PubMed
14) Jonsson JJ, Renieri A, Gallagher PG, et al : Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis : a new X linked contiguous gene deletion syndrome? J Med Genet 35 : 273-278, 1998.
PubMed
P.199 掲載の参考文献
1) Wallensky LD, Narla M, Lux SEIV : Disorders of the red blood cell membrane. In : Blood. Principles and Practice of Hematology, 2nd ed (ed by Handin RI, Lux SE, Stossel TP), p1817-1823, Lippincott Williams & Wilkins, Philadelphia, 2003.
 
2) Gallagher PG, Glader B : Chapter27 : Hereditary spherocytosis, hereditary elliptocytosis, and other disorders associated with abnormalities of the erythrocyte membrane In : Wintrobe's Clinical Hematology, 13th ed (ed by Greer JP, Arber DA), p722-724, Lippincott Williams & Wilkins, 2014.
 
3) Gallagher PG : Disorders of erythrocyte hydration. Blood 130 : 2699-2708, 2017.
PubMed
4) King MJ, Garcon L, Hoyer JD, et al : ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders. Int J Lab Hematol 37 : 304-325, 2015.
PubMed
5) Imashuku S, Muramatsu H, Sugihara T, et al : PIEZO1 gene mutation in a Japanese family with hereditary high phosphatidylcholine hemolytic anemia and hemochromatosis-induced diabetes mellitus. Int J Hematol 104 : 125-129, 2016.
 
6) Andolfo I, Russo R, Gambale A, et al : Hereditary stomatocytosis : An underdiagnosed condition. Am J Hematol 93 : 107-121, 2018.
PubMed
7) Andolfo I, Russo R, Rosato BE, et al : Genotype-phenotype correlation and risk stratification in a cohort of 123 hereditary stomatocytosis patients. Am J Hematol 93 : 1509-1517, 2018.
 
8) Picard V, Guitton C, Thuret I, et al : Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy : a retrospective series of 126 patients. Haematologica 104 : 1554-1564, 2019.
PubMed
9) Li J, Hou B, Tumova S, et al : Piezo1 integration of vascular architecture with physiological force. Nature 515 : 279-282, 2014.
 
10) Wang S, Chennupati R, Kaur H, et al : Endothelial cation channel PIEZO1 controls blood pressure by mediating flow-induced ATP release. J Clin Invest 126 : 4527-4536, 2016.
PubMed
11) Gallagher PG, Chang SH, Rettig MP, et al : Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 101 : 4625-4627, 2003.
PubMed
12) Bolton-Maggs PHB, Langer JC, Iolascon A, et al : Guidelines for the diagnosis and management of hereditary spherocytosis-2011 update. Br J Hematol 156 : 37-49, 2012.
 
13) Guizouarn H, Borgese F, Gabillat N, et al : South-east Asian ovalocytosis and the cryohydrocytosis form of hereditary stomatocytosis show virtually indistinguishable cation permeability defects. Br J Hematol 152 : 655-664, 2011.
 
14) Nakahara E, Yamamoto KS, Ogura H, et al : Variant spectrum of PIEZO1 and KCNN4 in Japanese patients with dehydrated hereditary stomatocytosis. Hum Genome Var 10 : 8, 2023.
PubMed
15) 小倉浩美, 菅野仁 : 先天性溶血性貧血の新知見. 血液内科 78 : 212-219, 2019.
 
P.204 掲載の参考文献
1) Zarkowsky HS, Mohandas N, Speaker CB, et al : A congenital haemolytic anaemia with thermal sensitivity of the erythrocyte membrane. Br J Haematol 29 : 537-543, 1975.
PubMed
2) Gallagher PG, Glader B : Hereditary spherocytosis, hereditary elliptocytosis, and other disorders associated with abnormalities of the erythrocyte membrane. In : Wintrobe's Clinical Hematology, 12th edition, Lippincott Williams & Wilkins, Philadelphia, 2009.
 
3) Coetzer T, Palek J, Lawler J, et al : Structural and functional heterogeneity of alpha spectrin mutations involving the spectrin heterodimer self-association site : relationships to hematologic expression of homozygous hereditary elliptocytosis and hereditary pyropoikilocytosis. Blood 75 : 2235-2244, 1990.
PubMed
4) 中西秀和, 和田秀穂, 末盛晋一郎, ほか : 日本における赤血球膜異常症-諸外国との比較-. 臨床血液 56 : 760-770, 2015.
 
5) Hanspal M, Hanspal JS, Sahr KE, et al : Molecular basis of spectrin deficiency in hereditary pyropoikilocytosis. Blood 82 : 1652-1660, 1993.
PubMed
6) Costa DB, Lozovatsky L, Gallagher PG, et al : A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred. Blood 106 : 4367-4369, 2005.
PubMed
7) Tolpinrud W, Maksimova YD, Forget BG, et al : Nonsense mutations of the alpha-spectrin gene in hereditary pyropoikilocytosis. Haematologica 93 : 1752-1754, 2008.
PubMed
8) Gallagher PG, Forget BG : Spectrin St Louis and the alpha LELY allele. Blood 84 : 1686-1687, 1994.
 
9) Niss O, Chonat S, Dagaonkar N, et al : Genotype-phenotype correlation in hereditary elliptocytosis and hereditary pyropoikilocytosis. Blood Cells Mo Dis 61 : 4-9, 2016.
 
10) Maillet P, Alloisio N, Morle L, et al : Spectrin mutations in hereditary elliptocytosis and hereditary spherocytosis. Hum Mutat 8 : 97-107, 1996.
PubMed
11) DePalma L, Luban NL : Hereditary pyropoikilocytosis. Clinical and laboratory analysis in eight infants and young children. Am J Dis Child 147 : 93-95, 1993.
PubMed
12) King MJ, Jepson MA, Guest A, et al : Detection of hereditary pyropoikilocytosis by the eosin-5-maleimide (EMA) -binding test is attributable to a marked reduction in EMA-reactive transmembrane proteins. Int J Lab Hematol 33 : 205-211, 2011.
PubMed
P.209 掲載の参考文献
1) Andolfo I, Russo R, Gambale A, et al : Hereditary stomatocytosis : An underdiagnosed condition. Am J Hematol 93 : 107-121, 2018.
PubMed
2) Kaufman HW, Niles JK, Gallagher DR, et al : Revised prevalence estimate of possible Hereditary Xerocytosis as derived from a large U.S. Laboratory database. Am J Hematol 93 : E9-E12, 2018.
PubMed
3) Andolfo I, Russo R, Gambale A, et al : New insights on hereditary erythrocyte membrane defects. Haematologica 101 : 1284-1294, 2016.
PubMed
4) Ma S, Dubin AE, Zhang Y, et al : A role of PIEZO1 in iron metabolism in mice and humans. Cell 184 : 969-982.e13, 2021.
 
5) Zarychanski R, Schulz VP, Houston BL, et al : Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis. Blood 120 : 1908-1915, 2012.
PubMed
6) Rapetti-Mauss R, Lacoste C, Picard V, et al : A mutation in the Gardos channel is associated with hereditary xerocytosis. Blood 126 : 1273-1280, 2015.
PubMed
7) Fermo E, Bogdanova A, Petkova-Kirova P, et al : "Gardos Channelopathy" : A variant of hereditary Stomatocytosis with complex molecular regulation. Sci Rep 7 : 1744, 2017.
 
8) Picard V, Guitton C, Thuret I, et al : Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy : a retrospective series of 126 patients. Haematologica 104 : 1554-1564, 2019.
PubMed
9) Andolfo I, Rosato BE, Manna F, et al : Gain-of-function mutations in PIEZO1 directly impair hepatic iron metabolism via the inhibition of the BMP/SMADs pathway. Am J Hematol 95 : 188-197, 2020.
PubMed
10) Andolfo I, Russo R, Rosato BE, et al : Genotype-phenotype correlation and risk stratification in a cohort of 123 hereditary stomatocytosis patients. Am J Hematol 93 : 1509-1517, 2018.
 
11) 菅野仁, 小倉浩美 : 網羅的遺伝子解析による先天性溶血性貧血診断の意義と課題. 臨床血液 62 : 472-479, 2021.
 
12) 槍澤大樹, 菅野仁, 大賀正一 : IX 先天性溶血性貧血. 遺伝性骨髄不全症診療ガイドライン 2023 (日本小児血液・がん学会編), p76-86, 診断と治療社, 2023.
 
13) Shander A, Sazama K : Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion 50 : 1144-1155, 2010.
PubMed
14) 輸血後鉄過剰症の診療参照ガイド, 令和4年度改定版. 厚生労働科学研究費補助金難治性疾患政策研究事業特発性造血障害に関する調査研究班, 2023.
 
15) Ballas SK, Zeidan AM, Duong VH, et al : The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia : A systematic review. Am J Hematol 93 : 943-952, 2018.
 
P.213 掲載の参考文献
1) Carton JP : RH blood group system and molecular basis of Rh-deficiency. Baillieres Best Pract Res Clin Haematol 12 : 655-689, 1999.
 
2) Ushiki T, Tsuneyama H, Masuko M, et al : Rh null phenotype caused by a RHAG mutation, c.945+1G>A, in the Japanese population. Transfusion 59 : 2519-2522, 2019.
PubMed
3) Tian L, Song N, Yao ZQ, et al : A family study of the Chinese Rhnull individual of the regulator type : a novel single missense mutation identified in RHAG gene. Transfusion 51 : 2686-2689, 2011.
PubMed
4) Junca TG, Pinilla JJ, Sanjuanelo M, et al : A novel mutation in RHAG causing Rh null phenotype in Colombia. Transfusion 61 : E62-E64, 2021.
PubMed
5) Cherif-Zahar B, Raynal V, Gane P, et al : Candidate gene acting as a suppressor of the RH locus in most cases of Rh-deficiency. Nat Genet 12 : 168-173, 1996.
PubMed
6) Kamesaki T, Iwamoto S, Kajii E, et al : A new mutation detected in RhAG of a Japanese family with Rh (mod) syndrome may form a longer RhAG protein. Transfusion 42 : 383-384, 2002.
 
7) Gomez-Torreiro E, Eiras-Martinez A, Rodriguez-Calvo MI, et al : Rh-null phenotype caused by a complete RHAG deletion. Transfusion 55 : 197-198, 2015.
PubMed
8) Kato-Yamazaki M, Okuda H, Kawano M, et al : Molecular genetic analysis of the Japanese amorph rh (null) phenotype. Transfusion 40 : 617-618, 2000.
PubMed
9) Cherif-Zahar B, Matassi G, Raynal V, et al : Molecular defects of the RHCE gene in Rh-deficient individuals of the amorph type. Blood 92 : 639-646, 1998.
PubMed
10) Huang CH, Chen Y, Reid ME, et al : Rhnull disease : the amorph type results from a novel double mutation in RhCe gene on D-negative background. Blood 92 : 664-671, 1998.
 
11) Rosa KA, Reid ME, Lomas-Francis C, et al : Rh null syndrome : identification of a novel mutation in RHce. Trasfusion 45 : 1796-1798, 2005.
 
12) Nance S, Scharberg EA, Thornton N, et al : International rare donor panels : a review. Vox Sang 110 : 209-218, 2016.
PubMed
13) Kuypers F, van Linde-Sibenius-Trip M, Roelofsen B, et al : Rhnull human erythrocytes have an abnormal membrane phospholipid organization. Biochem J 221 : 931-934, 1984.
PubMed
14) Ballas SK, Clark MR, Mohandas N, et al : Red cell membrane and cation deficiency in Rh null syndrome. Blood 63 : 1046-1055, 1984.
PubMed
P.220 掲載の参考文献
1) Yawata Y : Hereditary spherocytosis (HS). In : Cell Membrane : The Red Blood Cell as a Model (ed by Yawata Y), p173-212, Wiley-VCH, Darmstadt, 2003.
 
2) Perrotta S, Gallagher PG, Mohandas N : Hereditary spherocytosis. Lancet 372 : 1411-1426, 2008.
PubMed
3) Walensky LD, Nara M, Lux SE : Disorders of the red cell membrane. In : Blood : Principles and Practice of Hematology, 2nd ed (ed by Handin RI, Lux SE, Stossel TP), p1709-1858, Lippincott Williams and Wilkins, Philadelphia, 2003.
 
4) Eber SW, Gonzalez JM, Lux ML, et al : Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis. Nat Genet 13 : 214-218, 1996.
 
5) Nakanishi H, Kanzaki A, Yawata A, et al : Ankyrin gene mutations in japanese patients with hereditary spherocytosis. Int J Hematol 73 : 54-63, 2001.
PubMed
6) 中西秀和 : 日本人の遺伝性球状赤血球症におけるankyrin遺伝子変異の解析. 川崎医学会誌 28 : 73-82, 2002.
Medical*Online
7) Choi HS, Choi Q, Kim JA, et al : Molecular diagnosis of hereditary spherocytosis by multi-gene target sequencing in Korea : matching with osmotic fragility test and presence of spherocyte. Orphanet J Rare Dis 14 : 114, 2019.
PubMed
8) Aggarwal A, Jamwal M, Sharma P, et al : Deciphering molecular heterogeneity of Indian families with hereditary spherocytosis using targeted next-generation sequencing : First South Asian study. Br J Haematol 188 : 784-795, 2020.
PubMed
9) Peng GX, Yang WR, Zhao X, et al : The characteristic of hereditary spherocytosis related gene mutation in 37 Chinese hereditary spherocytisis patients. Zhonghua Xue Ye Xue Za Zhi 39 : 898-903, 2018.
PubMed
10) Yawata Y : Anchoring proteins. In : Cell Membrane : The Red Blood Cell as a Model (ed by Yawata Y), p115-132, Wiley-VCH, Darmstadt, 2003.
 
11) Sharma N, Bham K, Senapati S : Human ankyrins and their contribution to disease biology : An update. J Biosci 45 : 146, 2020.
PubMed
12) Lux SE 4th : Anatomy of the red cell membrane skeleton : unanswered questions. Blood 127 : 187-199, 2016.
PubMed
13) Hayette S, Carre G, Bozon M, et al : Two distinct truncated variants of ankyrin associated with hereditary spherocytosis. Am J Hematol 58 : 36-41, 1998.
PubMed
14) Ozcan R, Jarolim P, Lux SE, et al : Simultaneous (AC) n microsatellite polymorphism analysis and single-stranded conformation polymorphism screening is an efficient strategy for detecting ankyrin-1 mutations in dominant hereditary spherocytosis. Br J Haematol 122 : 669-677, 2003.
 
15) Leite RC, Basseres DS, Ferreira JS, et al : Low frequency of ankyrin mutations in hereditary spherocytosis : identification of three novel mutations. Hum Mutat 16 : 529, 2000.
PubMed
16) Gallagher PG, Nilson DG, Wong C, et al : A dinucleotide deletion in the ankyrin promoter alters gene expression, transcription initiation and TFIID complex formation in hereditary spherocytosis. Hum Mol Genet 14 : 2501-2509, 2005.
 
17) More TA, Devendra R, Dongerdiye R, et al : Targeted next-generation sequencing identifies novel deleterious variants in ANK1 gene causing severe hereditary spherocytosis in Indian patients : expanding the molecular and clinical spectrum. Mol Genet Genomics 298 : 427-439, 2023.
PubMed
18) van Vuren A, van der Zwaag B, Huisjes R, et al : The Complexity of Genotype-Phenotype Correlations in Hereditary Spherocytosis : A Cohort of 95 Patients : Genotype-Phenotype Correlation in Hereditary Spherocytosis. Hemasphere 3 : e276, 2019.
PubMed
19) Tole S, Dhir P, Pugi J, et al : Genotype-phenotype correlation in children with hereditary spherocytosis. Br J Haematol 191 : 486-496, 2020.
PubMed
P.226 掲載の参考文献
1) Walensky LD, Nara M, Lux SE : Disorders of the red cell membrane. In : Blood : Principles and Practice of Hematology, 2nd ed (ed by Handin RI, Lux SE, Stossel TP), p1709-1858, Lippincott Williams and Wilkins, Philadelphia, 2003.
 
2) Machnicka B, Czogalla A, Hryniewicz-Jankowska A, et al : Spectrins : a structural platform for stabilization and activation of membrane channels, receptors and transporters. Biochim Biophys Acta 1838 : 620-634, 2014.
PubMed
3) An X, Mohandas N : Disorders of red cell membrane. Br J Haematol 141 : 367-375, 2008.
PubMed
4) Da Costa L, Galimand J, Fenneteau O, et al : Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood Rev 27 : 167-178, 2013.
PubMed
5) Yawata Y : Abnormalities of skeletal proteins. In : Cell Membrane : The Red Blood Cell as a Model (ed by Yawata Y), p261-296, Wiley-VCH, Darmstadt, 2006.
 
6) Yawata Y, Kanzaki A, Yawata A, et al : Hereditary Red Cell Membrane Disorders in Japan : Their Genotypic and Phenotypic Features in 1014 Cases Studied. Hematology 6 : 399-422, 2001.
PubMed
7) Gallagher PG, Zhang Z, Morrow JS, et al : Mutation of a highly conserved isoleucine disrupts hydrophobic interactions in the alpha beta spectrin self-association binding site. Lab Invest 84 : 229-234, 2004.
PubMed
8) Parquet N, Devaux I, Boulanger L, et al : Identification of three novel spectrin alpha I/74 mutations in hereditary elliptocytosis : further support for a triple-stranded folding unit model of the spectrin heterodimer contact site. Blood 84 : 303-308, 1994.
PubMed
9) Coetzer TL, Sahr K, Prchal J, et al : Four different mutations in codon 28 of alpha spectrin are associated with structurally and functionally abnormal spectrin alpha I/74 in hereditary elliptocytosis. J Clin Invest 88 : 743-749, 1991.
PubMed
10) Floyd PB, Gallagher PG, Valentino LA, et al : Heterogeneity of the molecular basis of hereditary pyropoikilocytosis and hereditary elliptocytosis associated with increased levels of the spectrin alpha I/74-kilodalton tryptic peptide. Blood 78 : 1364-1372, 1991.
PubMed
11) Garbarz M, Lecomte MC, Feo C, et al : Hereditary pyropoikilocytosis and elliptocytosis in a white French family with the spectrin alpha I/74 variant related to a CGT to CAT codon change (Arg to His) at position 22 of the spectrin alpha I domain. Blood 75 : 1691-1698, 1990.
 
12) Maillet P, Alloisio N, Morle L, et al : Spectrin mutations in hereditary elliptocytosis and hereditary spherocytosis. Hum Mutat 8 : 97-107, 1996.
PubMed
13) Perrotta S, Miraglia del Giudice E, Alloisio N, et al : Mild elliptocytosis associated with the alpha 34 Arg→Trp mutation in spectrin Genova (alpha I/74). Blood 83 : 3346-3349, 1994.
 
14) Swierczek S, Agarwal AM, Naidoo K, et al : Novel exon 2 α spectrin mutation and intragenic crossover : three morphological phenotypes associated with four distinct α spectrin defects. Haematologica 98 : 1972-1979, 2013.
 
15) Morle L, Morle F, Roux AF, et al : Spectrin Tunis (Sp alpha I/78), an elliptocytogenic variant, is due to the CGG→TGG codon change (Arg→Trp) at position 35 of the alpha I domain. Blood 74 : 828-832, 1989.
 
16) Perrotta S, Iolascon A, De Angelis F, et al : Spectrin Anastasia (alpha I/78) : a new spectrin variant (alpha 45 Arg→Thr) with moderate elliptocytogenic potential. Br J Haematol 89 : 933-936, 1995.
 
17) Lecomte MC, Garbarz M, Grandchamp B, et al : Sp alpha I/78 : a mutation of the alpha I spectrin domain in a white kindred with HE and HPP phenotypes. Blood 74 : 1126-1133, 1989.
 
18) Morle L, Roux AF, Alloisio N, et al : Two elliptocytogenic alpha I/74 variants of the spectrin alpha I domain. Spectrin Culoz (GGT→GTT ; alpha I 40 Gly→Val) and spectrin Lyon (CTT→TTT ; alpha I 43 Leu→Phe). J Clin Invest 86 : 548-554, 1990.
 
19) He Y, Jia S, Dewan RK, et al : Novel mutations in patients with hereditary red blood cell membrane disorders using next-generation sequencing. Gene 627 : 556-562, 2017.
PubMed
20) Boulanger L, Dhermy D, Garbarz M, et al : A second allele of spectrin alpha-gene associated with the alpha I/65 phenotype (allele alpha Ponte de Sor). Blood 84 : 2056, 1994.
PubMed
21) Gallagher PG, Tse WT, Coetzer T, et al : A common type of the spectrin alpha I 46-50a-kD peptide abnormality in hereditary elliptocytosis and pyropoikilocytosis is associated with a mutation distant from the proteolytic cleavage site. Evidence for the functional importance of the triple helical model of spectrin. J Clin Invest 89 : 892-898, 1992.
PubMed
22) Sahr KE, Tobe T, Scarpa A, et al : Sequence and exon-intron organization of the DNA encoding the alpha I domain of human spectrin. Application to the study of mutations causing hereditary elliptocytosis. J Clin Invest 84 : 1243-1252, 1989.
 
23) Anil More T, Kedar P : Unravelling the genetic and phenotypic heterogeneity of SPTA1 gene variants in Hereditary Elliptocytosis and Hereditary Pyropoikilocytosis patients using next-generation sequencing. Gene 843 : 146796, 2022.
PubMed
24) Alloisio N, Wilmotte R, Morle L, et al : Spectrin Jendouba : an alpha II/31 spectrin variant that is associated with elliptocytosis and carries a mutation distant from the dimer self-association site. Blood 80 : 809-815, 1992.
PubMed
25) Lin PC, Chiou SS, Lin CY, et al : Whole-exome sequencing for the genetic diagnosis of congenital red blood cell membrane disorders in Taiwan. Clin Chim Acta 487 : 311-317, 2018.
PubMed
26) Ma S, Song K, Niu J : Analysis of SPTA1 gene mutations in a patient with hereditary elliptocytosis. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 35 : 703-706, 2018.
 
27) Hassoun H, Coetzer TL, Vassiliadis JN, et al : A novel mobile element inserted in the alpha spectrin gene : spectrin dayton. A truncated alpha spectrin associated with hereditary elliptocytosis. J Clin Invest 94 : 643-648, 1994.
 
28) Baklouti F, Marechal J, Wilmotte R, et al : Elliptocytogenic alpha I/36 spectrin Sfax lacks nine amino acids in helix 3 of repeat 4. Evidence for the activation of a cryptic 5'-splice site in exon 8 of spectrin alpha-gene. Blood 79 : 2464-2470, 1992.
PubMed
29) Roux AF, Morle F, Guetarni D, et al : Molecular basis of Sp alpha I/65 hereditary elliptocytosis in North Africa : insertion of a TTG triplet between codons 147 and 149 in the alpha-spectrin gene from five unrelated families. Blood 73 : 2196-2201, 1989.
PubMed
30) Iolascon A, King MJ, Robertson S, et al : A genomic deletion causes truncation of α-spectrin and ellipto-poikilocytosis. Blood Cells Mol Dis 46 : 195-200, 2011.
 
31) Gallagher PG, Roberts WE, Benoit L, et al : Poikilocytic hereditary elliptocytosis associated with spectrin Alexandria : an alpha I/50b Kd variant that is caused by a single amino acid deletion. Blood 82 : 2210-2215, 1993.
PubMed
32) Wilmotte R, Marechal J, Delaunay J : Mutation at position -12 of intron 45 (c→t) plays a prevalent role in the partial skipping of exon 46 from the transcript of allele alphaLELY in erythroid cells. Br J Haematol 104 : 855-859, 1999.
 
33) Wichterle H, Hanspal M, Palek J, et al : Combination of two mutant alpha spectrin alleles underlies a severe spherocytic hemolytic anemia. J Clin Invest 98 : 2300-2307, 1996.
PubMed
34) Gallagher PG, Maksimova Y, Lezon-Geyda K, et al : Aberrant splicing contributes to severe α-spectrin-linked congenital hemolytic anemia. J Clin Invest 129 : 2878-2887, 2019.
 
35) Tole S, Dhir P, Pugi J, et al : Genotype-phenotype correlation in chilren with hereditary spherocytosis. Br J of Haematol 191 : 486-496, 2020.
 
36) van Vuren A, van der Zwaag B, Huisjes R, et al : The Complexity of Genotype-Phenotype Correlations in Hereditary Spherocytosis : A Cohort of 95 Patients : Genotype-Phenotype Correlation in Hereditary Spherocytosis. Hemasphere 3 : e276, 2019.
PubMed
37) Choi HS, Choi Q, Kim JA, et al : Molecular diagnosis of hereditary spherocytosis by multi-gene target sequencing in Korea : matching with osmotic fragility test and presence of spherocyte. Orphanet J Rare Dis 14 : 114, 2019.
PubMed
38) Peng GX, Yang WR, Zhao X, et al : The characteristic of hereditary spherocytosis related gene mutation in 37 Chinese hereditary spherocytisis patients. Zhonghua Xue Ye Xue Za Zhi 39 : 898-903, 2018.
PubMed
39) Aggarwal A, Jamwal M, Sharma P, et al : Deciphering molecular heterogeneity of Indian families with hereditary spherocytosis using targeted next-generation sequencing : First South Asian study. Br J Haematol 188 : 784-795, 2020.
PubMed
40) Svidnicki MCCM, Zanetta GK, Congrains-Castillo A, et al : Targeted next-generation sequencing identified novel mutations associated with hereditary anemias in Brazil. Ann Hematol 99 : 955-962, 2020.
PubMed
41) Yamamoto KS, Utshigisawa T, Ogura H, et al : Clinical and genetic diagnosis of thirteen Japanese patients with hereditary spherocytosis. Hum Genome Var 9 : 1, 2022.
PubMed
42) Chonat S, Risinger M, Sakthivel H, et al : Corrigendum : The Spectrum of SPTA1-Associated Hereditary Spherocytosis. Front Physiol 10 : 00815, 2019.
PubMed
P.234 掲載の参考文献
1) Walensky LD, Nara M, Lux SE : Disorders of the red cell membrane. In : Blood : Principles and Practice of Hematology, 2nd ed (ed by Handin RI, Lux SE, Stossel TP), p1709-1858, Lippincott Williams and Wilkins, Philadelphia, 2003.
 
2) Machnicka B, Czogalla A, Hryniewicz-Jankowska A, et al : Spectrins : a structural platform for stabilization and activation of membrane channels, receptors and transporters. Biochim Biophys Acta 1838 : 620-634, 2014.
PubMed
3) An X, Mohandas N : Disorders of red cell membrane. Br J Haematol 141 : 367-375, 2008.
PubMed
4) Yawata Y : Abnormalities of skeletal proteins. In : Cell Membrane : The Red Blood Cell as a Model (ed by Yawata Y), p173-212, Wiley-VCH, Darmstadt, 2006.
 
5) Yawata Y : Skeletal proteins. In : Cell Membrane : The Red Blood Cell as a Model (ed by Yawata Y), p61-80, Wiley-VCH, Darmstadt, 2003.
 
6) Sahr KE, Coetzer TL, Moy LS, et al : Spectrin cagliari. an Ala→Gly substitution in helix 1 of beta spectrin repeat 17 that severely disrupts the structure and self-association of the erythrocyte spectrin heterodimer. J Biol Chem 268 : 22656-22662, 1993.
 
7) Dhermy D, Galand C, Bournier O, et al : Coinheritance of alpha-and beta-spectrin gene mutations in a case of hereditary elliptocytosis. Blood 92 : 4481-4482, 1998.
 
8) Gallagher PG, Weed SA, Tse WT, et al : Recurrent fatal hydrops fetalis associated with a nucleotide substitution in the erythrocyte beta-spectrin gene. J Clin Invest 95 : 1174-1182, 1995.
 
9) Parquet N, Devaux I, Boulanger L, et al : Identification of three novel spectrin alpha I/74 mutations in hereditary elliptocytosis : further support for a triple-stranded folding unit model of the spectrin heterodimer contact site. Blood 84 : 303-308, 1994.
PubMed
10) Tse WT, Lecomte MC, Costa FF, et al : Point mutation in the beta-spectrin gene associated with alpha I/74 hereditary elliptocytosis. Implications for the mechanism of spectrin dimer self-association. J Clin Invest 86 : 909-916, 1990.
PubMed
11) Qualtieri A, Pasqua A, Bisconte MG, et al : Spectrin Cosenza : a novel beta chain variant associated with Sp alphaI/74 hereditary elliptocytosis. Br J Haematol 97 : 273-278, 1997.
 
12) Maillet P, Inoue T, Kanzaki A, et al : Stop codon in exon 30 (E2069X) of beta-spectrin gene associated with hereditary elliptocytosis in spectrin Nagoya. Hum Mutat 8 : 366-368, 1996.
PubMed
13) Jarolim P, Wichterle H, Hanspal M, et al : Beta spectrin PRAGUE : a truncated beta spectrin producing spectrin deficiency, defective spectrin heterodimer self-association and a phenotype of spherocytic elliptocytosis. Br J Haematol 91 : 502-510, 1995.
 
14) Basseres DS, Pranke PH, Sales TS, et al : Beta-spectrin Campinas : a novel shortened beta-chain variant associated with skipping of exon 30 and hereditary elliptocytosis. Br J Haematol 97 : 579-585, 1997.
 
15) Yoon SH, Yu H, Eber S, et al : Molecular defect of truncated beta-spectrin associated with hereditary elliptocytosis. Beta-spectrin Gottingen. J Biol Chem 266 : 8490-8494, 1991.
PubMed
16) Gallagher PG, Tse WT, Costa F, et al : A splice site mutation of the beta-spectrin gene causing exon skipping in hereditary elliptocytosis associated with a truncated beta-spectrin chain. J Biol Chem 266 : 15154-15159, 1991.
 
17) Marechal J, Wada H, Koffa T, et al : Hereditary elliptocytosis associated with spectrin Le Puy in a Japanese family : ultrastructural aspect of the red cell skeleton. Eur J Haematol 52 : 92-98, 1994.
 
18) Garbarz M, Tse WT, Gallagher PG, et al : Spectrin Rouen (beta 220-218), a novel shortened beta-chain variant in a kindred with hereditary elliptocytosis. Characterization of the molecular defect as exon skipping due to a splice site mutation. J Clin Invest 88 : 76-81, 1991.
 
19) Garbarz M, Boulanger L, Pedroni S, et al : Spectrin beta Tandil, a novel shortened beta-chain variant associated with hereditary elliptocytosis is due to a deletional frameshift mutation in the beta-spectrin gene. Blood 80 : 1066-1073, 1992.
PubMed
20) Tse WT, Gallagher PG, Pothier B, et al : An insertional frameshift mutation of the beta-spectrin gene associated with elliptocytosis in spectrin nice (beta 220/216). Blood 78 : 517-523, 1991.
PubMed
21) Wilmotte R, Miraglia del Giudice E, Marechal J, et al : A deletional frameshift mutation in spectrin beta-gene associated with hereditary elliptocytosis in spectrin Napoli. Br J Haematol 88 : 437-439, 1994.
PubMed
22) Kanzaki A, Rabodonirina M, Yawata Y, et al : A deletional frameshift mutation of the beta-spectrin gene associated with elliptocytosis in spectrin Tokyo (beta 220/216). Blood 80 : 2115-2121, 1992.
PubMed
23) Ipsaro JJ, Harper SL, Messick TE, et al : Crystal structure and functional interpretation of the erythrocyte spectrin tetramerization domain complex. Blood 115 : 4843-4852, 2010.
PubMed
24) Hassoun H, Vassiliadis JN, Murray J, et al : Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 90 : 398-406, 1997.
PubMed
25) Tole S, Dhir P, Pugi J, et al : Genotype-phenotype correlation in children with hereditary spherocytosis. Br J of Haematol 191 : 486-496, 2020.
PubMed
26) van Vuren A, van der Zwaag B, Huisjes R, et al : The Complexity of Genotype-Phenotype Correlations in Hereditary Spherocytosis : A Cohort of 95 Patients : Genotype-Phenotype Correlation in Hereditary Spherocytosis. Hemasphere 3 : e276, 2019.
PubMed
27) Choi HS, Choi Q, Kim JA, et al : Molecular diagnosis of hereditary spherocytosis by multi-gene target sequencing in Korea : matching with osmotic fragility test and presence of spherocyte. Orphanet J Rare Dis 14 : 114, 2019.
PubMed
28) Peng GX, Yang WR, Zhao X, et al : The characteristic of hereditary spherocytosis related gene mutation in 37 Chinese hereditary spherocytisis patients. Zhonghua Xue Ye Xue Za Zhi 39 : 898-903, 2018.
PubMed
29) Aggarwal A, Jamwal M, Sharma P, et al : Deciphering molecular heterogeneity of Indian families with hereditary spherocytosis using targeted next-generation sequencing : First South Asian study. Br J Haematol 188 : 784-795, 2020.
PubMed
30) Svidnicki MCCM, Zanetta GK, Congrains-Castillo A, et al : Targeted next-generation sequencing identified novel mutations associated with hereditary anemias in Brazil. Ann Hematol 99 : 955-962, 2020.
PubMed
31) Yamamoto KS, Utshigisawa T, Ogura H, et al : Clinical and genetic diagnosis of thirteen Japanese patients with hereditary spherocytosis. Hum Genome Var 9 : 1, 2022.
PubMed
32) Maciag M, Plochocka D, Adamowicz-Salach A, et al : Novel beta-spectrin mutations in hereditary spherocytosis associated with decreased levels of mRNA. Br J Haematol 146 : 326-332, 2009.
PubMed
33) Hassoun H, Vassiliadis JN, Murray J, et al : Molecular basis of spectrin deficiency in beta spectrin Durham. A deletion within beta spectrin adjacent to the ankyrin-binding site precludes spectrin attachment to the membrane in hereditary spherocytosis. J Clin Invest 96 : 2623-2629, 1995.
 
34) Becker PS, Tse WT, Lux SE, et al : Beta spectrin kissimmee : a spectrin variant associated with autosomal dominant hereditary spherocytosis and defective binding to protein 4.1. J Clin Invest 92 : 612-616, 1993.
PubMed
P.239 掲載の参考文献
1) Luzzatto L : Disorders of the red cell membrane. In : Nathan and Oski's Hematology and Oncology of Infancy and Childhood, Eighth edition (ed by Orkin SH, Nathan DG, Ginsburg D, etal). p455-511. Saunders, Philadelphia, 2014.
 
2) Jarolim P, Wichterle H, Hanspal M, et al : Beta spectrin PRAGUE : a truncated beta spectrin producing spectrin deficiency, defective spectrin heterodimer self-association and a phenotype of spherocytic elliptocytosis. Br J Haematol 91 : 502-510, 1995.
 
3) Basseres DS, Pranke PH, Sales TS, et al : Beta-spectrin Campinas : a novel shortened beta-chain variant associated with skipping of exon 30 and hereditary elliptocytosis. Br J Haematol 97 : 579-585, 1997.
 
4) Daniels GL, Reid ME, Anstee DJ, et al : Transient reduction in erythrocyte membrane sialoglycoprotein beta associated with the presence of elliptocytes. Br J Haematol 70 : 477-481, 1988.
PubMed
5) Aksoy M, Erdem S, Dincol G, et al : Combination of hereditary elliptocytosis and hereditary spherocytosis. Clin Genet 6 : 46-50, 1974.
PubMed
6) Moyer JD, Nowak RB, Kim NE, et al : Tropomodulin 1-null mice have a mild spherocytic elliptocytosis with appearance of tropomodulin 3 in red blood cells and disruption of the membrane skeleton. Blood 116 : 2590-2599, 2010.
PubMed
7) Rice HE, Crary SE, Langer JC, et al : Comparative effectiveness of different types of splenectomy for children with congenital hemolytic anemias. J Pediatr 160 : 684-689.e13, 2012.
 
P.243 掲載の参考文献
1) 岩瀬孝志 : Stomatocytic elliptocytosis. 別冊日本臨牀血液症候群 (第2版) I, p235-237, 日本臨牀社, 2013.
 
2) Castelino D, Saul A, Myler P, et al : Ovalocytosis in Papua New Guinea : dominantly inherited resistance to malaria. Southeast Asian J Trop Med Public Health 12 : 549-555, 1981.
PubMed
3) 八幡義人 : 赤血球膜研究史-基礎科学と臨床医学が織りなす一世紀, p148-169, 医薬ジャーナル社, 2007.
 
4) 八幡義人 : 遺伝性楕円赤血球症 (HE). 三輸血液学 第3版 (浅野茂隆, 池田康夫, 内山卓監), p1067-1079, 文光堂, 2006.
 
5) Samuel E, et al : Disorder of the red cell membrane. In : Nathan and Oski's Hematology and Oncology of Infancy and Childhood (ed by Orkin SH, Nathan DG, Ginsburg D, et al), p515-579, Saunders, Philadelphia, 2014.
 
6) Liu SC, Zhai S, Palek J, et al : Molecular defect of the band 3 protein in southeast Asian ovalocytosis. N Engl J Med 323 : 1530-1538, 1990.
PubMed
7) Jarolim P, Palek J, Amato D, et al : Deletion in erythrocyte band 3 gene in malaria-resistant Southeast Asian ovalocytosis. Proc Natl Acad Sci U S A 88 : 11022-11026, 1991.
PubMed
8) Jarolim P, Palek J, Rubin HL, et al : Band 3 Tuscaloosa : Pro327→Arg327 substitution in the cytoplasmic domain of erythrocyte band 3 protein associated with spherocytic hemolytic anemia and partial deficiency of protein 4.2. Blood 80 : 523-529, 1992.
 
9) Hansen JC, Skalak R, Chien S, et al : Influence of network topology on the elasticity of the red blood cell membrane skeleton. Biophys J 72 : 2369-2381, 1997.
PubMed
10) Okoye VC, Bennett V : Plasmodium falciparum malaria : band 3 as a possible receptor during invasion of human erythrocytes. Science 227 : 169-171, 1985.
PubMed
11) Schofield AE, Reardon DM, Tanner MJ : Defective anion transport activity of the abnormal band 3 in hereditary ovalocytic red blood cells. Nature 355 : 836-838, 1992.
PubMed
12) Booth PB, Serjeantson S, Woodfield DG, et al : Selective depression of blood group antigens associated with hereditary ovalocytosis among melanesians. Vox Sang 32 : 99-110, 1977.
PubMed
13) Nixon CP, Satyagraha AW, Baird GL, et al : Accurate light microscopic diagnosis of South-East Asian ovalocytosis. Int J Lab Hematol 40 : 655-662, 2018.
PubMed
14) Tanner MJ, Bruce L, Martin PG, et al : Melanesian hereditary ovalocytes have a deletion in red cell band 3. Blood 78 : 2785-2786, 1991.
 
15) Laosombat V, Viprakasit V, Dissaneevate S, et al : Natural history of Southeast Asian Ovalocytosis during the first 3 years of life. Blood Cells Mol Dis 45 : 29-32, 2010.
PubMed
16) Liu SC, Jarolim P, Rubin HL, et al : The homozygous state for the band 3 protein mutation in Southeast Asian Ovalocytosis may be lethal. Blood 84 : 3590-3591, 1994.
PubMed
17) Wrong O, Bruce LJ, Unwin RJ, et al : Band 3 mutations, distal renal tubular acidosis, and Southeast Asian ovalocytosis. Kidney Int 62 : 10-19, 2002.
PubMed
P.246 掲載の参考文献
1) Yawata Y : Red cell membrane protein band 4.2 : Phenotypic, genetic and electron microscopic aspects. Biochim Biophys Acta 1204 : 131-148, 1994.
PubMed
2) Inoue T, Kanzaki A, Yawata A, et al : Uniquely higher incidence of isolated or combined deficiency of band 3 and/or band 4.2 as the pathogenesis of autosomal dominantly inherited hereditary spherocytosis in the Japanese population. Int J Hematol 60 : 227-238, 1994.
 
3) Bouhassira EE, Schwartz RS, Yawata Y, et al : An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2 NIPPON). Blood 79 : 1846-1854, 1992.
 
4) Yawata Y, Kanzaki A, Yawata A, et al : Hereditary Red Cell Membrane Disorders in Japan : Their Genotypic and Phenotypic Features in 1014 Cases Studied. Hematology 6 : 399-422, 2001.
PubMed
5) Yawata Y, Kanzaki A, Yawata A, et al : Characteristic features of the genotype and phenotype of hereditary spherocytosis in the Japanese population. Int J Hematol 71 : 118-135, 2000.
PubMed
6) 神崎暁郎, 井上孝文, 和田秀穂, ほか : 赤血球の形態異常を伴うその他の溶血貧血-とくにband 4.2完全欠損症について-. 日本臨牀 54 : 2492-2501, 1996.
 
7) Takaoka Y, Ideguchi H, Matsuda M, et al : A novel mutation in the erythrocyte protein 4.2 gene of Japanese patients with hereditary spherocytosis (protein 4.2 Fukuoka). Br J Haematol 88 : 527-533, 1994.
PubMed
8) Kanzaki A, Yawata Y, Yawata A, et al : Band 4.2 Komatsu : 523 GAT→TAT (175 Asp→Tyr) in exon 4 of the band 4.2 gene associated with total deficiency of band 4.2, hemolytic anemia with ovalostomatocytosis and marked disruption of the cytoskeletal network. Int J Hematol 61 : 165-178, 1995.
 
9) Matsuda M, Hatano N, Ideguchi H, et al : A novel mutation causing an aberrant splicing in the protein 4.2 gene associated with hereditary spherocytosis (protein 4.2 Notame). Hum Mol Genet 4 : 1187-1191, 1995.
 
10) Kanzaki A, Yasunaga M, Okamoto N, et al : Band 4.2 Shiga : 317 CGC→TGC in compound heterozygotes with 142 GCT→ACT results in band 4.2 deficiency and microspherocytosis. Br J Haematol 91 : 333-340, 1995.
 
11) Hammill AM, Risinger MA, Joiner CH, et al : Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient. Br J Haematol 152 : 780-783, 2011.
 
12) Bruce LJ, Ghosh S, King MJ, et al : Absence of CD47 in protein 4.2-deficient hereditary spherocytosis in man : an interaction between the Rh complex and the band 3 complex. Blood 100 : 1878-1885, 2002.
 
13) van den Akker E, Satchwell TJ, Pellegrin S, et al : Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2). Haematologica 95 : 1278-1286, 2010.
PubMed
14) Perrotta S, Iolascon A, Polito R, et al : 4.2 Nippon mutation in a non-Japanese patient with hereditary spherocytosis. Haematologica 84 : 660-662, 1999.
 
15) Inoue T, Kanzaki A, Yawata A, et al : Electron microscopic and physicobiochemical studies on disorganization of the cytoskeletal network and integral protein (band 3) in red cells of band 4.2 deficiency with a mutation (codon 142 : GCT→ACT). Int J Hematol 59 : 157-175, 1994.
 
P.251 掲載の参考文献
1) 八幡義人 : 赤血球膜構造と赤血球形態. 三輪血液病学 第3版 (浅野茂隆, 池田康夫, 内山卓監), p128-p155, 文光堂, 2006.
 
2) Wong P : A basis of the acanthocytosis in inherited and acquired disorders. Med Hypotheses 62 : 966-969, 2004.
 
3) Franceschi LD, Tomelleri C, Matte A, et al : Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity. Blood 118 : 5652-5663, 2011.
 
4) Bassen FA, Kornzweig AL : Malformation of the erythrocytes in a case of atypical retinitis pigmentosa. Blood 5 : 381-387, 1950.
 
5) Takahashi M, Okazaki H, Ohashi K, et al : Current Diagnosis and Management of Abetalipoproteinemia. J Atheroscler Thromb 28 : 1009-1019, 2021.
PubMed
6) Wetterau JR, Aggerbeck LP, Bouma ME, et al : Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258 : 999-1001, 1992.
PubMed
7) Jung HH, Danek A, Walker RH : Neuroacanthocytosis Syndromes. Orphanet J Rare Dis 6 : 68, 2011. [https://doi.org/10.1186/1750-1172-6-68]
 
8) Rampoldi L, Dobson-Stone C, Rubio JP, et al : A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet 28 : 119-120, 2001.
 
9) Ueno S, Maruki Y, Nakamura M, et al : The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat Genet 28 : 121-122, 2001.
PubMed
10) Kurano Y, Nakamura M, Ichiba M, et al : In vivo distribution and localization of chorein. Biochem Biophys Res Commun 353 : 431-435, 2007.
PubMed
11) Shiokawa N, Nakamura M, Sameshima M, et al : Chorein, the protein responsible for chorea-acanthocytosis, interacts with β-adducin and β-actin. Biochem Biophys Res Commun 441 : 96-101, 2013.
 
12) Lupo F, Tibaldi E, Matte A, et al : A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis. Blood 128 : 2976-2987, 2016.
 
13) 佐野輝, ほか : 神経有棘赤血球症診療の手引き. 厚生労働科学研究費補助金 (難治性疾患等政策研究事業) 神経変性疾患領域における基盤的調査研究班, 2017.
 
14) Roulis E, Hyland C, Flower R, et al : Molecular Basis and Clinical Overview of McLeod Syndrome Compared With Other Neuroacanthocytosis Syndromes : A Review. JAMA Neurol 75 : 1554-1562, 2018.
PubMed
15) Redman CM, Huima T, Robbins E, et al : Effect of phosphatidylserine on the shape of McLeod red cell acanthocytes. Blood 74 : 1826-1835, 1989.
PubMed
P.256 掲載の参考文献
1) Jaffe ER, Gottfried EL : Hereditary nonspherocytic hemolytic disease associated with an altered phospholipid composition of the erythrocytes. J Clin Invest 47 : 1375-1388, 1968.
PubMed
2) Yawata Y, Kanzaki A, Yawata A, et al : Hereditary Red Cell Membrane Disorders in Japan : Their Genotypic and Phenotypic Features in 1014 Cases Studied. Hematology 6 : 399-422, 2001.
PubMed
3) 菅野仁, 小倉浩美 : 網羅的遺伝子解析による先天性溶血性貧血診断の意義と課題. 臨床血液 62 : 472-479, 2021.
 
4) Shohet SB, Nathan DG, Livermore BM, et al : Hereditary hemolytic anemia associated with abnormal membrane lipid. II. Ion permeability and transport abnormalities. Blood 42 : 1-8, 1973.
PubMed
5) Clark MR, Shohet SB, Gottfried EL : Hereditary hemolytic disease with increased red blood cell phosphatidylcholine and dehydration : one, two, or many disorders? Am J Hematol 42 : 25-30, 1993.
PubMed
6) Delaunay J : The hereditary stomatocytoses : genetic disorders of the red cell membrane permeability to monovalent cations. Semin Hematol 41 : 165-172, 2004.
PubMed
7) Ellory JC, Gibson JS, Stewart GW : Pathophysiology of abnormal cell volume in human red cells. Contrib Nephrol 123 : 220-239, 1998.
PubMed
8) Shohet SB, Livermore BM, Nathan DG, et al : Hereditary hemolytic anemia associated with abnormal membrane lipids : mechanism of accumulation of phosphatidyl choline. Blood 38 : 445-456, 1971.
PubMed
9) Lane PA, Kuypers FA, Clark MR, et al : Excess of red cell membrane proteins in hereditary high-phosphatidylcholine hemolytic anemia. Am J Hematol 34 : 186-192, 1990.
PubMed
10) Albuisson J, Murthy SE, Bandell M, et al : Dehydrated hereditary stomatocytosis linked to gain-of-function mutations in mechanically activated PIEZO1 ion channels. Nat Commun 4 : 1884, 2013.
PubMed
11) Rapetti-Mauss R, Lacoste C, Picard V, et al : A mutation in the Gardos channel is associated with hereditary xerocytosis. Blood 126 : 1273-1280, 2015.
PubMed
12) Imashuku S, Muramatsu H, Sugihara T, et al : PIEZO1 gene mutation in a Japanese family with hereditary high phosphatidylcholine hemolytic anemia and hemochromatosis-induced diabetes mellitus. Int J Hematol 104 : 125-129, 2016.
 
13) Otsuka A, Sugihara T, Yawata Y : No beneficial effect of splenectomy in hereditary high red cell membrane phosphatidylcholine hemolytic anemia : clinical and membrane studies of 20 patients. Am J Hematol 34 : 8-14, 1990.
PubMed
14) Stewart GW, et al : Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol 93 : 303-310, 1996.
PubMed
15) Picard V, Guitton C, Thuret I, et al : Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy : a retrospective series of 126 patients. Haematologica 104 : 1554-1564, 2019.
PubMed
P.261 掲載の参考文献
1) Norum KR, Gjone E : Familial plasma lecithin : cholesterol acyltransfearse deficiency. Biochemical study of a new inborn error of metabolism. Scand J Clin Lab Invest 20 : 231-243, 1967.
 
2) McLean J, Fielding C, Drayna D, et al : Cloning and expression of human lecithin-cholesterol acyltransferase cDNA. Proc Natl Acad Sci USA 83 : 2335-2339, 1986.
PubMed
3) Murata Y, Maeda E, Yoshino G, et al : Cloning of rabbit LCAT cDNA : increase in LCAT mRNA abundance in the liver of cholesterol-fed rabbits. J Lipid Res 37 : 1616-1622, 1996.
PubMed
4) The Human Gene Mutation Database (HGMD). [http://www.hgmd.cf.ac.uk/ac/index.php]
PubMed
5) Kuroda M, Bujo H, Yokote K, et al : Current status of familial LCAT deficiency in Japan. J Atheroscler Thromb 28 : 679-691, 2021.
PubMed
6) Kuivenhoven JA, Pritchard H, Hill J, et al : The molecular pathology of lecithin : cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 38 : 191-205, 1997.
PubMed
7) Funke H, von Eckardstein A, Pritchard PH, et al : A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin : cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest 87 : 371-376, 1991.
PubMed
8) Myhre E, Gjone E, Flatmark A, et al : Renal failure in familial lecithin-cholesterol acyltransferase deficiency. Nephron 18 : 239-248, 1977.
PubMed
9) Hovig T, Gjone E : Familial plasma lecithin-cholesterol acyltransferase (LCAT) deficiency. Ultrastructural aspects of a new syndrome with particular reference to lesions in the kidneys and the spleen. Acta Pathol Microbiol Scand A 81 : 681-697, 1973.
PubMed
10) Imbasciati E, Paties C, Scarpioni L, et al : Renal lesions in familial lecithin-cholesterol acyltransferase deficiency. Ultrastructural heterogeneity of glomerular changes. Am J Nephrol 6 : 66-70, 1986.
PubMed
11) Gjone E : Familial lecithin : cholesterol acyltransferase deficiency-a clinical survey. Scand J Clin Lab Invest Suppl 137 : 73-82, 1974.
PubMed
12) Jacobsen CD, Gjone E, Hovig T : Sea-blue histiocytes in familial lecithin : cholesterol acyltransferase deficiency. Scand J Haematol 9 : 106-113, 1972.
PubMed
13) 前田英一 : 家族性lecithin-cholesterol acyltransferase (LCAT) 欠損症. 日本臨牀 59 (増刊 3 : 高脂血症 (下)) : 290-294, 2001.
 
14) Santamariana-Fojo S, et al : Lecithin cholesterol acyltransferase deficiency and fish eye disease. In : The Metabolic and Molecular Bases of Inherited Disease, 8th ed (ed by Scriver CR, Beaudet AL, Sly WS, Valle D, et al), p2817-2833, McGraw-Hill, New York, 2001.
 
15) Nagasaki T, Akanuma Y : A new colorimetric method for the determination of plasma lecithin-cholesterol acyltransferase activity. Clin Chim Acta 75 : 371-375, 1977.
PubMed
16) 板倉弘重, 伊藤洋, 斎藤康, ほか : リボソームを基質としたアナソルブLCATによるlecithin-cholesterol acyltransferase (LCAT) 活性の正常値の検討. 臨床検査機器・試薬 10 : 325-328, 1987.
 
17) Cooper RA, Diloy Puray M, Lando P, et al : An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease. J Clin Invest 51 : 3182-3192, 1972.
PubMed
18) Aso M, Yamamoto TT, Kuroda M, et al : First-in-human autologous implantation of genetically modified adipocytes expressing LCAT for the treatment of familial LCAT deficiency. Heliyon 8 : e11271, 2022.
PubMed
19) Holleboom AG, Kuivenhoven JA, van Olden CC, et al : Proteinuria in early childhood due to familial LCAT deficiency caused by loss of a disulfide bond in lecithin : cholesterol acyl transferase. Atherosclerosis 216 : 161-165, 2011.
PubMed
20) Yee MS, Pavitt DV, Richmond W, et al : Changes in lipoprotein profile and urinary albumin excretion in familial LCAT deficiency with lipid lowering therapy. Atherosclerosis 205 : 528-532, 2009.
PubMed
21) Aranda P, Valdivielso P, Pisciotta L, et al : Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs). Clin Nephrol 69 : 213-218, 2008.
PubMed
22) Miarka P, Idzior-Walus B, Kuzniewski M, et al : Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency. Clin Exp Nephrol 15 : 424-429, 2011.
 
P.267 掲載の参考文献
1) Grace RF, Barcellini W : Management of pyruvate kinase deficiency in children and adults. Blood 136 : 1241-1249, 2020.
PubMed
2) Bianchi P, Fermo E : Molecular heterogeneity of pyruvate kinase deficiency. Haematologica 105 : 2218-2228, 2020.
PubMed
3) Fattizzo B, Cavallaro F, Marcello APML, et al : Pyruvate Kinase Deficiency : Current Challenges and Future Prospects. J Blood Med 13 : 461-471, 2022.
PubMed
4) Chonat S, Eber SW, Holzhauer S, et al : Pyruvate kinase deficiency in children. Pediatr Blood Cancer 68 : e29148, 2021.
PubMed
5) Luke N, Hillier K, Al-Samkari H, et al : Updates and advances in pyruvate kinase deficiency. Trends Mol Med 29 : 406-418, 2023.
PubMed
6) Grace RF, Bianchi P, van Beers EJ, et al : Clinical spectrum of pyruvate kinase deficiency : data from the Pyruvate Kinase Deficiency Natural History Study. Blood 131 : 2183-2192, 2018.
PubMed
7) De SK : Mitapivat : A Novel Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency. Curr Med Chem, 2023. (DOI : 10.2174/0929867330666230430002709)
 
8) Schwartz JD, Barcellini W, Grace RF, et al : Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD) ? : Toward an expanded definition of severe PKD. Am J Hematol 97 : E120-E125, 2022.
PubMed
P.271 掲載の参考文献
1) Baughan MA, Valentine WN, Paglia DE, et al : Hereditary hemolytic anemia associated with glucosephosphate isomerase (GPI) deficiency-a new enzyme defect of human erythrocytes. Blood 32 : 236-249, 1968.
PubMed
2) Kugler W, Breme K, Laspe P, et al : Molecular basis of neurological dysfunction coupled with haemolytic anaemia in human glucose-6-phosphate isomerase (GPI) deficiency. Hum Genet 103 : 450-454, 1998.
PubMed
3) Repiso A, Oliva B, Vives-Corrons JL, et al : Red cell glucose phosphate isomerase (GPI) : a molecular study of three novel mutations associated with hereditary nonspherocytic hemolytic anemia. Hum Mutat 27 : 1159, 2006.
 
4) Beutler E, West C, Britton HA, et al : Glucosephosphate isomerase (GPI) deficiency mutations associated with hereditary nonspherocytic hemolytic anemia (HNSHA). Blood Cells Mol Dis 23 : 402-409, 1997.
PubMed
5) Kedar PS, Dongerdiye R, Chilwirwar P, et al : Glucose Phosphate Isomerase Deficiency : High Prevalence of p.Arg347His Mutation in Indian Population Associated with Severe Hereditary Non-Spherocytic Hemolytic Anemia Coupled with Neurological Dysfunction. Indian J Pediatr 86 : 692-699, 2019.
PubMed
6) Kugler W, Lakomek M : Glucose-6-phosphate isomerase deficiency. Baillieres Best Pract Res Clin Haematol 13 : 89-101, 2000.
PubMed
7) Manco L, Bento C, Victor BL, et al : Hereditary nonspherocytic hemolytic anemia caused by red cell glucose-6-phosphate isomerase (GPI) deficiency in two Portuguese patients : Clinical features and molecular study. Blood Cells Mol Dis 60 : 18-23, 2016.
PubMed
8) Zu Y, Wang H, Lin W, et al : Hereditary nonspherocytic hemolytic anemia caused by glucose-6-phosphate isomerase (GPI) deficiency in a Chinese patient : a case report. BMC Pediatr 22 : 461, 2022.
 
9) Fermo E, Vercellati C, Marcello AP, et al : Clinical and Molecular Spectrum of Glucose-6-Phosphate Isomerase Deficiency. Report of 12 New Cases. Front Physiol 10 : 467, 2019.
PubMed
10) Jamwal M, Aggarwal A, Das A, et al : Next-generation sequencing unravels homozygous mutation in glucose-6-phosphate isomerase, GPIc.1040G > A (p.Arg347His) causing hemolysis in an Indian infant. Clin Chim Acta 468 : 81-84, 2017.
 
11) Song Z, Wang K, Arthur DT, et al : Case report : Glucose 6-phosphate-isomerase deficiency combine with avascular necrosis of bilateral femoral head. Front Pediatr 10 : 909752, 2022.
PubMed
12) Sampagar A, Gosavi M, Kedar P, et al : Clinical, laboratory, and mutational profile of children with glucose phosphate isomerase deficiency : a single centre report. Int J Hematol 115 : 255-262, 2022.
PubMed
13) Fattizzo B, Giannotta JA, Cecchi N, et al : Confounding factors in the diagnosis and clinical course of rare congenital hemolytic anemias. Orphanet J Rare Dis 16 : 415, 2021.
PubMed
14) Park H, Haller J, Smith F, et al : Attenuation of Hemolysis Due to Glucose-6-Phosphate Isomerase Deficiency With Ketogenic Diet - A Case Report. Hemasphere 4 : e328, 2020.
 
P.276 掲載の参考文献
1) Beutler E : PGK deficiency. Br J Haematol 136 : 3-11, 2007.
PubMed
2) Baba K, Fukuda T, Furuta M, et al : A Mild Clinical Phenotype with Myopathic and Hemolytic Forms of Phosphoglycerate Kinase Deficiency (PGK Osaka) : A Case Report and Literature Review. Intern Med 61 : 3589-3594, 2022.
 
3) Pey AL, Mesa-Torres N, Chiarelli LR, et al : Structural and energetic basis of protein kinetic destabilization in human phosphoglycerate kinase 1 deficiency. Biochemistry 52 : 1160-1170, 2013.
PubMed
4) Matsumaru S, Oguni H, Ogura H, et al : A novel PGK1 mutation associated with neurological dysfunction and the absence of episodes of hemolytic anemia or myoglobinuria. Intractable Rare Dis Res 6 : 132-136, 2017.
PubMed
5) Baba S, Kobayashi A, Yokoyama H, et al : Slowly progressive leukodystrophy in an adolescent male with phosphoglycerate kinase deficiency. Brain Dev 40 : 150-154, 2018.
 
6) Echaniz-Laguna A, Nadjar Y, Behin A, et al : Phosphoglycerate kinase deficiency : A nationwide multicenter retrospective study. J Inherit Metab Dis 42 : 803-808, 2019.
PubMed
7) Lyapichev KA, Muthukumar A : Peripheral blood smear in a patient with phosphoglycerate kinase 1 mutation. Blood 139 : 2084, 2022.
 
8) Ward SK, Stevens CA, Keates-Baleeiro J, et al : Therapeutic Benefit of Blood Transfusion in a Patient With Novel PGK1 Mutation (c.461T>C [p.L154P]). J Pediatr Hematol Oncol 42 : e228-e230, 2020.
 
P.278 掲載の参考文献
1) Schneider AS : Triosephosphate isomerase deficiency : historical perspectives and molecular aspects. Baillieres Best Pract Res Clin Haematol 13 : 119-140, 2000.
PubMed
2) Arya R, Lalloz MR, Bellingham AJ, et al : Evidence for founder effect of the Glu104Asp substitution and identification of new mutations in triosephosphate isomerase deficiency. Hum Mutat 10 : 290-294, 1997.
PubMed
3) Roland BP, Amrich CG, Kammerer CJ, et al : Triosephosphate isomerase I170V alters catalytic site, enhances stability and induces pathology in a Drosophila model of TPI deficiency. Biochim Biophys Acta 1852 : 61-69, 2015.
 
4) Roland BP, Richards KR, Hrizo SL, et al : Missense variant in TPI1 (Arg189Gln) causes neurologic deficits through structural changes in the triosephosphate isomerase catalytic site and reduced enzyme levels in vivo. Biochim Biophys Acta Mol Basis Dis 1865 : 2257-2266, 2019.
PubMed
5) 菅野仁, 小倉浩美 : 網羅的遺伝子解析による先天性溶血性貧血診断の意義と課題. 臨床血液 62 : 472-479, 2021.
 
6) Vogt A, Eicher SL, Myers TD, et al : A High-Content Screening Assay for Small Molecules That Stabilize Mutant Triose Phosphate Isomerase (TPI) as Treatments for TPI Deficiency. SLAS Discov 26 : 1029-1039, 2021.
PubMed
P.282 掲載の参考文献
1) Murakami K, Kanno H, Miwa S, et al : Human HKR isozyme : organization of the hexokinase I gene, the erythroid-specific promoter, and transcription initiation site. Mol Genet Metab 67 : 118-130, 1999.
PubMed
2) Hantke J, Chandler D, King R, et al : A mutation in an alternative untranslated exon of hexokinase 1 associated with hereditary motor and sensory neuropathy-Russe (HMSNR). Eur J Hum Genet 17 : 1606-1614, 2009.
 
3) Kanno H, Murakami K, Hariyama Y, et al : Homozygous intragenic deletion of type-1 hexokinase gene causes lethal hemolytic anemia of the affected fetus. Blood 100 : 1930, 2002.
PubMed
4) van Wijk R, Rijksen G, Huizinga EG, et al : HK Utrecht : missense mutation in the active site of human hexokinase associated with hexokinase deficiency and severe nonspherocytic hemolytic anemia. Blood 101 : 345-347, 2003.
PubMed
5) Bianchi M, Magnani M : Hexokinase mutations that produce nonspherocytic hemolytic anemia. Blood Cells Mol Dis 21 : 2-8, 1995.
PubMed
6) de Vooght KM, van Solinge WW, van Wesel AC, et al : First mutation in the red blood cell-specific promoter of hexokinase combined with a novel missense mutation causes hexokinase deficiency and mild chronic hemolysis. Haematologica 94 : 1203-1210, 2009.
PubMed
7) Koralkova P, Mojzikova R, van Oirschot B, et al : Molecular characterization of six new cases of red blood cell hexokinase deficiency yields four novel mutations in HK1. Blood Cells Mol Dis 59 : 71-76, 2016.
PubMed
8) Jamwal M, Aggarwal A, Palodi A, et al : A nonsense variant in the Hexokinase 1 gene (HK1) causing severe non spherocytic haemolytic anaemia : genetic analysis exemplifies ambiguity due to multiple isoforms. Br J Haematol 186 : e142-e145, 2019.
PubMed
9) Khazal S, Polishchuk V, Manwani D, et al : Allogeneic bone marrow transplantation for treatment of severe hemolytic anemia attributable to hexokinase deficiency. Blood 128 : 735-737, 2016.
PubMed
10) Sullivan LS, Koboldt DC, Bowne ST, et al : A dominant mutation in hexokinase 1 (HK1) causes retinitis pigmentosa. Invest Ophthalmol Vis Sci 55 : 7147-7158, 2014.
 
11) Okur V, Cho MT, van Wijk R, et al : De novo variants in HK1 associated with neurodevelopmental abnormalities and visual impairment. Eur J Hum Genet 27 : 1081-1089, 2019.
PubMed
P.284 掲載の参考文献
1) Kishi H, Mukai T, Hirono A, et al : Human aldolase A deficiency associated with a hemolytic anemia : thermolabile aldolase due to a single base mutation. Proc Natl Acad Sci U S A 84 : 8623-8627, 1987.
PubMed
2) Hurst JA, Baraitser M, Winter RM : A syndrome of mental retardation, short stature, hemolytic anemia, delayed puberty, and abnormal facial appearance : similarities to a report of aldolase A deficiency. Am J Med Genet 28 : 965-970, 1987.
PubMed
3) Takasaki Y, Takahashi I, Mukai T, et al : Human aldolase A of a hemolytic anemia patient with Asp-128→Gly substitution : characteristics of an enzyme generated in E. coli transfected with the expression plasmid pHAAD128G. J Biochem 108 : 153-157, 1990.
 
4) Yao DC, Tolan DR, Murray MF, et al : Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA (Arg303X/Cys338Tyr). Blood 103 : 2401-2403, 2004.
PubMed
5) Papadopoulos C, Svingou M, Kekou K, et al : Aldolase A deficiency : Report of new cases and literature review. Mol Genet Metab Rep 27 : 100730, 2021.
PubMed
6) Kara E, Kor D, Bulut FD, et al : Glycogen storage disease type XII ; an ultra rare cause of hemolytic anemia and rhabdomyolysis : one new case report. J Pediatr Endocrinol Metab 34 : 1335-1339, 2021.
PubMed
7) Santoro L, Pjetraj D, Velmishi V, et al : A new phenotype of aldolase a deficiency in a 14 year-old boy with epilepsy and rhabdomyolysis-case report. Ital J Pediatr 48 : 39, 2022.
 
P.289 掲載の参考文献
1) Tarui S, Okuno G, Ikura Y, et al : phosphofructokinase deficiency in skeletai muscle. A new type of glycogenosis. Biochem Biophys Res Commun 19 : 517-523, 1965.
 
2) 垂井清一郎 : 6. 垂井病 (筋PFK 欠損症). 日本内科学会雑誌 91 : 1145-1148, 2002.
 
3) Nakajima H, Raben N, Hamaguchi T, et al : Phosphofructokinase deficiency ; past, present and future. Curr Mol Med 2 : 197-212, 2002.
PubMed
4) Lucia A, Martinuzzi A, Nogales-Gadea G, et al : Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group. Neuromuscul Disord 31 : 1296-1310, 2021.
 
5) Sharma PM, Reddy GR, Vora S, et al : Cloning and expression of a human muscle phosphofructokinase cDNA. Gene 77 : 177-183, 1989.
PubMed
6) 中島弘 : 糖原病の遺伝子診断ホスホフルクトキナーゼ欠損症遺伝子診断のあゆみ. 医学のあゆみ 181 : 493-496, 1997.
 
7) Nakajima H, Kono N, Yamasaki T, et al : Genetic defect in muscle phosphofructokinase deficiency. Abnormal splicing of the muscle phosphofructokinase gene due to a point mutation at the 5'-splice site. J Biol Chem 265 : 9392-9395, 1990.
PubMed
8) Raben N, Sherman J, Miller F, et al : A 5' splice junction mutation leading to exon deletion in an Ashkenazic Jewish family with phosphofructokinase deficiency (Tarui disease). J Biol Chem 268 : 4963-4967, 1993.
 
9) Musumeci O, Bruno C, Mongini T, et al : Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord 22 : 325-330, 2012.
PubMed
10) Vora S : Isozymes of phosphofructokinase. Isozymes Curr Top Biol Med Res 6 : 119-167, 1982.
PubMed
11) 山崎知行, 中島弘 : 遺伝子異常と高尿酸血症及び低尿酸血症筋PFK欠損症. 高尿酸血症と痛風 10 : 25-31, 2002.
 
12) 嶺尾郁夫, 出口有近, 岡内幸義 : 高尿酸血症・低尿酸血症-最近の診断と治療-高尿酸血症の臨床高尿酸血症の病理・病態二次性高尿酸血症 (産生過剰型・排泄低下型・混合型) 糖原病 (I, III, V, VII型). 日本臨牀 74 (増刊 9) : 136-140, 2016.
 
13) Toyoda H, Nakase T, Tomeoku M, et al : Improvement of hemolysis in muscle phosphofructokinase deficiency by restriction of exercise. Intern Med 35 : 222-226, 1996.
PubMed
14) 小児慢性特定疾病情報センター. 糖原病VII型診断の手引き. [https://www.shouman.jp/disease/instructions/08_05_071/] (2023.5.8 アクセス)
 
15) 新生児マススクリーニング対象疾患等診療ガイドライン 2019 (日本先天代謝異常学会編) : 糖原病と糖新生異常症 : 筋型糖原病. p305-309, 診断と治療社, 2019.
 
P.293 掲載の参考文献
1) George DL, Francke U : Gene dose effect : regional mapping of human glutathione reductase on chromosome 8. Cytogenet Cell Genet 17 : 282-286, 1976.
PubMed
2) Nevin NC, Morrison PJ, Jones J, et al : Inverted tandem duplication of 8p12→p23.1 in a child with increased activity of glutathione reductase. J Med Genet 27 : 135-136, 1990.
 
3) Krauth-Siegel RL, Blatterspiel R, Saleh M, et al : Glutathione reductase from human erythrocytes. The sequences of the NADPH domain and of the interface domain. Eur J Biochem 121 : 259-267, 1982.
PubMed
4) Tamura T, McMicken HW, Smith CV, et al : Gene structure for mouse glutathione reductase, including a putative mitochondrial targeting signal. Biochem Biophys Res Commun 237 : 419-422, 1997.
PubMed
5) Kelner MJ, Montoya MA : Structural organization of the human glutathione reductase gene : determination of correct cDNA sequence and identification of a mitochondrial leader sequence. Biochem Biophys Res Commun 269 : 366-368, 2000.
PubMed
6) Loehr GW, Waller HD : A new enzymopenic hemolytic anemia with glutathione reductase deficiency. Med Klin 57 : 1521-1525, 1962.
PubMed
7) Loos H, Roos D, Weening R, et al : Familial deficiency of glutathione reductase in human blood cells. Blood 48 : 53-62, 1976.
PubMed
8) Kamerbeek NM, van Zwieten R, de Boer M, et al : Molecular basis of glutathione reductase deficiency in human blood cells. Blood 109 : 3560-3566, 2007.
PubMed
9) Roos D, Weening RS, Voetman AA, et al : Protection of phagocytic leukocytes by endogenous glutathione : studies in a family with glutathione reductase deficiency. Blood 53 : 851-866, 1979.
 
10) Mojzikova R, Dolezel P, Pavlicek J, et al : Partial glutathione reductase deficiency as a cause of diverse clinical manifestations in a family with unstable hemoglobin (Hemoglobin Hana, β63 (E7) His-Asn). Blood Cells Mol Dis 45 : 219-222, 2010.
 
P.296 掲載の参考文献
1) Kosower NS, Kosower EM : The glutathione status of cells. Int Rev Cytol 54 : 109-160, 1978.
PubMed
2) Meister A : Glutathione metabolism and its selective modification. J Biol Chem 263 : 17205-17208, 1988.
PubMed
3) Jones DP : Redox potential of GSH/GSSG couple : assay and biological significance. Methods Enzymol 348 : 93-112, 2002.
PubMed
4) Boivin P, Galand C : Glutathione synthesis during congenital hemolytic anemia with reduced glutathione deficiency. Congenital erythrocytic glutathione-synthetase deficiency?. Nouv Rev Fr Hematol 5 : 707-720, 1965.
PubMed
5) Mohler DN, Majerus PW, Minnich V, et al : Glutathione synthetase deficiency as a cause of hereditary hemolytic disease. N Engl J Med 283 : 1253-1257, 1970.
PubMed
6) Jellum E, Kluge T, Borresen HC, et al : Pyroglutamic aciduria--a new inborn error of metabolism. Scand J Clin Lab Invest 26 : 327-335, 1970.
PubMed
7) Larsson A, Anderson ME : Glutathione synthetase deficiency and other disorders of the gamma-glutamyl cycle. In : The Metabolic and Molecular Bases of Inherited Disease, 8th ed (ed by Scriver CR, Beaudet AL, Sly WS, et al), p2205-2216, McGraw-Hill, New York, 2001.
 
8) Njalsson R : Glutathione synthetase deficiency. Cell Mol Life Sci 62 : 1938-1945, 2005.
PubMed
9) Xia H, Ye J, Wang L, et al : A case of severe glutathione synthetase deficiency with novel GSS mutations. Braz J Med Biol Res 51 : e6853, 2018.
 
10) Hirono A, Iyori H, Sekine I, et al : Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency. Blood 87 : 2071-2074, 1996.
PubMed
11) Ristoff E, Mayatepek E, Larsson A : Long-term clinical outcome in patients with glutathione synthetase deficiency. J Pediatr 139 : 79-84, 2001.
PubMed
12) Njalsson R, Ristoff E, Carlsson K, et al : Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase deficiency. Hum Genet 116 : 384-389, 2005.
PubMed
13) Atwal PS, Medina CR, Burrage LC, et al : Nineteen-year follow-up of a patient with severe glutathione synthetase deficiency. J Hum Genet 61 : 669-672, 2016.
PubMed
14) Ekuni S, et al : Severe hemolytic anemia and metabolic acidosis at birth with glutathione synthetase deficiency and progressive neurological symptoms on follow-up. Am J Case Rep 24 : e938396, 2023.
PubMed
15) Ristoff E, Larsson A : Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis 2 : 16, 2007.
 
16) Gunduz M, Unal O, Kavurt S, et al : Clinical findings and effect of sodium hydrogen carbonate in patients with glutathione synthetase deficiency. J Pediatr Endocrinol Metab 29 : 481-485, 2016.
PubMed
17) Boxer LA, Oliver JM, Spielberg SP, et al : Protection of granulocytes by vitamin E in glutathione synthetase deficiency. N Engl J Med 301 : 901-905, 1979.
PubMed
18) Pejaver RK, Watson AH : High-dose vitamin E therapy in glutathione synthetase deficiency. J Inherit Metab Dis 17 : 749-750, 1994.
PubMed
P.301 掲載の参考文献
1) Kosower NS, Kosower ES : The glutathione-glutathione disulfide system. In : Free Radicals in Biology (ed by Pryor WA), Academic Press, New York, 1976.
 
2) Meister A, Anderson ME : Glutathione. Annu Rev Biochem 52 : 711-760, 1983.
PubMed
3) Ristoff E, Augustson C, Geissler J, et al : A missense mutation in the heavy subunit of gamma-glutamylcysteine synthetase gene causes hemolytic anemia. Blood 95 : 2193-2196, 2000.
 
4) Richards F 2nd, Cooper MR, Pearce LA, et al : Familial spinocerebellar degeneration, hemolytic anemia, and glutathione deficiency. Arch Intern Med 134 : 534-537, 1974.
PubMed
5) Hamilton D, Wu JH, Alaoui-Jamali M, et al : A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production. Blood 102 : 725-730, 2003.
 
6) Beutler E, Gelbart T, Kondo T, et al : The molecular basis of a case of gamma-glutamylcysteine synthetase deficiency. Blood 94 : 2890-2894, 1999.
PubMed
7) Hirono A, Iyori H, Sekine I, et al : Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency. Blood 87 : 2071-2074, 1996.
PubMed
8) Beutler E, Moroose R, Kramer L, et al : Gamma-glutamylcysteine synthetase deficiency and hemolytic anemia. Blood 75 : 271-273, 1990.
PubMed
9) Konrad PN, Richards F 2nd, Valentine WN, et al : γ-Glutamyl-cysteine synthetase deficiency. A cause of hereditary hemolytic anemia. N Engl J Med 286 : 557-561, 1972.
 
10) Manu Pereira M, Gelbart T, Ristoff E, et al : Chronic non-spherocytic hemolytic anemia associated with severe neurological disease due to gamma-glutamylcysteine synthetase deficiency in a patient of Moroccan origin. Haematologica 92 : e102-105, 2007.
 
11) Almusafri F, Elamin HE, Khalaf TE, et al : Clinical and molecular characterization of 6 children with glutamate-cysteine ligase deficiency causing hemolytic anemia. Blood Cells Mol Dis 65 : 73-77, 2017.
PubMed
12) Ristoff E, Larsson A : Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis 2 : 16, 2007.
 
P.304 掲載の参考文献
1) Mills GC : Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown. J Biol Chem 229 : 189-197, 1957.
PubMed
2) 藤井寿一 : 赤血球の代謝. 三輪血液病学 第3版 (浅野茂隆, 池田康夫, 内山卓監), p214-220, 文光堂, 2006.
 
3) Mueller S, Riedel HD, Stremmel W : Direct evidence for catalase as the predominant H2O2-removing enzyme in human erythrocytes. Blood 90 : 4973-4978, 1997.
PubMed
4) Necheles TF, Boles TA, Allen DM : Erythrocyte glutathione-peroxidase deficiency and hemolytic disease of the newborn infant. J Pediatr 72 : 319-324, 1968.
 
5) Nishimura Y, Chida N, Hayashi T, et al : Homozygous glutathione-peroxidase deficiency of erythrocytes and leukocytes. Tohoku J Exp Med 108 : 207-217, 1972.
PubMed
6) Brigelius-Flohe R, Flohe L : Regulatory Phenomena in the Glutathione Peroxidase Superfamily. Antioxid Redox Signal 33 : 498-516, 2020.
PubMed
7) Whaun JM, Oski FA : Relation of red blood cell glutathione peroxidase to neonatal jaundice. J Pediatr 76 : 555-560, 1970.
PubMed
8) Beutler E, Matsumoto F : Ethnic variation in red cell glutathione peroxidase activity. Blood 46 : 103-110, 1975.
PubMed
9) Yang J, Wang T, Wu C, et al : Selenium level surveillance for the year 2007 of Keshan disease in endemic areas and analysis on surveillance results between 2003 and 2007. Biol Trace Elem Res 138 : 53-59, 2010.
PubMed
10) Thomson CD, Rea HM, Doesburg VM, et al : Selenium concentrations and glutathione peroxidase activities in whole blood of New Zealand residents. Br J Nutr 37 : 457-460, 1977.
PubMed
11) Cohen HJ, Brown MR, Hamilton D, et al : Glutathione peroxidase and selenium deficiency in patients receiving home parenteral nutrition : time course for development of deficiency and repletion of enzyme activity in plasma and blood cells. Am J Clin Nutr 49 : 132-139, 1989.
PubMed
12) Jablonska E, Gromadzinska J, Reszka E, et al : Association between GPx1 Pro198Leu polymorphism, GPx1 activity and plasma selenium concentration in humans. Eur J Nutr 48 : 383-386, 2009.
PubMed
13) Hopkins J, Tudhope GR : Glutathione peroxidase in human red cells in health and disease. Br J Haematol 25 : 563-575, 1973.
PubMed
14) Shukla VK, Jensen GE, Clausen J : Erythrocyte glutathione perioxidase deficiency in multiple sclerosis. Acta Neurol Scand 56 : 542-550, 1977.
PubMed
15) Zachara BA, Gromadzinska J, Wasowicz W, et al : Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease : a review. Acta Biochim Pol 53 : 663-677, 2006.
PubMed
16) Takata Y, King IB, Lampe JW, et al : Genetic variation in GPX1 is associated with GPX1 activity in a comprehensive analysis of genetic variations in selenoenzyme genes and their activity and oxidative stress in humans. J Nutr 142 : 419-426, 2012.
 
17) Arsova-Sarafinovska Z, Matevska N, Eken A, et al : Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk. Int Urol Nephrol 41 : 63-70, 2009.
PubMed
18) Necheles TF, Maldonado N, Barquet-Chediak A, et al : Homozygous erythrocyte glutathione-peroxidase deficiency : clinical and biochemical studies. Blood 33 : 164-169, 1969.
PubMed
19) Boivin P, Galand C, Hakim J, et al : Anemie hemolytique avec deficit en glutathione-peroxidase chez un adulte. Enzymol Biol Clin (Basel) 10 : 68-80, 1969.
PubMed
20) Boivin P, Galand C, Hakim J, et al : Deficit en glutathione-peroxidase erythrocytaire et anemie hemolytique medicamenteuse : Une nouvelle observation. Presse Med (1983) 78 : 171-174, 1970.
 
21) Steinberg M, Brauer MJ, Necheles TF : Acute hemolytic anemia associated with erythrocyte glutathione-peroxidase deficiency. Arch Intern Med 125 : 302-303, 1970.
PubMed
22) Necheles TF, Steinberg MH, Cameron D : Erythrocyte glutathione-peroxidase deficiency. Br J Haematol 19 : 605-612, 1970.
 
23) Gondo H, Ideguchi H, Hayashi S, et al : Acute hemolysis in glutathione peroxidase deficiency. Int J Hematol 55 : 215-218, 1992.
PubMed
24) Yamamoto M, Suzuki N, Hatakeyama N, et al : Carbamazepine-induced hemolytic and aplastic crises associated with reduced glutathione peroxidase activity of erythrocytes. Int J Hematol 86 : 325-328, 2007.
PubMed
25) Johnson RM, Goyette G Jr, Ravindranath Y, et al : Red cells from glutathione peroxidase-1-deficient mice have nearly normal defenses against exogenous peroxides. Blood 96 : 1985-1988, 2000.
PubMed
P.308 掲載の参考文献
1) Beutler E, Carson D, Dannawi H, et al : Metabolic compensation for profound erythrocyte adenylate kinase deficiency. A hereditary enzyme defect without hemolytic anemia. J Clin Invest 72 : 648-655, 1983.
PubMed
2) Szeinberg A, Kahana D, Gavendo S, et al : Hereditary deficiency of adenylate kinase in red blood cell. Acta Haematol 42 : 111-126, 1969.
PubMed
3) Boivin P, Galand C, Hakim J, et al : Congenital deficiency erythrocyte adenylate-kinase. Presse Med 78 : 1443, 1970.
PubMed
4) Miwa S, Fujii H, Tani K, et al : Red cell adenylate kinase deficiency associated with hereditary nonspherocytic hemolytic anemia : clinical and biochemical studies. Am J Hematol 14 : 325-333, 1983.
PubMed
5) Matsuura S, Igarashi M, Tanizawa Y, et al : Human adenylate kinase deficiency associated with hemolytic anemia. A single base substitution affecting solubility and catalytic activity of the cytosolic adenylate kinase. J Biol Chem 264 : 10148-10155, 1989.
PubMed
6) Lachant NA, Zerez CR, Barredo J, et al : Hereditary erythrocyte adenylate kinase deficiency : a defect of multiple phosphotransferases? Blood 77 : 2774-2784, 1991.
PubMed
7) Bianchi P, Zappa M, Bredi E, et al : A case of complete adenylate kinase deficiency due to a nonsense mutation in AK-1 gene (Arg 107→Stop, CGA→TGA) associated with chronic haemolytic anaemia. Br J Haematol 105 : 75-79, 1999.
 
8) Fermo E, Bianchi P, Vercellati C, et al : A new variant of adenylate kinase (delG138) associated with severe hemolytic anemia. Blood Cells Mol Dis 33 : 146-149, 2004.
PubMed
9) Corrons JL, Garcia E, Tusell JJ, et al : Red cell adenylate kinase deficiency : molecular study of 3 new mutations (118G>A, 190G>A, and GAC deletion) associated with hereditary nonspherocytic hemolytic anemia. Blood 102 : 353-356, 2003.
PubMed
10) Qualtieri A, Pedace V, Bisconte MG, et al : Severe erythrocyte adenylate kinase deficiency due to homozygous A→G substitution at codon 164 of human AK1 gene associated with chronic haemolytic anaemia. Br J Haematol 99 : 770-776, 1997.
 
11) Niizuma H, Kanno H, Sato A, et al : Splenectomy resolves hemolytic anemia caused by adenylate kinase deficiency. Pediatr Int 59 : 228-230, 2017.
PubMed
12) Dongerdiye R, Kamat P, Jain P, et al : Red cell adenylate kinase deficiency in India : identification of two novel missense mutations (c.71A>G and c.413G>A). J Clin Pathol 72 : 393-398, 2019.
 
13) Dongerdiye R, Sampagar A, Devendra R, et al : Rare hereditary nonspherocytic hemolytic anemia caused by a novel homozygous mutation, c.301C>A, (Q101K), in the AK1 gene in an Indian family. BMC Med Genomics 14 : 191, 2021.
 
14) He S, Chen H, Guo X, et al : Red cell adenylate kinase deficiency in China : molecular study of 2 new mutations (413G>A, 223dupA). BMC Med Genomics 15 : 102, 2022.
 
P.312 掲載の参考文献
1) Vives i Corrons JL : Chronic non-spherocytic haemolytic anaemia due to congenital pyrimidine 5' nucleotidase deficiency : 25 years later. Baillieres Best Pract Res Clin Haematol 13 : 103-118, 2000.
PubMed
2) Kanno H, Takizawa T, Miwa S, et al : Molecular basis of Japanese variants of pyrimidine 5'-nucleotidase deficiency. Br J Haematol 126 : 265-271, 2004.
PubMed
3) Boguslawska DM, Skulski M, Bartoszewski R, et al : A rare mutation (p.F149del) of the NT5C3A gene is associated with pyrimidine 5'-nucleotidase deficiency. Cell Mol Biol Lett 27 : 104, 2022.
 
4) Marinaki AM, Escuredo E, Duley JA, et al : Genetic basis of hemolytic anemia caused by pyrimidine 5' nucleotidase deficiency. Blood 97 : 3327-3332, 2001.
PubMed
5) Zanella A, Bianchi P, Fermo E, et al : Hereditary pyrimidine 5'-nucleotidase deficiency : from genetics to clinical manifestations. Br J Haematol 133 : 113-123, 2006.
PubMed
6) Kirschner M, Heinen IR, Koschmieder S, et al : Novel homozygous nonsense mutation in the P5'N-1 coding gene as an alternative cause for hereditary anemia with basophilic stippling. Clin Case Rep 10 : e05501, 2022.
PubMed
7) Rees DC, Duley JA, Marinaki AM : Pyrimidine 5' nucleotidase deficiency. Br J Haematol 120 : 375-383, 2003.
PubMed
8) Chiarelli LR, Fermo E, Zanella A, et al : Hereditary erythrocyte pyrimidine 5'-nucleotidase deficiency : a biochemical, genetic and clinical overview. Hematology 11 : 67-72, 2006.
PubMed
9) Warang P, Kedar P, Kar R, et al : New missense homozygous mutation (Q270Ter) in the pyrimidine 5' nucleotidase type I-related gene in two Indian families with hereditary nonspherocytic hemolytic anemia. Ann Hematol 92 : 715-717, 2013.
PubMed
10) Al-Jafar HA, Layton DM, Robertson L, et al : Diagnosis of pyrimidine 5'-nucleotidase deficiency suspected from a blood film. Am J Hematol 88 : 1089, 2013.
PubMed
11) Balta G, Gumruk F, Akarsu N, et al : Molecular characterization of Turkish patients with pyrimidine 5' nucleotidase-I deficiency. Blood 102 : 1900-1903, 2003.
PubMed
12) Chiarelli LR, Bianchi P, Fermo E, et al : Functional analysis of pyrimidine 5'-nucleotidase mutants causing nonspherocytic hemolytic anemia. Blood 105 : 3340-3345, 2005.
PubMed
P.317 掲載の参考文献
1) Shibata S, Tamura A, Iuchi I, et al : Hemoglobin M1 demonstration of a new abnormal hemoglobin in hereditary nigremia. Acta Haem. Jap 23 : 96-105, 1960.
 
2) 服部幸夫, 原野昭雄 : 異常ヘモグロビン血症およびサラセミア. 日本臨牀 59 (増刊号 7 : 本邦臨床統計集 (1)) : 437-451, 2001.
 
3) 山城安啓 : 溶血性貧血検査の最新の動向ヘモグロビン異常症の検査. Medical Technology 32 : 565-572, 2004.
 
4) Wanapirak C, Sirichotiyakul S, Luewan S, et al : Comparison of the accuracy of dichlorophenolindophenol (DCIP), modified DCIP, and hemoglobin E tests to screen for the HbE trait in pregnant women. Int J Gynaecol Obstet 107 : 59-60, 2009.
PubMed
5) 山城安啓, 服部幸夫, 日野未奈子, ほか : 改良型Hybridization Probe法 (Hybri-Probe法) を用いた遺伝子診断法の確立βサラセミアを対象として. 臨床病理 59 : 858-863, 2011.
 
P.320 掲載の参考文献
1) Pauling L, Itano HA : Sickle cell anemia a molecular disease. Science 110 : 543-548, 1949.
PubMed
2) Ingram VM : Specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature 178 : 792-794, 1956.
PubMed
3) Boyer SH, Panny SR, Smith KD, et al : Population and biological Aspects of Human Mutation, (ed by Hook ED, Porter IH), p35-48, Academic Press, New York), 1982.
 
4) Powars D, Hiti A : Sickle cell anemia. Beta s gene cluster haplotypes as genetic markers for severe disease expression. Am J Dis Child 147 : 1197-1202, 1993.
 
5) Powars DR, Meiselman HJ, Fisher TC, et al : Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia. Use in predicting clinical severity. Am J Pediatr Hematol Oncol 16 : 55-61, 1994.
 
6) 服部幸夫, 山城安啓, 山根明男, ほか : 遺伝子増幅とビオチン標識オリゴヌクレオチドプローブを用いた日本人βサラセミアの簡単な遺伝子診断. 臨床病理 4, 1989.
 
7) 山城安啓, 服部幸夫, 日野未奈子, ほか : 改良型Hybridization Probe法 (Hybri-Probe法) を用いた遺伝子診断法の確立βサラセミアを対象として. 臨床病理 59 : 858-863, 2011.
 
8) Charache S, Terrin ML, Moore RD, et al : Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332 : 1317-1322, 1995.
PubMed
9) Charache S, Barton FB, Moore RD, et al : Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 75 : 300-326, 1996.
PubMed
P.323 掲載の参考文献
1) Murachi T, Tanaka K, Hatanaka M, et al : Intracellular Ca2+-dependent protease (calpain) and its high-molecular-weight endogenous inhibitor (calpastatin). Adv Enzyme Regul 19 : 407-424, 1980.
 
2) Ciechanover A : The ubiquitin-proteasome pathway : on protein death and cell life. EMBO J 17 : 7151-7160, 1998.
PubMed
3) Landman H : Haemoglobinopathies and Pregnancy, Van Denderen Printing, Groningen, 1988.
 
4) 服部幸夫, 山城安啓 : 単一遺伝子疾患における表現型の多様性. 山口医学 53 : 204-205, 2004.
Medical*Online
5) 佐藤淳, 丹田恵美子, 安藤健明, ほか : Mentzer indexを指標に検索しえた血色素異常症. 日本検査血液学会雑誌 7 : 10-19, 2006.
 
6) 山城安啓 : 溶血性貧血検査の最新の動向ヘモグロビン異常症の検査. Medical Technology 32 : 565-572, 2004.
 
7) 山城安啓, 服部幸夫 : 貧血「古くて新しい病気, 貧血を見直す」1. 異常ヘモグロビン症及びサラセミア. 日本検査血液学会雑誌 8 : 208-216, 2007.
 
P.329 掲載の参考文献
1) Molchanova TP, Pobedimskaya DD, Huisman TH : (1994a). The differences in quantities of alpha 2- and alpha 1-globin gene variants in heterozygotes. Br J Haematol 88 : 300-306, 1994.
 
2) 佐藤淳, 丹田恵美子, 安藤健明, ほか : Mentzer indexを指標に検索しえた血色素異常症. 日本検査血液学会雑誌 7 : 10-19, 2006.
 
3) 服部幸夫, 原野昭雄 : 異常ヘモグロビン血症およびサラセミア. 日本臨牀 59 (増刊号 7 : 本邦臨床統計集 (1)) : 437-451, 2001.
 
4) 山城安啓 : 溶血性貧血検査の最新の動向ヘモグロビン異常症の検査. Medical Technology 32 : 565-572, 2004.
 
5) 山城安啓, 服部幸夫 : 貧血「古くて新しい病気, 貧血を見直す」1. 異常ヘモグロビン症及びサラセミア. 日本検査血液学会雑誌 8 : 208-216. 2007.
 
6) 服部幸夫, 山城安啓 : 単一遺伝子疾患における表現型の多様性. 山口医学 53 : 204-205, 2004.
Medical*Online
P.333 掲載の参考文献
1) 服部幸夫, 原野昭雄 : 異常ヘモグロビン血症およびサラセミア. 日本臨牀 59 (増刊号 7 : 本邦臨床統計集 (1)) : 437-451, 2001.
 
2) 山城安啓 : 溶血性貧血検査の最新の動向ヘモグロビン異常症の検査. Medical Technology 32 : 565-572, 2004.
 
3) 山城安啓, 服部幸夫 : 貧血「古くて新しい病気, 貧血を見直す」1. 異常ヘモグロビン症及びサラセミア. 日本検査血液学会雑誌 8 : 208-216, 2007.
 
4) Maquat LE : When cells stop making sense : effects of nonsense codons on RNA metabolism in vertebrate cells. RNA 1 : 453-465, 1995.
PubMed
5) 服部幸夫, 山城安啓, 山根明男, ほか : 遺伝子増幅とビオチン標識オリゴヌクレオチドプローブを用いた日本人βサラセミアの簡単な遺伝子診断. 臨床病理 (中国四国支部会誌) 4 : 421-430, 1989.
 
6) 山城安啓, 服部幸夫, 日野未奈子, ほか : 改良型Hybridization Probe法 (Hybri-Probe法) を用いた遺伝子診断法の確立βサラセミアを対象として. 臨床病理 59 : 858-863, 2011.
 
7) Nitta T, Kawano F, Yamashiro Y, et al : A new Kruppel-like factor 1 mutation (c.947G>A or p.C316Y) in humans causes β-thalassemia minor. Hemoglobin 39 : 121-126, 2015.
 
8) 服部幸夫, 山城安啓 : 単一遺伝子疾患における表現型の多様性. 山口医学 53 : 204-205, 2004.
Medical*Online
P.336 掲載の参考文献
1) Matsunaga E, Kimura A, Yamada H, et al : A novel deletion in delta beta-thalassemia found in Japan. Biochem Biophys Res Commun 126 : 185-191, 1985.
PubMed
2) Yamashiro Y, Hattori Y, Okayama N, et al : A novel GγAγ (αβ) 0 thalassemia with a 27 kb deletion. Hemoglobin 29 : 197-208, 2005.
 
3) 服部幸夫, 山城安啓 : 異常血色素およびサラセミアの遺伝子診断-特に広範囲遺伝子欠失型の欠失断端の決定-. 臨床病理 51 : 550-555, 2003.
Medical*Online
4) 日野未奈子 : 未知の広範囲遺伝子欠失の欠失断端決定法-Junction PCR-. 臨床血液 47 : 347-354, 2006.
 
5) 服部幸夫, 原野昭雄 : 本邦臨床統計集 (1) : 異常ヘモグロビン血症およびサラセミア. 日本臨牀 59巻 (増刊号 7) : 437-451, 2001.
 
6) 山城安啓 : 溶血性貧血検査の最新の動向ヘモグロビン異常症の検査. Medical Technology 32 : 565-572, 2004.
 
7) 山城安啓, 服部幸夫 : 貧血「古くて新しい病気, 貧血を見直す」1. 異常ヘモグロビン症及びサラセミア. 日本検査血液学会雑誌 8 : 208-216, 2007.
 
P.340 掲載の参考文献
1) Makis A, Georgiou I, Traeger-Synodinos J, et al : A Novel εγδβ-Thalassemia Deletion Associated with Severe Anemia at Birth and a β-Thalassemia Intermedia Phenotype Later in Life in Three Generations of a Greek Family. Hemoglobin 45 : 351-354, 2021.
 
2) 服部幸夫, 山城安啓 : 異常血色素およびサラセミアの遺伝子診断-特に広範囲遺伝子欠失型の欠失断端の決定-. 臨床病理 51 : 550-555, 2003.
Medical*Online
3) 日野未奈子 : 未知の広範囲遺伝子欠失の欠失断端決定法-Junction PCR-. 臨床血液 47 : 347-354, 2006.
 
4) Furuya C, Yamashiro Y, Hattori Y, et al : A novel epsilon gamma delta beta thalassemia of 1.4 Mb deletion found in a Japanese patient. Am J Hematol 83 : 84-86, 2008.
 
5) De Simone G, Quattrocchi A, Mancini B, et al : Thalassemias : from gene to therapy. Mol Aspects Med 84 : 101028, 2022.
PubMed
P.343 掲載の参考文献
1) Galanello R, Melis MA, Podda A, et al : Deletion delta-thalassemia : the 7.2 kb deletion of Corfu delta beta-thalassemia in a non-beta-thalassemia chromosome. Blood 75 : 1747-1749, 1990.
 
2) Ohta Y, Yasukawa M, Saito S, et al : Homozygous delta thalassemia in Japan. Hemoglobin 4 : 417-425, 1980.
PubMed
3) Gibson WT, Harvard C, Qiao Y, et al : Phenotype-genotype characterization of alpha-thalassemia mental retardation syndrome due to isolated monosomy of 16p13.3. Am J Med Genet A 146A : 225-232, 2008.
PubMed
4) Higgs DR, Wood WG, Barton C, et al : Clinical features and molecular analysis of acquired hemoglobin H disease. Am J Med 75 : 181-191, 1983.
PubMed
5) 服部幸夫, 山城安啓 : 異常血色素およびサラセミアの遺伝子診断-特に広範囲遺伝子欠失型の欠失断端の決定-. 臨床病理 51 : 550-555, 2003.
Medical*Online
6) 日野未奈子 : 未知の広範囲遺伝子欠失の欠失断端決定法-Junction PCR-. 臨床血液 47 : 347-354, 2006.
 
7) Harteveld CL, Kriek M, Bijlsma EK, et al : Refinement of the genetic cause of ATR-16. Hum Genet 122 : 283-292, 2007.
PubMed
P.345 掲載の参考文献
1) Valentine WN, Paglia DE, Tartaglia AP, et al : Hereditary hemolytic anemia with increased red cell adenosine deaminase (45- to 70-fold) and decreased adenosine triphosphate. Science 195 : 783-785, 1977.
PubMed
2) Miwa S, Fujii H, Matsumoto N, et al : A case of red-cell adenosine deaminase overproduction associated with hereditary hemolytic anemia found in Japan. Am J Hematol 5 : 107-115, 1978.
PubMed
3) Fujii H, Miwa S, Tani K, et al : Overproduction of structurally normal enzyme in man : hereditary haemolytic anaemia with increased red cell adenosine deaminase activity. Br J Haematol 51 : 427-430, 1982.
PubMed
4) Fujiwara T : GATA Transcription Factors : Basic Principles and Related Human Disorders. Tohoku J Exp Med 242 : 83-91, 2017.
PubMed
5) Cantor AB : GATA transcription factors in hematologic disease. Int J Hematol 81 : 378-384, 2005.
PubMed
6) Ludwig LS, Lareau CA, Bao EL, et al : Congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1. Blood 139 : 2534-2546, 2022.
PubMed
7) 菅野仁, 小倉浩美 : 網羅的遺伝子解析による先天性溶血性貧血診断の意義と課題. 臨床血液 62 : 472-479, 2021.
 
P.347 掲載の参考文献
1) Singleton BK, Burton NM, Green C, et al : Mutations in EKLF/KLF1 form the molecular basis of the rare blood group In (Lu) phenotype. Blood 112 : 2081-2088, 2008.
PubMed
2) Borg J, Papadopoulos P, Georgitsi M, et al : Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 42 : 801-805, 2010.
PubMed
3) Arnaud L, Saison C, Helias V, et al : A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet 87 : 721-727, 2010.
PubMed
4) Viprakasit V, Ekwattanakit S, Riolueang S, et al : Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression. Blood 123 : 1586-1595, 2014.
PubMed
5) Tangsricharoen T, Natesirinilkul R, Phusua A, et al : Severe neonatal haemolytic anaemia caused by compound heterozygous KLF1 mutations : report of four families and literature review. Br J Haematol 194 : 626-634, 2021.
PubMed
6) Xu L, Zhu D, Zhang Y, et al : Compound Heterozygosity for KLF1 Mutations Causing Hemolytic Anemia in Children : A Case Report and Literature Review. Front Genet 12 : 691461, 2021.
PubMed
7) 菅野仁, 小倉浩美 : 網羅的遺伝子解析による先天性溶血性貧血診断の意義と課題. 臨床血液 62 : 472-479, 2021.
 
8) Yang K, Nie W, Huang Q, et al : Hematopoietic cell transplantation for congenital dyserythropoietic anemia IV caused by compound heterozygous KLF1 mutations. Ann Hematol 102 : 1621-1624, 2023.
PubMed
P.352 掲載の参考文献
1) Dacie J : The Haemolytic Anaemias, Vol 3 : The Autoimmune Haemolytic Anaemias, 3rd Ed, Churchill Livingstone, London, 1992.
 
2) 張替秀郎, ほか : 厚生労働科学研究費補助金 (難治性疾患政策研究事業) 特発性造血障害に関する調査研究自己免疫性溶血性貧血診療の参照ガイド 令和4年度改訂版, 2023.
 
3) 川本晋一郎 : 続発性自己免疫性溶血性貧血における自己抗体の標的分子の同定. 臨床血液 61 : 491-501, 2020.
 
4) Tanios GE, Doley PB, Munker R : Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer : 68 cases from the Food and Drug Administration database and review. Eur J Haematol 102 : 157-162, 2019.
PubMed
5) Berentsen S, Sundic T : Red blood cell destruction in autoimmune hemolytic anemia : role of complement and potential new targets for therapy. Biomed Res Int 2015 : 363278, 2015.
PubMed
6) Jager U, Barcellini W, Broome CM, et al : Diagnosis and treatment of autoimmune hemolytic anemia in adults : Recommendations from the First International Consensus Meeting. Blood Rev 41 : 100648, 2020.
PubMed
7) Voulgaridou A, Kalfa TA : Autoimmune Hemolytic Anemia in the Pediatric Setting. J Clin Med 10 : 216, 2021.
PubMed
8) Nakasone H, Kako S, Endo H, et al : Diabetes mellitus is associated with high early-mortality and poor prognosis in patients with autoimmune hemolytic anemia. Hematology 14 : 361-365, 2009.
PubMed
9) Reardon JE, Marques MB : Laboratory evaluation and transfusion support of patients with autoimmune hemolytic anemia. Am J Clin Pathol 125 (Suppl) : S71-77, 2006.
 
10) Ness PM : How do I encourage clinicians to transfuse mismatched blood to patients with autoimmune hemolytic anemia in urgent situations? Transfusion 46 : 1859-1862, 2006.
PubMed
11) Suzuki Y, Nawata H, Soen S, et al : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update. J Bone Miner Metab 32 : 337-350, 2014.
PubMed
12) Quinquenel A, Willekens C, Dupuis, J, et al : Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia : A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). Am J Hematol 90 : 204-207, 2015.
PubMed
13) Chan M, Silverstein WK, Nikonova A, et al : Bendamustine-induced immune hemolytic anemia : a case report and systematic review of the literature. Blood Adv 4 : 1756-1759, 2020.
PubMed
14) Suzuki T, Miyakoshi S, Nanba A, et al : A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment. J Clin Exp Hematop 58 : 136-140, 2018.
PubMed
15) 小峰光博, 原田浩史, 三輪史朗, ほか : 自己免疫性溶血性貧血の長期予後 : 二つの症例集団の追跡調査成績. 平成8年度報告書, p64-66, 1997.
 
P.356 掲載の参考文献
1) Petz LD, Garratty G : Immune Hemolytic Anemias, 2nd ed, Churchill Livingstone, Philadelphia, 2004.
 
2) 張替秀郎, 和田秀穂, 西村純一, ほか : 自己免疫性溶血性貧血診療の参照ガイド (令和4年度改訂版). 特発性造血障害研究班, 2023. [http://zoketsushogaihan.umin.jp/file/2022/Autoimmune_hemolytic_anemia.pdf]
 
3) Barcellini W, Fattizzo B, Zaninoni A, et al : Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia : a GIMEMA study of 308 patients. Blood 124 : 2930-2936, 2014.
PubMed
4) Gehrs BC, Friedberg RC : Autoimmune hemolytic anemia. Am J Hematol 69 : 258-271, 2002.
PubMed
5) Kamesaki T, Toyotsuji T, Kajii E : Characterization of direct antiglobulin test-negative autoimmune hemolytic anemia : a study of 154 cases. Am J Hematol 88 : 93-96, 2013.
PubMed
6) Leddy JP, Falany JL, Kissel GE, et al : Erythrocyte membrane proteins reactive with human (warm-reacting) anti-red cell autoantibodies. J Clin Invest 91 : 1672-1680, 1993.
PubMed
7) 菅野直子, 小幡隆, 小野崎文子, ほか : カラム凝集法による赤血球凝集反応 : 試験管法, ビーズ法, ゲル法の比較検討. 医学検査 49 : 951-955, 2000.
 
8) Kamesaki T, Oyamada T, Omine M, et al : Cut-off value of red-blood-cell-bound IgG for the diagnosis of Coombs-negative autoimmune hemolytic anemia. Am J Hematol 84 : 98-101, 2009.
PubMed
9) Kamesaki T, Kajii E : A Comprehensive Diagnostic Algorithm for Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Reveals the Relative Ratio of Three Mechanisms in a Single Laboratory. Acta Haematol 140 : 10-17, 2018.
 
10) 大峠ふくみ, 山城安啓, 緒方静, ほか : フローサイトメトリーによる赤血球結合IgG測定法の開発. 医学検査 71 : 37-44, 2022.
Medical*Online
11) Meulenbroek EM, de Haas M, Brouwer C, et al : Complement deposition in autoimmune hemolytic anemia is a footprint for difficult-to-detect IgM autoantibodies. Haematologica 100 : 1407-1414, 2015.
PubMed
12) Kamesaki T : Diagnostic algorithm for classification and characterization of direct antiglobulin test-negative autoimmune hemolytic anemia with 1-year clinical follow-up. Transfusion 62 : 205-216, 2022.
PubMed
13) 緒方静, 木本真史, ほか : 福山臨床検査センターにおける自己免疫性溶血性貧血補助検査の現状. 日本血液学会学術集会83回, OS2-13C-1, 2021.
 
P.362 掲載の参考文献
1) 張替秀郎, 和田秀穂, 西村純一, ほか : 自己免疫性溶血性貧血診療の参照ガイド 令和4年度改訂版, 2023.
 
2) Berentsen S, Barcellini W : Autoimmune hemolytic anemia. N Engl J Med 385 : 1407-1419, 2021.
PubMed
3) 植田康敬 : 自己免疫性溶血性貧血の病態理解と治療の進歩. 臨床血液 63 : 1014-1025, 2022.
 
4) Berentsen S, Barcellini W, D'Sa S, et al : Cold agglutinin disease revisited : a multinational, observational study of 232 patients. Blood 136 : 480-488, 2020.
PubMed
5) Berentsen S : Cold agglutinin disease. Hematology Am Soc Hematol Educ Program 2016 : 226-231, 2016.
PubMed
6) Berentsen S : How I treat cold agglutinin disease. Blood 137 : 1295-1303, 2021.
 
7) Roth A, Barcellini W, D'sa S, et al : Sutimlimab in cold agglutinin disease. N Engl J Med 384 : 1323-1334, 2021.
PubMed
8) Roth A, Berentsen S, Barcellini W, et al : Sutimlimab in patients with cold agglutinin disease : results of the randomized placebo-controlled phase 3 CADENZA trial. Blood 140 : 980-991, 2022.
PubMed
P.366 掲載の参考文献
1) Eder AF : Review : acute Donath-Landsteiner hemolytic anemia. Immunohematology 21 : 56-62, 2005.
PubMed
2) Sokol RJ, Hewitt S, Stamps BK : Autoimmune haemolysis : an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Clin Res Ed) 282 : 2023-2027, 1981.
PubMed
3) Sokol RJ, Booker DJ, Stamps R : Erythropoiesis : Paroxysmal Cold Haemoglobinuria : A Clinico-Pathological Study of Patients with a Positive Donath-Landsteiner Test. Hematology 4 : 137-164, 1999.
PubMed
4) 中原衣里菜, 谷ヶ崎博, 菅野仁 : 我が国の発作性寒冷ヘモグロビン尿症～文献的考察. 日本輸血細胞治療学会誌 67 : 541-548, 2021.
Medical*Online
5) Hellberg A, Poole J, Olsson ML : Molecular basis of the globoside-deficient P (k) blood group phenotype. Identification of four inactivating mutations in the UDP-N-acetylgalactosamine : globotriaosylceramide 3-beta-N-acetylgalactosaminyltransferase gene. J Biol Chem 277 : 29455-29459, 2002.
 
6) Kaczmarek R, Buczkowska A, Mikolajewicz K, et al : P1PK, GLOB, and FORS blood group systems and GLOB collection : biochemical and clinical aspects. Do we understand it all yet? Transfus Med Rev 28 : 126-136, 2014.
PubMed
7) Jacobs JW, Figueroa Villalba CA, Booth GS, et al : Clinical and epidemiological features of paroxysmal cold hemoglobinuria : a systematic review. Blood Adv 7 : 2520-2527, 2023.
PubMed
8) Shanbhag S, Spivak J : Paroxysmal cold hemoglobinuria. Hematol Oncol Clin North Am 29 : 473-478, 2015.
PubMed
9) Zeller MP, Arnold DM, Al Habsi K, et al : Paroxysmal cold hemoglobinuria : a difficult diagnosis in adult patients. Transfusion 57 : 137-143, 2017.
PubMed
10) Sugimoto T, Masui E, Ohata S, et al : A Case of Paroxysmal Cold Hemoglobinuria Possessing Moderate Paroxysmal Nocturnal Hemoglobinuria-Type Erythrocytes. Am J Case Rep 22 : e933102, 2021.
PubMed
11) Lau-Braunhut SA, Stone H, Collins G, et al : Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Adv 3 : 3575-3578, 2019.
PubMed
12) Cooling LL : Kids, colds, and complement : paroxysmal cold hemoglobinuria. Transfusion 57 : 1332-1335, 2017.
PubMed
13) Wise SC, Tinsley SH, Cook LO : Paroxysmal cold hemoglobinuria : a case report. Immunohematology 28 : 118-123, 2012.
PubMed
14) Gregory GP, Opat S, Quach H, et al : Failure of eculizumab to correct paroxysmal cold hemoglobinuria. Ann Hematol 90 : 989-990, 2011.
PubMed
P.371 掲載の参考文献
1) 藤井康彦, 松崎道男, 宮田茂樹, ほか : ABO型不適合輸血の発生原因による解析. 日本輸血細胞治療学会誌 53 : 374-382, 2007.
Medical*Online
2) Fudenberg H, Allen FH Jr : Transfusion reactions in the absence of demonstrable incompatibility. N Engl J Med 256 : 1180-1184, 1957.
PubMed
3) 澤部孝昭, 宮達彦, 屋代達, ほか : 遅発性溶血性輸血副作用の検討-過去10年間の健康-. 日本輸血学会雑誌 39 : 974-978, 1993.
 
4) Popovsky MA (ed) : Transfusion Reactions, 3rd ed, AABB, Bethesda, 2007.
 
5) 藤井康彦 : 溶血性副作用. 改訂第4版 日本輸血・細胞治療学会認定医制度指定カリキュラム (日本輸血・細胞治療学会認定医制度審議会カリキュラム委員会編), p328-331, 2019.
 
6) 石丸健, 佐藤進一郎, 藤井康彦 : 遅発性溶血性輸血副作用. 輸血副反応ガイド Version 1.0. (日本輸血・細胞治療学会輸血副作用対応ガイド改訂版作成タスクホース委員会編), 37-40, 日本輸血・細胞治療学会, 2014.
 
7) 石丸健, 天満智佳, 藤原義一, ほか : 一次免疫反応により惹起されたと考えられる遅発性溶血性輸血副作用の1症例. 日本輸血学会誌 50 : 768-773, 2004.
 
8) 北澤淳一, 猪股真喜子, 鎌田千鶴, ほか : 一次免疫反応により産生された抗C+e抗体による遅発性溶血性輸血副作用を呈した1例. 日本輸血学会雑誌 51 : 594-600, 2005.
Medical*Online
9) 水野洸太, 山崎理恵, 上村知恵, ほか : 一次免疫応答による異なる不規則抗体によって2回続けて発症した遅発性溶血性輸血副作用. 臨床血液 61 : 1482-1486, 2020.
 
10) Fujii Y, Shibata Y, Miyata S, et al : Consecutive national surveys of ABO-incompatible blood transfusion in Japan. Vox Sang 97 : 240-246, 2009.
PubMed
11) 北澤淳一, 猪股真喜子, 山口千鶴, ほか : 携帯「不規則抗体カード」が輸血副作用防止に有効であった1例. 日本輸血細胞治療学会誌 54 : 503-506, 2008.
Medical*Online
P.374 掲載の参考文献
1) Nakahara E, Yamamoto KS, Ogura H, et al : Variant spectrum of PIEZO1 and KCNN4 in Japanese patients with dehydrated hereditary stomatocytosis. Hum Genome Var 10 : 8, 2023.
PubMed
2) ACOG Practice Bulletin No. 192 : Management of Alloimmunization During Pregnancy. Obstet Gynecol 131 : e82-e90, 2018.
PubMed
3) Delaney M, Matthews DC : Hemolytic disease of the fetus and newborn : managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program 2015 : 146-151, 2015.
PubMed
4) Metcalf RA, Khan J, Andrews J, et al : Severe ABO Hemolytic Disease of the Newborn Requiring Exchange Transfusion. J Pediatr Hematol Oncol 41 : 632-634, 2019.
PubMed
5) Yamamoto S, Shiraishi A, Ishimura M, et al : Cytomegalovirus-Associated Hemolytic Anemia in an Infant Born to a Mother with Lupus. Neonatology 118 : 368-372, 2021.
 
6) Kiyokoba R, Hidaka N, Sakata Y, et al : Fetal cytomegalovirus infection manifesting as transient pancytopenia. Congenit Anom (Kyoto) 55 : 164-166, 2015.
PubMed
7) 厚生労働省医薬・生活衛生局 : 血液製剤の使用指針-新生児・小児に対する輸血療法. (最終更新 2019年3月) [https://www.mhlw.go.jp/content/11127000/000493546.pdf]
 
8) Kuboi T, Kusaka T, Kawada K, et al : Hour-specific nomogram for transcutaneous bilirubin in Japanese neonates. Pediatr Int 55 : 608-611, 2013.
PubMed
9) Sato K, Hara T, Kondo T, et al : High-dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility. Acta Paediatr Scand 80 : 163-166, 1991.
PubMed
10) Fukushima K, Morokuma S, Fujita Y, et al : Short-term and long-term outcomes of 214 cases of non-immune hydrops fetalis. Early Hum Dev 87 : 571-575, 2011.
PubMed
P.379 掲載の参考文献
1) Garratty G : Immune hemolytic anemia associated with drug therapy. Blood Rev 24 : 143-150, 2010.
PubMed
2) Garratty G : Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2009 : 73-79, 2009.
PubMed
3) Friedberg RC, Johari VP : Autoimmune hemolytic anemia. In : Greer JP, et al : editors. Wintrobe's Clinical Hematology, 14th edition (ed by Geer JP, Rodgers GM, Glader B, et al), p762, Lippencott Williams & Wilkins, Philadelphia, 2019.
 
4) 自己免疫性溶血性貧血の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ : 自己免疫性溶血性貧血診療の参照ガイド 令和4年度改訂版. 2023. [http://zoketsushogaihan.umin.jp/file/2022/Autoimmune_hemolytic_anemia.pdf]
 
5) Hill QA, Stamps R, Massey E, et al : Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol 177 : 208-220, 2017.
PubMed
6) 医薬品医療機器総合機構 : 副作用が疑われる症例報告に関する情報. [https://www.info.pmda.go.jp/fsearchnew/jsp/menu_fukusayou_base.jsp]
 
7) Arndt PA, Garratty G : The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol 42 : 137-144, 2005.
PubMed
8) Garratty G, Arndt PA : Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests : some interesting findings since 2007. Immunohematology 30 : 66-79, 2014.
 
9) Hwang SR, Saliba AN, Wolanskyj-Spinner AP : Immunotherapy-associated autoimmune hemolytic anemia. Hematol Oncol Clin North Am 36 : 365-380, 2022.
PubMed
10) Tanios GE, Doley PB, Munker R : Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer : 68 cases from the Food and Drug Administration database and review. Eur J Haematol 102 : 157-162, 2019.
PubMed
11) Leaf RK, Ferreri C, Rangachari D, et al : Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol 94 : 563-574, 2019.
PubMed
12) Leger RM, Arndt PA, Garratty G : How we investigate drug-induced immune hemolytic anemia. Immunohematology 30 : 85-94, 2014.
PubMed
P.384 掲載の参考文献
1) Gasser C, Gautier E, Steck A, et al : Hemolytic-uremic syndrome : bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 85 : 905-909, 1955.
PubMed
2) 松本雅則 : 血栓性微小血管障害症 (TMA). -TTP, HUS, 移植後TMAを中心に. 医学のあゆみ 238 : 136-140, 2011.
Medical*Online
3) Magnus T, Rother J, Simova O, et al : The neurological syndrome in adults during the 2011 northern German E. coli serotype O104 : H4 outbreak. Brain 135 : 1850-1859, 2012.
 
4) Roumenina LT, Loirat C, Dragon-Durey MA, et al : Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 365 : 8-26, 2011.
 
5) Dragon-Durey MA, Blanc C, Garnier A, et al : Anti-factor H autoantibody-associated hemolytic uremic syndrome : review of literature of the autoimmune form of HUS. Semin Thromb Hemost 36 : 633-640, 2010.
PubMed
6) Noris M, Remuzzi G : Atypical hemolytic-uremic syndrome. N Engl J Med 361 : 1676-1687, 2009.
PubMed
7) 藤村吉博, 松本雅則, 八木秀男 : 溶血性尿毒症症候群, 血栓性血小板減少性紫斑病. 日本内科学会雑誌 100 : 1296-1307, 2011.
 
8) Taylor CM, Machin S, Wigmore SJ, et al : Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 148 : 37-47, 2010.
PubMed
9) Furlan M, Robles R, Galbusera M, et al : von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 : 1578-1584, 1998.
PubMed
10) Tsai HM, Lian EC : Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339 : 1585-1594, 1998.
PubMed
11) 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド 2023 (厚生労働科学研究費補助金 (難治性疾患政策研究事業) 「血液凝固異常症等に関する研究班」非典型溶血性尿毒症症候群 (aHUS) 診療ガイド改定委員会編), 東京医学社, 2023.
 
12) Panos GZ, Betsi GI, Falagas ME : Systematic review : are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157 : H7 infection? Aliment Pharmacol Ther 24 : 731-742, 2006.
PubMed
13) Noris M, Remuzzi G : Hemolytic uremic syndrome. J Am Soc Nephrol 16 : 1035-1050, 2005.
PubMed
14) Kavanagh D, Goodship TH : Membrane cofactor protein and factor I : mutations and transplantation. Semin Thromb Hemost 32 : 155-159, 2006.
PubMed
15) Gruppo RA, Rother RP : Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 360 : 544-546, 2009.
PubMed
P.388 掲載の参考文献
1) Crexells C, Aerichide N, Bonny Y, et al : Factors influencing hemolysis in valve prosthesis. Am Heart J 85 : 161-170, 1972.
 
2) Febres-Roman PR, Bourg WC, Crone RA, et al : Chronic intravascular hemolysis after aortic valve replacement with Ionescu-Shiley xenograft : comparative study with Bjork-Shiley prosthesis. Am J Cardiol 46 : 735-738, 1980.
PubMed
3) Rodgers BM, Sabiston DC : Hemolytic anemia following prosthetic valve replacement. Circulation 39 (5 Suppl 1) : I-155-I-161, 1969.
 
4) Yamashita M, Saigenji H, Shimokawa S, et al : Severe mechanical hemolysis after valve replacement with St. Jude Medical valve--a report of five cases. Nihon Kyobu Geka Gakkai Zasshi 34 : 2142-2146, 1986.
 
5) Hammermeister KE, Sethi GK, Henderson WG, et al : A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease. N Engl J Med 328 : 1289-1296, 1993.
PubMed
6) Skoularigis J, Essop MR, Skudicky D, et al : Frequency and severity of intravascular hemolysis after left-sided cardiac valve replacement with Medtronic Hall and St. Jude Medical prostheses, and influence of prosthetic type, position, size and number. Am J Cardiol 71 : 587-591, 1993.
PubMed
7) Garcia MJ, Vandervoort P, Stewart WJ, et al : Mechanisms of hemolysis with mitral prosthetic regurgitation. Study using transesophageal echocardiography and fluid dynamic simulation. J Am Coll Cardial 27 : 399-406, 1996.
 
8) Laflamme J, Puri R, Urena M, et al : Incidence and risk factors of hemolysis sfter transcatheter aortic valve imlantation with a balloon expandable valvc. Am J Cardiol 115 : 1574-1579, 2015.
 
9) Cannata A, Cantoni S, Sciortino A, et al : Mechanical Hemolysis Complicating Transcatheter Intervention for Valvular Heart Disease : JACC State of-the-Art Review. J Am Coll Cardiol 77 : 2323-2334, 2021.
PubMed
10) Marchand A, Galen RS, Van Lente F : The predictive value of serum haptoglobin in hemolytic disease. JAMA 243 : 1909-1911, 1980.
PubMed
11) Kliger C, Eiros R, Isasti G, et al : Review of surgical prosthetic paravalvular leaks : diagnosis and catheter-based closure. Eur Heart J 34 : 638-649, 2013.
PubMed
12) Onorato EM, Muratori M, Smolka G, et al : Midterm procedural and clinical outcomes of percutaneous paravalvular leak closure with the Occlutech Paravalvular Leak Device. EuroIntervention 15 : 1251-1259, 2020.
PubMed
P.393 掲載の参考文献
1) Fleischer R : Ueber eine neue Form von Haemoglobinure beim Menschen. Berl Klin Wschr 18 : 691, 1881.
 
2) 浅井隆善, 伊藤国明, 王伯銘, ほか : 剣道により発症した行軍血色素尿症の3例 : 剣道負荷試験, 赤血球膜SDS-PAGEについて. 臨床血液 27 : 179-184, 1986.
 
3) 大嶋勇成, 南部光彦, 垣内敏孝, ほか : 剣道により発症した行軍性血色素尿症の1例. 小児科臨床 42 : 29-32, 1989.
Medical*Online
4) 西岡里香, 祖父江理, 大西啓右, ほか : 尿細管への鉄沈着を認めた剣道行軍ヘモグロビン尿症候群の1例. 日本内科学会誌 106 : 1191-1198, 2017.
 
5) Yoshida M, Suzuki H, Hamaguchi S, et al : March hemoglobinuria progressed to acute kidney injury after kendo practice : a case report. BMC Nephrol 23 : 368, 2022.
 
6) Furie B, Penn AS : Pigmenturia from conga drumming. Hemoglobinuria and myoglobinuria. Ann Intern Med 80 : 727-729, 1974.
PubMed
7) Vasudev M, Bresnahan BA, Cohen EP, et al : Percussion hemoglobinuria-a novel term for hand trauma-induced mechanical hemolysis : a case report. J Med Case Rep 5 : 508, 2011.
PubMed
8) Streeton JA : Traumatic haemogloinuria caused by karate exercises. Lancet 2 : 191-192, 1967.
PubMed
9) Gilligan DR, Altschule MD, Katersky EM : Physiological intravascular hemolysis of exercise. hemoglobinemia and hemoglobinuria following cross-country runs. J Clin Invest 22 : 859-869, 1943.
PubMed
10) 白石元昭 : ミオグロビン尿症と剣道. 臨床スポーツ医学 6 : 543-550, 1989.
 
11) 血尿診断ガイドライン 2013 (血尿診断ガイドライン編集委員会編), ライフサイエンス出版, 2013.
 
12) Banga JP, Pinder JC, Gratzer WB, et al : An erythrocyte membrane-protein anomaly in march haemoglobinuria. Lancet 2 : 1048-1049, 1979.
PubMed
13) Davidson RJ : Exertionai haemoglobinuria : a report on three cases with studies on the haemolytic mechanism. J Clin Pathol 17 : 536-540, 1964.
PubMed
14) Payne RB : Low plasma haptoglobin in march haemoglobinuria. J Clin Pathol 19 : 170-172, 1966.
 
15) 山口美尚, 保元裕一郎, 竹之内賢一, ほか : 発作性夜間血色素尿症に合併した急性腎不全に対する血液透析療法. 日本透析医学会雑誌 27 : 1215-1221, 1994.
 
16) Kanakura Y, Ohyashiki K, Shichishima T, et al : Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria : the AEGIS clinical trial. Int J Hematol 93 : 36-46, 2011.
PubMed
17) Zhou XJ, Laszik Z, Wang XQ, et al : Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 80 : 1905-1914, 2000.
PubMed
P.401 掲載の参考文献
1) 船山信次 : 毒と薬の科学, p49-53, 朝倉書店. 2007.
 
2) 佐藤哲男, 仮家公夫, 北田光一 (編) : 医薬品トキシコロジー, 改訂第3版, p37-42, 南江堂, 2006.
 
3) 藤田正一 (編) : 毒性学, p84-87, 朝倉書店, 1999.
 
4) 谷憲三朗 : 化学物質, 寄生虫, 微生物による赤血球損傷. 三輪血液病学, 第3版, p1233-1237, 文光堂, 2006.
 
5) 渋谷温 : メトヘモグロビン血症. 小児内科 35 (増刊号) : 1143-1146, 2003.
 
6) 藤井寿一 : 赤血球酵素異常症. 小児内科 35 (増刊号) : 1133-1137, 2003.
 
7) Miller DR, Baehner RL : Blood Diseases of infancy and childhood. hemolytic anemias : metabolic detects Mosby, p360-361, 1995.
 
8) 黒川顕 (編) : 中毒症のすべて-いざという時に役立つ, 的確な治療のために-, 永井書店, 2006.
 
9) 小林尚明 : 薬剤による貧血. 小児科診療 72 : 368-378, 2009.
Medical*Online
10) 矢田純一 : 医科免疫学 12版. 中外医学社, p663-665, 2013
 
11) 矢田純一 : 医科免疫学 16版. 中外医学社, 2021
 
12) 渋谷温 : 小児溶血性貧血の臨床と検査技術, 診断と治療社, 2019.
 
P.405 掲載の参考文献
1) 野村武夫 : 二次性貧血, 最新内科学大系 18, 血液・造血器疾患 1 貧血, 多血症, p399-416, 中山書店, 1992.
 
2) Cooper RA, Diloy Puray M, Lando P, et al : An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease. J Clin Invest 51 : 3182-3192, 1972.
PubMed
3) Ammus S, Yunis AA : Drug-induced red cell dyscrasias. Blood Rev 3 : 71-82, 1989.
PubMed
4) Michot F, Gut J : Alcohol-induced bone marrow damage. A bone marrow study in alcohol-dependent individuals. Acta Haematol 78 : 252-257, 1987.
 
5) Lee P, Peng H, Gelbart T, et al : Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 102 : 1906-1910, 2005.
 
6) Nemeth E, Rivera S, Gabayan V, et al : IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 : 1271-1276, 2004.
 
7) Nemeth E, Tuttle MS, Powelson J, et al : Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 : 2090-2093, 2004.
PubMed
8) Quirt I, Robeson C, Lau CY, et al : Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19 : 4126-4134, 2001.
PubMed
9) Brown KE, Tisdale J, Barrett AJ, et al : Hepatitis-associated aplastic anemia. N Engl J Med 336 : 1059-1064, 1997.
PubMed
10) Young NS, Maciejewski J : The pathophysiology of acquired aplastic anemia. N Engl J Med 336 : 1365-1372, 1997.
PubMed
P.408 掲載の参考文献
1) Wopereis DM, Du Puy RS, van Heemst D, et al : The Relation Between Thyroid Function and Anemia : A Pooled Analysis of Individual Participant Data. J Clin Endocrinol Metab 103 : 3658-3667, 2018.
 
2) Das KC, Mukherjee M, Sarkar TK, et al : Erythropoiesis and erythropoietin in hypo- and hyperthyroidism. J Clin Endocrinol Metab 40 : 211-220, 1975.
PubMed
3) Soliman AT, De Sanctis V, Yassin M, et al : Chronic anemia and thyroid function. Acta Biomed 88 : 119-127, 2017.
PubMed
4) Brenner B, Fandrey J, Jelkmann W : Serum immunoreactive erythropoietin in hyper- and hypothyroidism : clinical observations related to cell culture studies. Eur J Haematol 53 : 6-10, 1994.
PubMed
5) Rivlin RS, Wagner HN Jr : Anemia in hyperthyroidism. Ann Intern Med 70 : 507-516, 1969.
PubMed
6) Jyo-Oshiro Y, Nomura S, Fukushima T, et al : Primary hyperthyroidism induced erythropoietin-resistant anemia? Intern Med 36 : 903-905, 1997.
PubMed
7) Boxer M, Ellman L, Geller R, et al : Anemia in primary hyperparathyroidism. Arch Intern Med 137 : 588-593, 1977.
PubMed
8) Sikole A : Pathogenesis of anaemia in hyperparathyroidism. Med Hypotheses 54 : 236-238, 2000.
PubMed
9) Peschle C, Sasso GF, Mastroberardino G, et al : The mechanism of endocrine influences on erythropoiesis. J Lab Clin Med 78 : 20-29, 1971.
PubMed
10) Shahani S, Braga-Basaria M, Maggio M, et al : Androgens and erythropoiesis : past and present. J Endocrinol Invest 32 : 704-716, 2009.
PubMed
11) Roy CN, Snyder PJ, Stephens-Shields AJ, et al : Association of Testosterone Levels With Anemia in Older Men : A Controlled Clinical Trial. JAMA Intern Med 177 : 480-490, 2017.
 
12) Esposito A, Capalbo D, De Martino L, et al : Long-term effects of growth hormone (GH) replacement therapy on hematopoiesis in a large cohort of children with GH deficiency. Endocrine 53 : 192-198, 2016.
 
13) Meazza C, Bonomelli I, Pagani S, et al : Effect of human recombinant growth hormone therapy on circulating levels of erythropoietin and granulocyte-colony stimulating factor in short children. J Pediatr Endocrinol Metab 22 : 837-843, 2009.
 
14) Livnah O, Stura EA, Johnson DL, et al : Functional mimicry of a protein hormone by a peptide agonist : the EPO receptor complex at 2.8 A. Science 273 : 464-471, 1996.
PubMed
15) Nishioka H, Haraoka J : Hypopituitarism and anemia : effect of replacement therapy with hydrocortisone and/or levothyroxine. J Endocrinol Invest 28 : 528-533, 2005.
PubMed
P.413 掲載の参考文献
1) 日本透析医学会 : 2015年版 慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌 49 : 89-158, 2016.
 
2) Sofue T, Nakagawa N, Kanda E, et al : Prevalence of anemia in patients with chronic kidney disease in Japan : A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One 15 : e0236132, 2020.
PubMed
3) Suzuki N : Erythropoietin gene expression : developmental-stage specificity, cell-type specificity, and hypoxia inducibility. Tohoku J Exp Med 235 : 233-240, 2015.
PubMed
4) Asada N, Takase M, Nakamura J, et al : Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 121 : 3981-3990, 2011.
PubMed
5) Konishi Y, Nishiyama A, Morikawa T, et al : Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy. Hypertension 58 : 205-211, 2011.
PubMed
6) Nangaku M : Chronic hypoxia and tubulointerstitial injury : a final common pathway to end-stage renal failure. J Am Soc Nephrol 17 : 17-25, 2006.
PubMed
7) Naito Y, Masuyama T, Ishihara M : Iron and cardiovascular diseases. J Cardiol 77 : 160-165, 2021.
PubMed
8) Miyake T, Kung CK, Goldwasser E : Purification of human erythropoietin. J Biol Chem 252 : 5558-5564, 1977.
PubMed
9) Gupta N, Wish JB : Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors : A Potential New Treatment for Anemia in Patients With CKD. Am J Kidney Dis 69 : 815-826, 2017.
PubMed
10) 日本腎臓学会 : HIF-PH阻害薬適正使用に関するrecommendation, 2020年9月29日版. 日腎会誌 62 : 711-716, 2020.
 
11) Ichii M, Mori K, Miyaoka D, et al : Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis. BMC Nephrol 22 : 104, 2021.
 
12) Akizawa T, Saito A, Gejyo F, et al : Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients. Ther Apher Dial 18 : 404-413, 2014.
PubMed
13) Tsubakihara Y, Akizawa T, Iwasaki M, et al : High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment. Ther Apher Dial 19 : 457-465, 2015.
 
14) エビデンスに基づくCKD診療ガイドライン 2023 (日本腎臓学会編), 東京医学社, 2023.
 
15) Akizawa T, Gejyo F, Nishi S, et al : Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis : a randomized controlled study. Ther Apher Dial 15 : 431-440, 2011.
 
P.418 掲載の参考文献
1) Robert DC : Neonatal Erythrocyte Disorders. In : Avery's Diseases of the Newborn, 10th ed (ed by Gleason CA, Juul SE), p1152-1179, Elsevier, Philadelphia, 2017.
 
2) Cibulskis CC, Maheshwari A, Rao R, et al : Anemia of prematurity : how low is too low? J Perinatol 41 : 1244-1257, 2021.
 
3) Strauss RG : Anaemia of prematurity : pathophysiology and treatment. Blood Rev 24 : 221-225, 2010.
PubMed
4) Saito-Benz M, Flanagan P, Berry MJ : Management of anaemia in pre-term infants. Br J Haematol 188 : 354-366, 2020.
PubMed
5) Widness JA : Pathophysiology of anemia during the neonatal period, including anemia of prematurity. Neoreviews 9 : e520, 2008.
PubMed
6) Juul SE, Robert DC : Developmental Hematology. In : Avery's Diseases of the Newborn,10th ed (ed by Gleason CA, Juul SE), p1113-1120, Elsevier, Philadelphia, 2017.
 
7) Ross MP, Christensen RD, Rothstein G, et al : A randomized trial to develop criteria for administering erythrocyte transfusions to anemic preterm infants 1 to 3 months of age. J Perinatol 9 : 246-253, 1989.
 
8) Lenhartova N, Ochiai M, Sawano T, et al : Serum erythroferrone levels during the first month of life in premature infants. J Perinatol 42 : 97-102, 2022.
PubMed
9) 厚生労働省医薬・生活衛生局 : 新生児・小児に対する輸血療法. 血液製剤の使用指針, p42, 2019.
 
10) Ibrahim M, Ho SK, Yeo CL : Restrictive versus liberal red blood cell transfusion thresholds in very low birth weight infants : a systematic review and meta-analysis. J Paediatr Child Health 50 : 122-130, 2014.
PubMed
11) Wang P, Wang X, Deng H, et al : Restrictive versus liberal transfusion thresholds in very low birth weight infants : a systematic review with meta-analysis. PLoS One 16 : e0256810, 2021.
 
12) Alan S, Arsan S : Prevention of the anaemia of prematurity. Int J Pediatr Adolesc Med 2 : 99-106, 2015.
PubMed
13) Aher SM, Ohlsson A : Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. Cochrane Database Syst Rev 1 : CD004868, 2020.
 
14) 楠田聡, 板橋家頭夫, 落合正行, ほか日本新生児成育医学会医療の標準化委員会鉄剤投与のガイドライン改訂ワーキング・グループ : 新生児に対する鉄剤投与のガイドライン 2017, 早産児・低出生体重児の重症貧血予防と神経発達と成長の向上を目的として. 日本新生児成育医学会雑誌 31 : 159-185, 2019.
 
P.424 掲載の参考文献
1) 森眞由美 : 高齢者の貧血をどう診るか. 日本老年医学会雑誌 45 : 594-596, 2008.
 
2) 小船雅義 : 鉄欠乏・鉄欠乏性貧血の疫学・症状. 鉄剤の適正使用による貧血治療指針, 改訂 [第3版] (日本鉄バイオサイエンス学会治療指針作成委員会編), p9-13, 2015.
 
3) Stauder R, Valent P, Theurl I : Anemia at older age : etiologies, clinical implications, and management. Blood 131 : 505-514, 2018.
PubMed
4) Bach V, Schruckmayer G, Sam I, et al : Prevalence and possible causes of anemia in the elderly : a cross-sectional analysis of a large European university hospital cohort. Clin Interv Aging 9 : 1187-1196, 2014.
PubMed
5) 川端浩 : 慢性疾患に伴う貧血 (anemia of chronic disease : ACD). 鉄剤の適正使用による貧血治療指針, 改訂 [第3版] (日本鉄バイオサイエンス学会治療指針作成委員会編), p27-29, 2015.
 
6) Babitt JL, Lin HY : Mechanisms of anemia in CKD. J Am Soc Nephrol 23 : 1631-1634, 2012.
PubMed
7) Sofue T, Nakagawa N, Kanda E, et al : Prevalence of anemia in patients with chronic kidney disease in Japan : A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One 15 : e0236132, 2020.
PubMed
8) 山本裕康, ほか : 2015年版 日本透析医学会慢性腎臓病患者における腎性貧血治療のガイドライン. 日本透析医学会雑誌 49 : 89-158, 2016.
 
9) 松田晃 : 骨髄異形成症候群 (MDS) の診断基準を満たさないMDS類似病態. 臨床検査 64 : 766-770, 2020.
 
10) Malcovati L, Galli A, Travaglino E, et al : Clinical significance of somatic mutation in unexplained blood cytopenia. Blood 129 : 3371-3378, 2017.
PubMed
11) 張替秀郎 : 貧血診療のコツとピットフォール. 日本内科学会雑誌 112 : 495-500, 2023.
 
12) 高見昭良 : 微量金属と貧血. 臨床血液 62 : 909-913, 2021.
 
13) Erdogan M, Kosenli A, Ganidagli S, et al : Characteristics of anemia in subclinical and overt hypothyroid patients. Endocr J 59 : 213-220, 2012.
PubMed
14) Culleton BF, Manns BJ, Zhang J, et al : Impact of anemia on hospitalization and mortality in older adults. Blood 107 : 3841-3846, 2006.
PubMed
P.429 掲載の参考文献
1) Kroll MH, Rojas-Hernandez C, Yee C : Hematologic complications of immune checkpoint inhibitors. Blood 139 : 3594-3604, 2022.
PubMed
2) Richard CF, Vandita PJ : Autoimmune Hemolytic Anemia Red cell aplasia : Acquired and Congenital Disorders In : Wintrobe's Clinical Hematology, 14th edition (ed by Greer JP, Rodgers GM, Glader B, eT al), p762-782, Lippincott Williams & Wilkins, Philadelphia, London, 2019.
 
3) 半下石明 : 薬剤性貧血 : 発症機序・分類・病態 (溶血性, 骨髄性). 日本臨牀 75 (増刊 1 : 貧血学) : 540-544, 2017.
 
4) Garratty G, Arndt PA : Positive direct antiglobulin tests and haemolytic anaemia following therapy with beta-lactamase inhibitor containing drugs may be associated with nonimmunologic adsorption of protein onto red blood cells. Br J Haematol 100 : 777-783, 1998.
PubMed
5) 難治性疾患等政策研究事業「血液凝固異常症に関する調査研究班」TTPグループ (松本雅則, ほか) : 血栓性血小板減少性紫斑病 (TTP) 診療ガイド 2017. 臨床血液 58 : 271-281, 2017.
 
6) Sugio Y, Okamura T, Shimoda K, et al : Ticlopidine-Associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity. Int J Hematol 74 : 347-351, 2001.
PubMed
7) Zakarija A, Kwaan HC, Moake JL, et al : Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP) : review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl (112) S20-S24, 2009.
PubMed
8) George JM, Cuker A : Drug-induced thrombotic microangiopathy (DITMA). UpToDate. [http://www.uptodate.com] (Accessed on April 19, 2023)
 
9) Filippis SD, Moore C, Ezell K, et al : Immune Checkpoint Inhibitor-Associated Thrombotic Thrombocytopenic Purpura in a Patient with Metastatic Non-Small-Cell Lung Cancer. Cureus 13 : e16035, 2021.
 
10) De Franceschi L, Fattovich G, Turrini F, et al : Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection : role of membrane oxidative damage. Hepatology 31 : 997-1004, 2000.
PubMed
11) Ochi H, Maekawa T, Abe H, et al : ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 139 : 1190-1197, 2010.
PubMed
12) Marsh JC, Ball SE, Cavenagh J, et al : Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 147 : 43-70, 2009.
PubMed
13) Naria A, Lipton JM, Means RT : Red cell aplasia : Acquired and Congenital Disorders. In : Wintrobe's Clinical Hematology, 14th edition (ed by Greer JP, Rodgers GM, Glader B, eT al, p990-1001, Lippincott Williams & Wilkins, Philadelphia, London, 2019.
 
14) Dessypris EN, Redline S, Harris JW, et al : Diphenylhydantoin-induced pure red cell aplasia. Blood 65 : 789-794, 1985.
PubMed
15) 脇本直樹, 松田晃 : 巨赤芽球性貧血の病態・臨床像. 日本臨牀 75 (増刊 1 : 貧血学) : 167-171, 2017.
 
P.433 掲載の参考文献
1) 国立がん研究センターがん情報サービス. [https://ganjoho.jp/public/index.html]
 
2) Hall EJ, Giaccia AJ : Radiobiology for the Radiologist, 6th ed, Lippincott Williams & Wilkins, Philadelphia, 2005.
 
3) Joiner M, von der Kongel A (ed) : Basic Clinical Radiobiology (ed by Steel GG). 4th ed. Oxford University Press. London, 2009.
 
4) Jefferies S, Rajan B, Ashley S, et al : Haematological toxicity of cranio-spinal irradiation. Radiother Oncol 48 : 23-27, 1998.
PubMed
5) Mac Manus M, Lamborn K, Khan W, et al : Radiotherapy-associated neutropenia and thrombocytopenia : analysis of risk factors and development of a predictive model. Blood 89 : 2303-2310, 1997.
PubMed
6) Samper Ots PM, Munoz J, Biete A, et al : PITASOR epidemiological study : prevalence, incidence and treatment of anaemia in radiation therapy oncology departments in Spain. Clin Transl Oncol 13 : 322-327, 2011.
PubMed
7) Harrison LB, Shasha D, Homel P : Prevalence of anemia in cancer patients undergoing radiotherapy : prognostic significance and treatment. Oncology 63 (Suppl 2) : 11-18, 2002.
 
8) Verbeke N, Beguin Y, Wildiers H, et al : High prevalence of anaemia and limited use of therapy in cancer patients : a Belgian survey (Anaemia Day 2008). Support Care Cancer 20 : 23-28, 2012.
PubMed
9) Harrison LB, Shasha D, White C, et al : Radiotherapy-associated anemia : The scope of the problem. Oncologist 5 (Suppl 2) : 1-7, 2000.
 
10) Mell LK, Schomas DA, Salama JK, et al : Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 70 : 1431-1437, 2008.
PubMed
11) Nunia V, Goyal PK : Prevention of gamma radiation induced anaemia in mice by diltiazem. J Radiat Res 45 : 11-17, 2004.
PubMed
12) Maahs L, Ghanem AI, Gutta R, et al : Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy. BMC Cancer 22 : 626, 2022.
PubMed
13) Dunst J, Kuhnt T, Strauss HG, et al : Anemia in cervical cancers : impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 56 : 778-787, 2003.
PubMed
14) Fein DA, Lee WR, Hanlon AL, et al : Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13 : 2077-2083, 1995.
PubMed
15) Shenouda G, Zhang Q, Ang KK, et al : Long-term results of radiation therapy oncology group 9903 : a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 91 : 907-915, 2015.
PubMed
P.438 掲載の参考文献
1) Robert T, et al : Acquired nonimmune hemolytic anemia. In : Wintrobe's Clinical Hematology. 15th edition, Volume 1 (ed by Means RT, Rodgers GM, Glader B, et al), p821-832, Wolters Kluwer, Philadelphia, 2023.
 
2) WHO : Global trends in the burden of malaria. In : World malaria report 2022, p14-33, WHO Press, Geneva, 2022.
 
3) 加藤康幸 : マラリア. 寄生虫症薬物治療の手引き-2020-, 改訂10.2版 (丸山治彦, 木村幹男, 小山佳祐編), p1-7, 熱帯病治療薬研究班, 2020.
 
4) 狩野繁之, 鈴木守 : 日本における輸血マラリア-血小板輸血により感染したと考えられる熱帯熱マラリア1症例を中心に-. 日本熱帯医学会雑誌 22 : 193-198, 1994.
 
5) 斎藤あつ子, Dantrakool A, 河合敦子, ほか : 原虫感染症バベシア症. 日本臨牀 61 (Suppl 2) : 623-628, 2003.
 
6) Herwaldt BL, Neitzel DF, Gorlin JB, et al : Transmission of Babesia microti in Minnesota through four blood donations from the same donor over a 6-month period. Transfusion 42 : 1154-1158, 2002.
 
7) 松井利充, 井之上竜一, 梶本和義, ほか : 輸血後に発症したバーベシア症の本邦第1例. 臨床血液 41 : 628-634, 2000.
 
8) Antinori S, Galimberti L, Milazzo L, et al : Plasmodium knowlesi : the emerging zoonotic malaria parasite. Acta Trop 125 : 191-201, 2013.
PubMed
9) Tanizaki R, Ujiie M, Kato Y, et al : First case of Plasmodium knowlesi infection in a Japanese traveller returning from Malaysia. Malar J 12 : 128, 2013.
 
10) Homer MJ, Aguilar-Delfin I, Telford SR 3rd, et al : Babesiosis. Clin Microbiol Rev 13 : 451-469, 2000.
PubMed
11) 長野基子, 大森志保, 斎藤あつ子, ほか : 兵庫県西宮市におけるマダニのBabesia属原虫保有状況調査. 兵庫医療大学紀要 9 : 3-7, 2021.
 
12) Hanspal M, Dua M, Takakuwa Y, et al : Plasmodium falciparum cysteine protease falcipain-2 cleaves erythrocyte membrane skeletal proteins at late stages of parasite development. Blood 100 : 1048-1054, 2002.
PubMed
13) 堤寛 : 感染症の病理〔44〕マラリア, バベシア症. 病理と臨床 16 : 1340-1344, 1998.
 
14) Komaki-Yasuda K, Kutsuna S, Kawaguchi M, et al : Clinical performance testing of the automated haematology analyzer XN-31 prototype using whole blood samples from patients with imported malaria in Japan. Malar J 21 : 229, 2022.
PubMed
15) Baneth G : Antiprotozoal treatment of canine babesiosis. Vet Parasitol 254 : 58-63, 2018.
PubMed
P.443 掲載の参考文献
1) Varlamov O, Bucher M, Myatt L, et al : Daily Ethanol Drinking Followed by an Abstinence Period Impairs Bone Marrow Niche and Mitochondrial Function of Hematopoietic Stem/Progenitor Cells in Rhesus Macaques. Alcohol Clin Exp Res 44 : 1088-1098, 2020.
PubMed
2) Latvala J, Parkkila S, Niemela O : Excess alcohol consumption is common in patients with cytopenia : studies in blood and bone marrow cells. Alcohol Clin Exp Res 28 : 619-624, 2004.
PubMed
3) Varela-Rey M, Woodhoo A, Martinez-Chantar ML, et al : Alcohol, DNA methylation, and cancer. Alcohol Res 35 : 25-35, 2013.
PubMed
4) Halsted CH, Villanueva JA, Devlin AM, et al : Metabolic interactions of alcohol and folate. J Nutr 132 : 2367S-2372S, 2002.
PubMed
5) Yokoyama M, Yokoyama A, Yokoyama T, et al : Mean corpuscular volume and the aldehyde dehydrogenase-2 genotype in male Japanese workers. Alcohol Clin Exp Res 27 : 1395-1401, 2003.
PubMed
6) Koivisto H, Hietala J, Anttila P, et al : Long-term ethanol consumption and macrocytosis : diagnostic and pathogenic implications. J Lab Clin Med 147 : 191-196, 2006.
PubMed
7) Meagher RC, Sieber F, Spivak JL : Suppression of hematopoietic-progenitor-cell proliferation by ethanol and acetaldehyde. N Engl J Med 307 : 845-849, 1982.
PubMed
8) Kohgo Y, Ohtake T, Ikuta K, et al : Dysregulation of systemic iron metabolism in alcoholic liver diseases. J Gastroenterol Hepatol 23 (Suppl 1) : S78-S81, 2008.
 
9) Simet SM, Sisson JH : Alcohol's Effects on Lung Health and Immunity. Alcohol Res 37 : 199-208, 2015.
PubMed
10) Jareo PW, Preheim LC, Gentry MJ : Ethanol ingestion impairs neutrophil bactericidal mechanisms against Streptococcus pneumoniae. Alcohol Clin Exp Res 20 : 1646-1652, 1996.
PubMed
11) Das SK, Vasudevan DM : Alcohol-induced oxidative stress. Life Sci 81 : 177-187, 2007.
PubMed
12) Singhal PC, Patel P, Nahar N, et al : Ethanol-induced neutrophil apoptosis is mediated through nitric oxide. J Leukoc Biol 66 : 930-936, 1999.
PubMed
13) Jonsson AS, Palmblad JE : Effects of ethanol on NF-kappaB activation, production of myeloid growth factors, and adhesive events in human endothelial cells. J Infect Dis 184 : 761-769, 2001.
PubMed
14) Malherbe DC, Messaoudi I : Transcriptional and Epigenetic Regulation of Monocyte and Macrophage Dysfunction by Chronic Alcohol Consumption. Front Immunol 13 : 911951, 2022.
PubMed
15) Levine RF, Spivak JL, Meagher RC, et al : Effect of ethanol on thrombopoiesis. Br J Haematol 62 : 345-354, 1986.
PubMed
P.447 掲載の参考文献
1) Gibson Q : Introduction : congenital methemoglobinemia revisited. Blood 100 : 3445-3446, 2002.
PubMed
2) Hultquist DE, Passon PG : Catalysis of methaemoglobin reduction by erythrocyte cytochrome B5 and cytochrome B5 reductase. Nat New Biol 229 : 252-254, 1971.
PubMed
3) Shirabe K, Yubisui T, Takeshita M : Expression of human erythrocyte NADH-cytochrome b5 reductase as an α-thrombin-cleavable fused protein in Escherichia coli. Biochim Biophys Acta 1008 : 189-192, 1989.
 
4) Shirabe K, Yubisui T, Borgese N, et al : Enzymatic instability of NADH-cytochrome b5 reductase as a cause of hereditary methemoglobinemia type I (red cell type). J Biol Chem 267 : 20416-20421, 1992.
PubMed
5) Nagai T, Shirabe K, Yubisui T, et al : Analysis of mutant NADH-cytochrome b5 reductase : apparent "type III" methemoglobinemia can be explained as type I with an unstable reductase. Blood 81 : 808-814, 1993.
PubMed
6) Shirabe K, Fujimoto Y, Yubisui T, et al : An in-frame deletion of codon 298 of the NADH-cytochrome b5 reductase gene results in hereditary methemoglobinemia type II (generalized type). A functional implication for the role of the COOH-terminal region of the enzyme. J Biol Chem 269 : 5952-5957, 1994.
 
7) Bando S, Takano T, Yubisui T, et al : Structure of human erythrocyte NADH-cytochrome b5 reductase. Acta Crystallogr D Biol Crystallogr 60 : 1929-1934, 2004.
PubMed
8) Toelle SP, Boltshauser E, Mossner E, et al : Severe neurological impairment in hereditary methaemoglobinaemia type 2. Eur J Pediatr 163 : 207-209, 2004.
PubMed
9) Leroux A, Leturcq F, Deburgrave N, et al : Prenatal diagnosis of recessive congenital methaemoglobinaemia type II : novel mutation in the NADH-cytochrome b5 reductase gene leading to stop codon read-through. Eur J Haematol 74 : 389-395, 2005.
PubMed
10) Hegesh E, Hegesh J, Kaftory A : Congenital methemoglobinemia with a deficiency of cytochrome b5. N Engl J Med 314 : 757-761, 1986.
PubMed
11) Iyanagi T, Watanabe S, Anan KF : One-electron oxidation-reduction properties of hepatic NADH-cytochrome b5 reductase. Biochemistry 23 : 1418-1425, 1984.
PubMed
12) Oshino N, Imai Y, Sato R : A function of cytochrome b5 in fatty acid desaturation by rat liver microsomes. J Biochem 69 : 155-167, 1971.
 
13) Keyes SR, Cinti DL : Biochemical properties of cytochrome b5-dependent microsomal fatty acid elongation and identification of products. J Biol Chem 255 : 11357-11364, 1980.
PubMed
14) Reddy VV, Kupfer D, Caspi E : Mechanism of C-5 double bond introduction in the biosynthesis of cholesterol by rat liver microsomes. J Biol Chem 252 : 2797-2801, 1977.
PubMed
15) Shirabe K, Landi MT, Takeshita M, et al : A novel point mutation in a 3' splice site of the NADH-cytochrome b5 reductase gene results in immunologically undetectable enzyme and impaired NADH-dependent ascorbate regeneration in cultured fibroblasts of a patient with type II hereditary methemoglobinemia. Am J Hum Genet 57 : 302-310, 1995.
 
16) Carew NT, Schmidt HM, Yuan S, et al : Loss of cardiomyocyte CYB5R3 impairs redox equilibrium and causes sudden cardiac death. J Clin Invest 132 : e147120, 2022.
PubMed
17) Ishimura R, El-Gowily AH, Noshiro D, et al : The UFM1 system regulates ER-phagy through the ufmylation of CYB5R3. Nat Commun 13 : 7857, 2022.
PubMed
18) Pietrini G, Aggujaro D, Carrera P, et al : A single mRNA, transcribed from an alternative, erythroid-specific, promoter, codes for two non-myristylated forms of NADH-cytochrome b5 reductase. J Cell Biol 117 : 975-986, 1992.
 
19) Aalfs CM, Salieb-Beugelaar GB, Wanders RJ, et al : A case of methemoglobinemia type II due to NADH-cytochrome b5 reductase deficiency : determination of the molecular basis. Hum Mutat 16 : 18-22, 2000.
 
20) Yubisui T, Shirabe K, Takeshita M, et al : Structural role of serine 127 in the NADH-binding site of human NADH-cytochrome b5 reductase. J Biol Chem 266 : 66-70, 1991.
PubMed
21) Percy MJ, Gillespie MJ, Savage G, et al : Familial idiopathic methemoglobinemia revisited : original cases reveal 2 novel mutations in NADH-cytochrome b5 reductase. Blood 100 : 3447-3449, 2002.
PubMed
P.451 掲載の参考文献
1) Percy MJ, McFerran NV, Lappin TR : Disorders of oxidised haemoglobin. Blood Rev 19 : 61-68, 2005.
 
2) Lichtman M, Kaushansky K, Prchal J, et al : Williams Hematology, 10th ed, McGraw Hill, New York, 2022.
 
3) Proteopedia : Hemoglobin. [http://proteopedia.org/wiki/index.php/Hemoglobin]
 
4) Nagai M, Aki M, Li R, et al : Heme structure of hemoglobin M Iwate [alpha 87 (F8) His→Tyr] : a UV and visible resonance Raman study. Biochemistry 39 : 13093-13105, 2000.
 
5) Ameri A, Fairbanks VF, Yanik GA, et al : Identification of the molecular genetic defect of patients with methemoglobin M-Kankakee (M-Iwate), alpha87 (F8) His→Tyr : evidence for an electrostatic model of alphaM hemoglobin assembly. Blood 94 : 1825-1826, 1999.
 
6) Shin C, Hong M, Kim M, et al : Exon sequencing of the alpha-2-globin gene for the differential diagnosis of central cyanosis in newborns : a case report. BMC Pediatr 19 : 221, 2019.
 
P.455 掲載の参考文献
1) Blanc PD : メトヘモグロビン血症. 中毒ハンドブック 原著第2版 (Olson KR 編・坂本哲也監訳), p178-180, メディカル・サイエンス・インターナショナル, 1999.
 
2) 内藤裕史 : 酸アミド系除草剤. 中毒百科事例・病態・治療工業製品/ガス/農薬/医薬品/動植物 改訂第2版, p313-315, 南江堂, 2001.
 
3) 石津澄子 : 化学物質による職業性障害について. 東女医大誌 51 : 79-89, 1981.
 
4) 内藤裕史 : メトヘモグロビン生成物質. 中毒百科事例・病態・治療工業製品/ガス/農薬/医薬品/動植物 改訂第2版, p126-130, 南江堂, 2001.
 
5) 森浩介, 岩下眞之, 大川卓巳, ほか : アニリン中毒による重症メトヘモグロビン血症の1例. 日本救急医学会関東地方会雑誌 30 : 158-159, 2009.
 
6) 中央労働災害防止協会 : 事例5 4-トリフルオロメチルアニリンによる中毒. 平成13年度労働衛生のしおり (厚生労働省労働基準局編), p254-256, 中央労働災害防止協会, 2001.
 
7) 田島啓一 : チアノーゼ (メトヘモグロビン血症) -専門医が明かす診断・治療チャート中毒系-. 治療 76 : 781-784, 1994.
 
8) 林昭 : 血液毒-メトヘモグロビン. 中毒研究 1 : 135-141, 1988.
 
9) 南正康 : 血球化学検査-メトヘモグロビン. 日本臨床 68 (増刊 1 広範囲血液・尿化学検査免疫学的検査 (第7版) (2)) : 829-832, 2010.
 
P.460 掲載の参考文献
1) 小山完二, ほか : 血液毒-スルフヘモグロビン. 中毒研究 1 : 143-148, 1988.
 
2) Chatfield MJ, La Mar GN : 1H nuclear magnetic resonance study of the prosthetic group in sulfhemoglobin. Arch Biochem Biophys 295 : 289-296, 1992.
PubMed
3) 大庭雄三 : スルフヘモグロビン血症-赤血球の異常メトヘモグロビン血症と類似疾患. 別冊日本臨牀血液症候群 I, p449-452, 1998.
 
4) 清田和也 : 石灰硫黄合剤-スルフヘモグロビン血症, 腐食性食道炎を呈した経口摂取例 (特集 症例・事例から学ぶ中毒診療-殺虫剤). 救急医学 33 : 383-386, 2009.
 
5) 米川力, 中永士師明 : 石灰硫黄合剤による1中毒例. 日本臨床救急医学会雑誌 5 : 66-69, 2002.
Medical*Online
6) 南正康 : 血球化学検査-スルフヘモグロビン. 日本臨牀 68 (増刊 1 : 広範囲血液・尿化学検査免疫学的検査 (第7版) (2)) : 825-828, 2010.
 
7) Finch CA : Methemoglobinemia and sulfhemoglobinemia. N Engl J Med 239 : 470-478, 1948.
PubMed
8) 田島啓一 : チアノーゼ (メトヘモグロビン血症) -専門医が明かす診断・治療チャート中毒系-. 治療 76 : 781-784, 1994.
 
9) Nichol AW, Morell DB : Spectrophotometric determination of mixtures of sulphhaemoglobin and methaemoglobin in blood. Clin Chim Acta 22 : 157-160, 1968.
PubMed
10) 水野嘉夫, 中沢博江, 坂口博邦, ほか : サルフヘモグロビン血症の1例. 臨床血液 13 : 392-396, 1972.
 
11) 大森見布江, ほか : 石灰硫黄中毒の1例. 日本救急医学会関東地方会雑誌 22 : 66-67, 2001.
 
P.464 掲載の参考文献
1) Watts RN, Ponka P, Richardson DR : Effects of nitrogen monoxide and carbon monoxide on molecular and cellular iron metabolism : Mirror-image effector molecules that target iron. Biochem J 369 : 429-440, 2003.
PubMed
2) Christiansen J, Douglas CG, Haldane JS : The absorption and dissociation of carbon dioxide by human blood. J Physiol 48 : 244-271, 1914.
 
3) 政府統計e-stat. [https://www.e-stat.go.jp/]
 
4) Cronje FJ, Carraway MS, Freiberger JJ, et al : Carbon monoxide actuates O2 -limited heme degradation in the rat brain. Free Radic Biol Med 37 : 1802-1812, 2004.
PubMed
5) Alonso JR, Cardellach F, Lopez S, et al : Carbon monoxide specifically inhibits cytochrome c oxidase of human mitochondrial respiratory chain. Pharmacol Toxicol 93 : 142-146, 2003.
PubMed
6) Chin BY, Jiang G, Wegiel B, et al : Hypoxia-inducible factor 1alpha stabilization by carbon monoxide results in cytoprotective preconditioning. Proc Natl Acad Sci U S A 104 : 5109-5114, 2007.
PubMed
7) Piantadosi CA, Zhang J, Levin ED, et al : Apoptosis and delayed neuronal damage after carbon monoxide poisoning in the rat. Exp Neurol 147 : 103-114, 1997.
PubMed
8) Thom SR, Bhopale VM, Han ST, et al : Intravascular neutrophil activation due to carbon monoxide poisoning. Am J Respir Crit Care Med 174 : 1239-1248, 2006.
PubMed
9) Weaver LK, Hopkins RO, Chan KJ, et al : Hyperbaric oxygen for acute carbon monoxide poisoning. N Engl J Med 347 : 1057-1067, 2002.
PubMed
10) Thom SR : Carbon monoxide pathophysiology and treatment. In : Physiology and Medicine of Hyperbaric Oxygen Therapy. (ed by Newman TS, Thom SR), p321-347, Saunders, Philadelphia : 2008.
 
11) Kao LW, Nanagas KA : Carbon monoxide poisoning. Emerg Med Clin North Am 22 : 985-1018, 2004.
PubMed
12) Touger M, Gallagher EJ, Tyrell J : Relationship between venous and arterial carboxyhemoglobin levels in patients with suspected carbon monoxide poisoning. Ann Emerg Med 25 : 481-483, 1995.
PubMed
13) Fujita M, Todani M, Kaneda K, et al : Use of hyperbaric oxygen therapy for preventing delayed neurological sequelae in patients with carbon monoxide poisoning : A multicenter, prospective, observational study in Japan. PLoS One 16 : e0253602, 2021.
PubMed
14) Pace N, Strajman E, Walker EL : Acceleration of carbon monoxide elimination in man by high pressure oxygen. Science 111 : 652-654, 1950.
 
15) Ozturan IU, Yaka E, Suner S, et al : Determination of carboxyhemoglobin half-life in patients with carbon monoxide toxicity treated with high flow nasal cannula oxygen therapy. Clin Toxicol (Phila) 57 : 617-623, 2019.
PubMed
16) Gesel LB, Hyperbaric oxygen 2009 : indications and results : the Hyperbaric Oxygen Therapy Committee report. Durham, NC : Undersea and Hyperbaric Medical Society, 2008.
 
17) Weaver LK, Hopkins RO, Churchill S, et al : Neurological outcomes 6 years after acute carbon monoxide poisoning. Undersea Hyperb Med 35 : 258-259, 2008.
 
P.470 掲載の参考文献
1) Schultz JH : Ein fall von pemphigus leprosusc omplicirt durch lepra visceralis (thesisi), p44, Kunike, 1874.
 
2) Gunther H : Die Haematoporphyrie. Dtsch Arch Klin Med 105 : 89-146, 1911.
 
3) 近藤雅雄, 矢野雄三, 浦田郡平 : 日本の遺伝性ポルフィリン症. 1920年 (第1例報告) から91年間 (2010年) の集計. ALA-Porphyrin Science 1 : 73-82, 2012.
 
4) Fritsch C, Bolsen K, Ruzicka T, et al : Congenital erythropoietic porphyria. J Am Acad Dermatol 36 : 594-610, 1997.
PubMed
5) 佐藤彰, 高橋寛 : 一種の家族的貧血症か儀血色素尿性貧血症. 児科雑誌 239 : 47-48, 1920.
 
6) 近藤雅雄, 矢野雄三, 浦田郡平, ほか : 本邦で報告された先天性赤芽球性ポルフィリン症の全症例解析. Porphyrins 14 : 69-84, 2005.
 
7) Fontanellas A, Bensidhoum M, Enriquez de Salamanca R, et al : A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Eur J Hum Genet 4 : 274-282, 1996.
PubMed
8) Takamura N, Hombrados I, Tanigawa K, et al : Novel point mutation in the uroporphyrinogen III synthase gene causes congenital erythropoietic porphyria of a Japanese family. Am J Med Genet 70 : 299-302, 1997.
PubMed
9) Desnick RJ, Astrin KH : Congenital erythropoietic porphyria : advances in pathogenesis and treatment. Br J Haematol 117 : 779-795, 2002.
PubMed
10) 谷川健, 高村昇, 山下俊一, ほか : 先天性骨髄性ポルフィリン症. 日本臨牀 53 : 1422-1426, 1995.
Medical*Online
11) Haining RG, Cowger ML, Shurtleff DB, et al : Congenital erythropoietic porphyria. I. Case report, special studies and therapy. Am J Med 45 : 624-637, 1968.
PubMed
12) Rank JM, Straka JG, Weimer MK, et al : Hematin therapy in late onset congenital erythropoietic porphyria. Br J Haematol 75 : 617-618, 1990.
PubMed
13) Kauffman L, Evans DI, Stevens RF, et al : Bone-marrow transplantation for congenital erythropoietic porphyria. Lancet 337 : 1510-1511, 1991.
PubMed
14) Thomas C, Ged C, Nordmann Y, et al : Correction of congenital erythropoietic porphyria by bone marrow transplantation. J Pediatr 129 : 453-456, 1996.
PubMed
15) Mazurier F, Moreau-Gaudry F, Salesse S, et al : Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria. J Inherit Metab Dis 20 : 247-257, 1997.
PubMed
P.474 掲載の参考文献
1) Whatley SD, Ducamp S, Gouya L, et al : C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 83 : 408-414, 2008.
PubMed
2) 近藤雅雄, 網中雅仁 : 遺伝性ポルフィリン症. 第1例報告 (1920) から91年間 (2010) の累積. 厚生労働科学研究補助金 (難治性疾患克服事業) 平成23年度総括分担研究報告書, p24-30, 2012.
 
3) Gouya L, Puy H, Robreau AM, et al : The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 30 : 27-28, 2002.
PubMed
4) Mizawa M, Makino T, Nakano H, et al : Incomplete erythropoietic protoporphyria caused by a splice site modulator homozygous IVS3-48C polymorphism in the ferrochelatase gene. Br J Dermatol 174 : 172-175, 2016.
PubMed
5) Mizawa M, Makino T, Nakano H, et al : Erythropoietic Protoporphyria in a Japanese Population. Acta Derm Venereol 99 : 634-639, 2019.
 
6) Asada N, Kitamoto M, Aisaka Y, et al : Recovery from acute cholestasis associated with erythropoietic protoporphyria treated by antibiotics. Clin Chim Acta 282 : 197-201, 1999.
PubMed
7) Tsuchiyama T, Kaneko S, Matsushita E, et al : Improvement of hepatic protoporphyrin accumulation after antibioyic treatment. Dis Dis Sci 45 : 2411-2413, 2000.
PubMed
8) Honda Y, Kawakami Y, Kan H, et al : A senond attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion. Clin J Gastroenterol 7 : 333-337, 2014.
 
P.477 掲載の参考文献
1) Anderson KE, et al : Disorders of heme biosynthesis : X-linked sideroblastic anemia and the porphyrias. In : The Metabolic and Molecular Bases of Inherited Disease, 8th ed (ed by Scriver CR, Beaudet AL, Sly WS, et al), p.2991-3062, McGraw Hill, New York, 2001.
 
2) Elder GH, Smith SG, Herrero C, et al : Hepatoerythropoietic porphyria : a new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda? Lancet 1 : 916-919, 1981.
PubMed
3) Roberts AG, Elder GH, De Salamanca RE, et al : A mutation (G281E) of the human uroporphyrinogen decarboxylase gene causes both hepatoerythropoietic porphyria and overt familial porphyria cutanea tarda : biochemical and genetic studies on Spanish patients. J Invest Dermatol 104 : 500-502, 1995.
PubMed
4) Aguade JP, Castells A, Indacochea A, et al : A case of biochemically unclassifiable hepatic porphyria. Br J Dermatol 81 : 270-275, 1969.
 
5) Kondo M, Kubo T Porphyria in Japan : the past, present, and future. The Society of Porphyrin Research 17 : 1-5, 2009.
 
6) de Verneuil H, Grandchamp B, Romeo PH, et al : Molecular analysis of uroporphyrinogen decarboxylase deficiency in a family with two cases of hepatoerythropoietic porphyria. J Clin Invest 77 : 431-435, 1986.
 
7) Elder GH : Hepatic porphyrias in children. J Inherit Metab Dis 20 : 237-246, 1997.
 
8) Moran-Jimenez MJ, Ged C, Romana M, et al : Uroporphyrinogen decarboxylase : complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria. Am J Hum Genet 58 : 712-721, 1996.
PubMed
9) Armstrong DK, Sharpe PC, Chambers CR, et al : Hepatoerythropoietic porphyria : a missense mutation in the UROD gene is associated with mild disease and an unusual porphyrin excretion pattern. Br J Dermatol 151 : 920-923, 2004.
 
10) To-Figueras J, Phillips JD, Gonzalez-Lopez JM, et al : Hepatoerythropoietic porphyria due to a novel mutation in the uroporphyrinogen decarboxylase gene. Br J Dermatol 165 : 499-505, 2011.
PubMed
11) Cantatore-Francis JL, Cohen-Pfeffer J, Balwani M, et al : Hepatoerythropoietic porphyria misdiagnosed as child abuse : cutaneous, arthritic, and hematologic manifestations in siblings with a novel UROD mutation. Arch Dermatol 146 : 529-533, 2010.
PubMed
12) Phillips JD, Whitby FG, Stadtmueller BM, et al : Two novel uroporphyrinogen decarboxylase (URO-D) mutations causing hepatoerythropoietic porphyria (HEP). Transl Res 149 : 85-91, 2007.
PubMed
13) Bundino S, Topi GC, Zina AM, et al : Hepatoerythropoietic porphyria. Pediatr Dermatol 4 : 229-233, 1987.
PubMed
P.484 掲載の参考文献
1) Mauzerall DC : Evolution of porphyrins. Clin Dermatol 16 : 195-201, 1998.
PubMed
2) Anderson KE, et al : Disorders of heme biosynthesis : X-linked sideroblastic anemia and the porphyrias. In : Metabolic and Molecular Bases of Inherited Disease, 8th ed (ed by Scriver CR, Beaudet AL, Sly WS, et al), p.2991-3062, McGraw Hill, New York, 2001
 
3) Sassa S : Modern diagnosis and management of the porphyrias. Br J Haematol 135 : 281-292, 2006.
PubMed
4) Kondo M, et al : Porphyria in Japan : the past, present, and future. The Society for Porphyrin Research 17 : 1-8, 2009.
 
5) Anderson KE, Bloomer JR, Bonkovsky HL, et al : Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 142 : 439-450, 2005.
PubMed
6) Grandchamp B, De Verneuil H, Beaumont C, et al : Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene. Eur J Biochem 162 : 105-110, 1987.
PubMed
7) Sassa S, Kappas A : Molecular aspects of the inherited porphyrias. J Intern Med 247 : 169-178, 2000.
PubMed
8) Maeda N, Horie Y, Sasaki Y, et al : A splicing mutation in the hydroxymethylbilane synthase gene in a Japanese family with acute intermittent porphyria. Clin Biochem 32 : 411-417, 1999.
 
9) Maeda N, Horie Y, Adachi K, et al : Two deletion mutations in the hydroxymethylbilane synthase gene in two unrelated Japanese patients with acute intermittent porphyria. J Hum Genet 45 : 263-268, 2000.
PubMed
10) 川田暁 (研究代表), ほか : 遺伝性ポルフィリン症の全国疫学調査ならびに診断・治療法の開発に関する研究, 平成23年度総括・分担研究報告書. 厚生労働省科学研究費補助金難治性疾患克服研究事業, 2012.
 
11) Herrick AL, McColl KE, Moore MR, et al : Controlled trial of haem arginate in acute hepatic porphyria. Lancet 1 : 1295-1297, 1989.
PubMed
12) Badminton MN, Deybach JC : Treatment of an acute attack of porphyria during pregnancy. Eur J Neurol 13 : 668-669, 2006.
PubMed
13) Ventura P, Bonkovsky HL, Gouya L, et al : Efficacy and safety of givosiran for acute hepatic porphyria : 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int 42 : 161-172, 2022.
PubMed
14) Soonawalla ZF, Orug T, Badminton MN, et al : Liver transplantation as a cure for acute intermittent porphyria. Lancet 363 : 705-706, 2004.
PubMed
15) Singal AK, Parker C, Bowden C, et al : Liver transplantation in the management of porphyria. Hepatology 60 : 1082-1089, 2014.
PubMed
P.488 掲載の参考文献
1) Phillips JD : Heme biosynthesis and the porphyrias. Mol Genet Metab 128 : 164-177, 2019.
PubMed
2) Peters T : King George III, bipolar disorder, porphyria and lessons for historians. Clin Med (Lond) 11 : 261-264, 2011.
 
3) Meissner PN, Dailey TA, Hift RJ, et al : A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 13 : 95-97, 1996.
PubMed
4) Kondo M, Kubo T Porphyria in Japan : the past, present, and future. The Society of Porphyrin Research 17 : 1-5, 2009.
 
5) Frank J, McGrath J, Lam H, et al : Homozygous variegate porphyria : identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband. J Invest Dermatol 110 : 452-455, 1998.
 
6) Corrigall AV, Hift RJ, Davids LM, et al : Homozygous variegate porphyria in South Africa : genotypic analysis in two cases. Mol Genet Metab 69 : 323-330, 2000.
PubMed
7) Enriquez de Salamanca R, Sepulveda P, Moran MJ, et al : Clinical utility of fluorometric scanning of plasma porphyrins for the diagnosis and typing of porphyrias. Clin Exp Dermatol 18 : 128-130, 1993.
PubMed
8) Whatley SD, Mason NG, Woolf JR, et al : Diagnostic strategies for autosomal dominant acute porphyrias : retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem 55 : 1406-1414, 2009.
PubMed
9) Maeda N, Horie Y, Sasaki Y, et al : Three novel mutations in the protoporphyrinogen oxidase gene in Japanese patients with variegate porphyria. Clin Biochem 33 : 495-500, 2000.
PubMed
10) Stojeba N, Meyer C, Jeanpierre C, et al : Recovery from a variegate porphyria by a liver transplantation. Liver Transpl 10 : 935-938, 2004.
PubMed
11) Balwani M, Sardh E, Ventura P, et al : Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med 382 : 2289-2301, 2020.
PubMed
P.491 掲載の参考文献
1) Phillips JD : Heme biosynthesis and the porphyrias. Mol Genet Metab 128 : 164-177, 2019.
PubMed
2) Doss M, von Tiepermann R, Schneider J, et al : New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. Klin Wochenschr 57 : 1123-1127, 1979.
PubMed
3) Thunell S, Holmberg L, Lundgren J : Aminolaevulinate dehydratase porphyria in infancy. A clinical and biochemical study. J Clin Chem Clin Biochem 25 : 5-14, 1987.
PubMed
4) Hassoun A, Verstraeten L, Mercelis R, et al : Biochemical diagnosis of an hereditary aminolaevulinate dehydratase deficiency in a 63-year-old man. J Clin Chem Clin Biochem 27 : 781-786, 1989.
 
5) Doss MO, Stauch T, Gross U, et al : The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany. J Inherit Metab Dis 27 : 529-536, 2004.
 
6) Akagi R, Kato N, Inoue R, et al : delta-Aminolevulinate dehydratase (ALAD) porphyria : the first case in North America with two novel ALAD mutations. Mol Genet Metab 87 : 329-336, 2006.
PubMed
7) Uche-Holub E, et al : Compound Heterozygosity for Novel Mutations in the Delta-Aminolevulinate Dehydratase Gene Associated wtih Childhood Onset of Severe Acute Hepatic Porphyria. Clin Chem Lab Med 51 : eA25, 2013.
 
8) Neeleman RA, van Beers EJ, Friesema EC, et al : Clinical Remission of Delta-Aminolevulinic Acid Dehydratase Deficiency Through Suppression of Erythroid Heme Synthesis. Hepatology 70 : 434-436, 2019.
PubMed
9) Plewinska M, Thunell S, Holmberg L, et al : delta-Aminolevulinate dehydratase deficient porphyria : identification of the molecular lesions in a severely affected homozygote. Am J Hum Genet 49 : 167-174, 1991.
 
10) Ishida N, Fujita H, Fukuda Y, et al : Cloning and expression of the defective genes from a patient with delta-aminolevulinate dehydratase porphyria. J Clin Invest 89 : 1431-1437, 1992.
PubMed
11) Akagi R, Shimizu R, Furuyama K, et al : Novel molecular defects of the delta-aminolevulinate dehydratase gene in a patient with inherited acute hepatic porphyria. Hepatology 31 : 704-708, 2000.
 
12) Doss M, Laubenthal F, Stoeppler M : Lead poisoning in inherited delta-aminolevulinic acid dehydratase deficiency. Int Arch Occup Environ Health 54 : 55-63, 1984.
PubMed
13) Dyer J, Garrick DP, Inglis A, et al : Plumboporphyria (ALAD deficiency) in a lead worker : a scenario for potential diagnostic confusion. Br J Ind Med 50 : 1119-1121, 1993.
 
14) Thunell S, Henrichson A, Floderus Y, et al : Liver transplantation in a boy with acute porphyria due to aminolaevulinate dehydratase deficiency. Eur J Clin Chem Clin Biochem 30 : 599-606, 1992.
 
15) Graff E, et al : Case Report : Lack of Response to Givosiran in a Case of ALAD Porphyria. Front Genet 4 : 13, 2022.
 
P.495 掲載の参考文献
1) Sassa S : Modern diagnosis and management of the porphyrias. Br J Haematol 135 : 281-292, 2006.
PubMed
2) 近藤雅雄, 網中雅仁, 石塚昌宏 : 遺伝性ポルフィリン症の生化学診断法および診断基準案の作成. ALA-Porphyrin Science 1 : 33-43, 2012.
 
3) 佐々木英夫, 大門真, 森田義宏 : 急性ポルフィリン症. ポルフィリン・ヘムの生命科学, 現代化学増刊 27 (ポルフィリン研究会編), p145-153, 東京化学同人, 1995.
 
4) 佐々木英夫, 金子兼三, 常山秀夫, ほか : 肝性コプロポルフィリン症, Hepatic Coproporphyria (遺伝性コプロポルフィリン症, Hereditary Coproporphyria) の9例. 最新医学 25 : 1978-1995, 1970.
 
5) 近藤雅雄, 矢野雄三, 浦田郡平 : 日本の遺伝性ポルフィリン症～1920年 (第1例報告) から91年間 (2010年) の集計. ALA-Porphyrin Science 2 : 73-82, 2012.
 
6) 工藤吉郎 : 尿ポルフィリンのスクリーニング法-ポルフィリン症発見のために-. 日本臨牀 53 : 1503-1506, 1995.
Medical*Online
7) Lamoril J, Martasek P, Deybach JC, et al : A molecular defect in coproporphyrinogen oxidase gene causing harderoporphyria, a variant form of hereditary coproporphyria. Hum Mol Genet 4 : 275-278, 1995.
PubMed
8) Nordmann Y, Grandchamp B, de Verneuil H, et al : Harderoporphyria : a variant hereditary coproporphyria. J Clin Invest 72 : 1139-1149, 1983.
PubMed
9) 近藤雅雄, 宮田隆光, 池嶋健一, ほか : 骨髄異形成症候群に合併したハルデロポルフィリン症が疑われた特発性ポルフィリン症. Porphyrins 5 : 363-374, 1996.
 
10) Watson CJ, Schwartz S : A simple test for urinary porphobilinogen. Proc Soc Exp Biol Med 47 : 393-394, 1941.
 
11) 近藤雅雄, 中山健, 矢野雄三 : ポルフィリン症と薬剤. Porphyrins 8 : 87-96, 1999.
 
12) 山守育雄, 近藤雅雄, 長谷川晴彦 : 遺伝性コプロポルフィリン症治療における静注用ヘミンの有用性と限界. ポルフィリン 6 : 35-40, 1997.
 
13) Balwani M, Sardh E, Ventura P, et al : Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med 382 : 2289-2301, 2020.
PubMed
14) Horie Y, Okano J, Yamada S, et al : Cimetidine and interferon-New managements of porphyrias. Jpn J Clin Pharmacol Ther 26 : 357-358, 1995.
 
P.499 掲載の参考文献
1) Singal AK : Porphyria cutanea tarda : Recent update. Mol Genet Metab 128 : 271-281, 2019.
PubMed
2) 立林めぐ美, 川田暁, 松尾仁子, ほか : 晩発性皮膚ポルフィリン症の1例. 皮膚の科学 13 : 382-386, 2014.
 
3) 三神絵理奈, 船坂陽子, 川原崎麻衣, ほか : HIV陽性患者に発症した晩発性皮膚ポルフィリン症の1例. 皮膚科の臨床 59 : 1299-1302, 2017.
 
4) 橋本健 : 皮膚病理のみかた (27) -光線過敏症-ポルフィリン症. 皮膚の科学 8 : 518-526, 2009.
 
5) Gou EW, Anderson KE, The porphyrias. In : Fitzpatrick's Dermatology, 9th ed, Vol II (ed by Kang S, Amagai M, Brucner AL, et al), p2235-2257, McGraw-Hill, New York, 2019.
 
6) 伊藤幹, 佐藤英嗣 : 晩発性皮膚ポルフィリン症の1例. 皮膚科の臨床 53 : 858-860, 2011.
 
7) Fargion S, Piperno A, Cappellini MD, et al : Hepatitis C virus and porphyria cutanea tarda : evidence of a strong association. Hepatology 16 : 1322-1326, 1992.
 
8) Kondo M, Yano Y, Shirataka M, et al : Porphyrias in Japan : Complication of all cases reported through 2002. Int J Hematol 79 : 446-456, 2004.
 
9) Egbert BM, LeBoit PE, McCalmont T, et al : Caterpillar bodies : distinctive, basement membrane-containing structures in blisters of porphyria. Am J Dermatopathol 15 : 199-202, 1993.
PubMed
10) 福島彩乃, 小幡洋子, 市村佳子, ほか : 晩発性皮膚ポルフィリン症の1例. 臨床皮膚科 69 : 491-496, 2015.
 
11) 中野創 : ポルフィリン症. 皮膚科の臨床 59 : 903-908, 2017.
 
12) Matsui A, Akasaka E, Rokunohe D, et al : The first Japanese case of familial porphyria cutanea tarda diagnosed by a UROD mutation. J Dermatol Sci 93 : 65-67, 2019.
PubMed
13) 野中薫雄, 三浦隆 : 晩発性皮膚ポルフィリン症 (市橋正光, 堀尾武編), p150-152, 金原出版株式会社, 2002.
 
14) Fujita Y, Sato-Matsumura KC : Effective treatment for porphyria cutanea tarda with oral cimetidine. J Dermatol 37 : 677-679, 2010.
PubMed
15) 飛澤慎一, 高橋英俊, 山本明美, ほか : C 型慢性肝炎を伴った晩発性皮膚ポルフィリン症. 皮膚科の臨床 43 : 647-650, 2001.
 
P.504 掲載の参考文献
1) 近藤雅雄 : ポルフィリン-ヘム代謝異常. 別冊日本臨牀新領域別症候群シリーズ No.20 先天代謝異常症候群 (第2版) ・下, p165-175, 2012.
 
2) Surkan PJ, Zhang A, Trachtenberg F, et al : Neuropsychological function in children with blood lead levels < 10 microg/dL. Neurotoxicology 28 : 1170-1177, 2007.
PubMed
3) 後藤稠, 池田正之, 原一郎 (編) : 産業中毒便覧 増補版, 医歯薬出版, 1981.
 
4) 川西正祐, 及川伸二 : 遺伝子損傷性の金属, 3-C代謝異常を起こす重金属鉛 (lead). 分子予防環境医学, p644-645, 本の泉社, 2010.
 
5) Sahu JK, Sharma S, Kamate M, et al : Lead encephalopathy in an infant mimicking a neurometabolic disorder. J Child Neurol 25 : 390-392, 2010.
 
6) Rolston DD : Uncommon sources and some unsual manifestations of lead poisoning in a tropical developing country. Trop Med Health 39 : 127-132, 2011.
 
7) Porter RS, Kaplan LJ : Plumbism. In : The Merck Manual online medical library, 18th Edition, 2005.
 
P.507 掲載の参考文献
1) European Association For The Study Of The Liver : EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 53 : 3-22, 2010.
 
2) Bacon BR, Adams PC, Kowdley KV, et al : Diagnosis and management of hemochromatosis : 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54 : 328-343, 2011.
 
3) Brissot P, Pietrangelo A, Adams PC, et al : Haemochromatosis. Nat Rev Dis Primers 4 : 18016, 2018.
PubMed
4) Girelli D, Busti F, Brissot P, et al : Hemochromatosis classification : update and recommendations by the BIOIRON Society. Blood 139 : 3018-3029, 2022.
PubMed
5) Rouault TA : Iron metabolism in the CNS : implications for neurodegenerative diseases. Nat Rev Neurosci 14 : 551-564, 2013.
PubMed
6) Lakhal-Littleton S, Wolna M, Carr CA, et al : Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function. Proc Natl Acad Sci U S A 112 : 3164-3169, 2015.
PubMed
7) Pietrangelo A : Genetics, Genetic Testing, and Management of Hemochromatosis : 15 Years Since Hepcidin. Gastroenterology 149 : 1240-1251.e4, 2015.
 
8) Powell LW, Seckington RC, Deugnier Y : Haemochromatosis. Lancet 388 : 706-716, 2016.
PubMed
9) Pietrangelo A : Ferroportin disease : pathogenesis, diagnosis and treatment. Haematologica 102 : 1972-1984, 2017.
PubMed
10) Honma Y, Karasuyama T, Kumamoto K, et al : Type 4B hereditary hemochromatosis due to heterozygous p.D157A mutation in SLC40A1 complicated with hypopituitarism. Med Mol Morphol 54 : 60-67, 2021.
PubMed
11) Wang H, An P, Xie E, et al : Characterization of ferroptosis in murine models of hemochromatosis. Hepatology 66 : 449-465, 2017.
 
12) 西尾仁, 本間雄一, 熊元啓一郎, ほか : TfR2ヘテロ接合型変異で発症したヘモクロマトーシスの1例. 肝臓 63 : 151-157, 2022.
 
13) Hattori A, Miyajima H, Tomosugi N, et al : Clinicopathological study of Japanese patients with genetic iron overload syndromes. Pathol Int 62 : 612-618, 2012.
PubMed
14) Harada M, Hirai K, Sakisaka S, et al : Comparative study of magnetic resonance imaging, computed tomography and histology in the assessment of liver iron overload. Intern Med 31 : 180-184, 1992.
PubMed
15) Bardou-Jacquet E, Philip J, Lorho R, et al : Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. Hepatology 59 : 839-847, 2014.
PubMed
P.510 掲載の参考文献
1) European Association For The Study Of The Liver : EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 53 : 3-22, 2010.
 
2) Bacon BR, Adams PC, Kowdley KV, et al : Diagnosis and management of hemochromatosis : 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54 : 328-343, 2011.
 
3) Brissot P, Loreal O : Hemochromatoses. J Hepatol 75 : 723-724, 2021.
PubMed
4) Girelli D, Busti F, Brissot P, et al : Hemochromatosis classification : update and recommendations by the BIOIRON Society. Blood 139 : 3018-3029, 2022.
PubMed
5) Pietrangelo A : Ferroportin disease : pathogenesis, diagnosis and treatment. Haematologica 102 : 1972-1984, 2017.
PubMed
6) Wang CY, Xu Y, Traeger L, et al : Erythroferrone lowers hepcidin by sequestering BMP2/6 heterodimer from binding to the BMP type I receptor ALK3. Blood 135 : 453-456, 2020.
 
7) Fertrin KY, Lanaro C, Franco-Penteado CF, et al : Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15. Am J Hematol 89 : 385-390, 2014.
PubMed
8) Kautz L, Jung G, Valore EV, et al : Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46 : 678-684, 2014.
PubMed
9) Srole DN, Ganz T : Erythroferrone structure, function, and physiology : Iron homeostasis and beyond. J Cell Physiol 236 : 4888-4901, 2021.
PubMed
10) Rouault TA : Iron metabolism in the CNS : implications for neurodegenerative diseases. Nat Rev Neurosci 14 : 551-564, 2013.
PubMed
11) Hsu CC, Senussi NH, Fertrin KY, et al : Iron overload disorders. Hepatol Commun 6 : 1842-1854, 2022.
PubMed
12) Harada M, Hirai K, Sakisaka S, et al : Comparative study of magnetic resonance imaging, computed tomography and histology in the assessment of liver iron overload. Intern Med 31 : 180-184, 1992.
PubMed
P.515 掲載の参考文献
1) 長澤純子, 和田友香, 佐々木愛子, ほか : 日本における新生児ヘモクロマトーシス実態調査 : 2010-2014年. 日周産期・新生児会誌 56 : 23-30, 2020.
 
2) Feldman AG, Whitington PF : Neonatal hemochromatosis. J Clin Exp Hepatol 3 : 313-320, 2013.
PubMed
3) Pan X, Kelly S, Melin-Aldana H, et al : Novel mechanism of fetal hepatocyte injury in congenital alloimmune hepatitis involves the terminal complement cascade. Hepatology 51 : 2061-2068, 2010.
PubMed
4) Kelly AL, Lunt PW, Rodrigues F, et al : Classification and genetic features of neonatal haemochromatosis : a study of 27 affected pedigrees and molecular analysis of genes implicated in iron metabolism. J Med Genet 38 : 599-610, 2001.
PubMed
5) Bonilla S, Prozialeck JD, Malladi P, et al : Neonatal iron overload and tissue siderosis due to gestational alloimmune liver disease. J Hepatol 56 : 1351-1355, 2012.
PubMed
6) Zoller H, Knisely AS : Control of iron metabolism--lessons from neonatal hemochromatosis. J Hepatol 56 : 1226-1229, 2012.
PubMed
7) Rodrigues F, Kallas M, Nash R, et al : Neonatal hemochromatosis--medical treatment vs. transplantation : the king's experience. Liver Transpl 11 : 1417-1424, 2005.
 
8) Debray FG, de Halleux V, Guidi O, et al : Neonatal liver cirrhosis without iron overload caused by gestational alloimmune liver disease. Pediatrics 129 : e1076-1079, 2012.
PubMed
9) Dubruc E, Nadaud B, Ruchelli E, et al : Relevance of C5b9 immunostaining in the diagnosis of neonatal hemochromatosis. Pediatr Res 81 : 712-721, 2017.
PubMed
10) 小児慢性特定疾病情報センターホームページ : 20 新生児ヘモクロマトーシス. [https://www.shouman.jp/disease/instructions/12_07_020/] (2023年5月25日アクセス)
 
11) Sheflin-Findling S, Annunziato RA, Chu J, et al : Liver transplantation for neonatal hemochromatosis : analysis of the UNOS database. Pediatr Transplant 19 : 164-169, 2015.
 
12) Rand EB, Karpen SJ, Kelly S, et al : Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin. J Pediatr 155 : 566-571, 2009.
PubMed
13) Whitington PF, Kelly S, Taylor SA, et al : Antenatal Treatment with Intravenous Immunoglobulin to Prevent Gestational Alloimmune Liver Disease : Comparative Effectiveness of 14-Week versus 18-Week Initiation. Fetal Diagn Ther 43 : 218-225, 2018.
PubMed
14) Tanaka H, Haba R, Itoh S, et al : Prenatal high-dose immunoglobulin treatment for neonatal hemochromatosis : a case report and review of the literature. J Obstet Gynaecol Res 37 : 1891-1894, 2011.
PubMed
15) 長澤純子, 和田友香, 藤野修平, ほか : 母体への高用量γグロブリン療法後に出生した新生児ヘモクロマトーシスの一例. 日周産期・新生児会誌 54 : 219-223, 2018.
 
P.519 掲載の参考文献
1) 熊坂一成 : ヘモジデリン. 臨床検査項目辞典 (桜林郁之介, 熊坂一成監, 伊藤機一ほか編), p19, 医歯薬出版, 2003.
 
2) Hillmen P, Elebute M, Kelly R, et al : Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 85 : 553-559, 2010.
 
3) Tracz MJ, Alam J, Nath KA : Physiology and pathophysiology of heme : implications for kidney disease. J Am Soc Nephrol 18 : 414-420, 2007.
PubMed
4) Nath KA, Croatt AJ, Haggard JJ, et al : Renal response to repetitive exposure to heme proteins : chronic injury induced by an acute insult. Kidney Int 57 : 2423-2433, 2000.
PubMed
5) Nath KA, Grande JP, Croatt AJ, et al : Intracellular targets in heme protein-induced renal injury. Kidney Int 53 : 100-111, 1998.
PubMed
6) Kokoris SI, Gavriilaki E, Miari A, et al : Renal involvement in paroxysmal nocturnal hemoglobinuria : an update on clinical features, pathophysiology and treatment. Hematol 23 : 558-566, 2018.
 
7) Dacie JV, Lewis SM : Paroxysmal nocturnal haemoglobinuria : clinical manifestations, haematology, and nature of the disease. Ser Haematology 5 : 3-23, 1972.
PubMed
8) Kanakura Y, Ohyashiki K, Shichishima T, et al : Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria : the AEGIS clinical trial. Int J Hematol 93 : 36-46, 2011.
PubMed
9) Stevens LA, Coresh J, Greene T, et al : Assessing kidney function?measured and estimated glomerular filtration rate. N Engl J Med 354 : 2473-2483, 2006.
PubMed
10) Taguchi S, Hidaka S, Yanai M, et al : Renal hemosiderosis presenting with acute kidney Injury and macroscopic hematuria in Immunoglobulin A nephropathy : a case report. BMC Nephrol 22 : 132, 2021.
PubMed
11) Moreno JA, Martin-Cleary C, Gutierrez E, et al : AKI associated with macroscopic glomerular hematuria : clinical and pathophysiologic consequences. Clin J Am Soc Nephrol 7 : 175-184, 2012.
PubMed
12) Qian Q, Nath KA, Wu Y, et al : Hemolysis and acute kidney failure. Am J Kidney Dis 56 : 780-784, 2010.
PubMed
13) Verswijvel G, Vanbeckevoort D, Maes B, et al : Paroxysmal nocturnal haemoglobinuria. MRI of renal cortical haemosiderosis in two patients, including one renal transplant. Nephrol Dial Transplant 14 : 1586-1589, 1999.
PubMed
14) Relia N, Kaushik C : Renal hemosiderosis : a case of black kidneys causing renal failure. J Postgrad Med 56 : 216-217, 2010.
PubMed
15) Nishimura JI, Kanakura Y, Ware RE, et al : Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 83 : 193-207, 2004.
PubMed
P.523 掲載の参考文献
1) Means RT Jr : Erythrocytosis. In Wintrobe's Clinical Hematology, 11th ed by (ed Greer JP, Forester J, Lukens JN, et al), p1495-1508, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
2) 前田信治 : 赤血球の微小環境とレオロジー. ながれ 21 : 129-134, 2002.
 
3) 水上尚典 : HELLP症候群, 日本血栓止血学会誌 19 : 366-368, 2008.
 
4) Siervo M, Bunn D, Prado CM, et al : Accuracy of prediction equations for serum osmolarity in frail older people with and without diabetes. Am J Clin Nutr 100 : 867-876, 2014.
PubMed
5) 後藤明彦 : 赤血球増加症. モダンフィジシャン 27 : 491-494, 2007.
 
P.526 掲載の参考文献
1) Geislotick F : Die Bedeutung der Blutdruck messung fur die Praxis. Deutsch Arch klin Med 83 : 363-406, 1905
 
2) Russell RP, Conley CL : Benign polycythemia : Gaisboeck's syndrome. Arch Intern Med 114 : 734-740, 1964.
PubMed
3) Lawrence JH, Berlin NI : Relative polycythemia : the polycythemia of stress. Yale J Biol Med 24 : 498-505, 1952.
PubMed
4) el-Yousef MK, Bakewell WE Jr : The Gaisbock syndrome. JAMA 220 : 864, 1972.
PubMed
5) Means RT Jr : Erythrocytosis. In : Wintrobe's Clinical Hematology, 11th ed. (ed by Greer JP, Forester J, Lukens JN, et al) p1495-1508, Lippincott Williams & Wilkins, Philadelphia, 2004.
 
6) Weinreb NJ, Shih CF : Spurious polycythemia. Semin Hematol 12 : 397-407, 1975.
PubMed
7) Smith JR, Landaw SA : Smokers' polycythemia. N Engl J Med 298 : 6-10, 1978.
PubMed
8) 大野伸広, 東條有伸 : 相対的赤血球増加症. 三輪血液病学, 第3版 (浅野茂隆, 池田康夫, 内山卓監) p1242-1245, 文光堂. 2006.
 
9) 後藤明彦 : 赤血球増加症. モダンフィジシャン 27 : 491-494, 2007.
 
10) Scott LM, Tong W, Levine RL, et al : JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 : 459-468, 2007.
PubMed
11) Sirhan S, Fairbanks VF, Tefferi A : Red cell mass and plasma volume measurements in polycythemia : evaluation of performance and practical utility. Cancer 104 : 213-215, 2005.
PubMed
12) Humphrey PR, Michael J, Pearson TC : Management of relative polycythaemia : studies of cerebral blood flow and viscosity. Br J Haematol 46 : 427-433, 1980.
PubMed
13) Biswas M, Prakash PK, Cossburn M, et al : Life-threatening thrombotic complications of relative polycythaemia. J Intern Med 253 : 481-483, 2003.
PubMed
14) 村井淳志 : 赤血球増加症を合併した高血圧症の臨床的研究. 脳卒中 8 : 177-181, 1986.
 
P.529 掲載の参考文献
1) Lee G, Arcasoy MO : The clinical and laboratory evaluation of the patient with erythrocytosis. Eur J Intern Med 26 : 297-302, 2015.
PubMed
2) Oechslin E : Management of adults with cyanotic congenital heart disease. Heart 101 : 485-494, 2015.
PubMed
3) Mukai N, Nakayama Y, Murakami S, et al : Potential contribution of erythrocyte microRNA to secondary erythrocytosis and thrombocytopenia in congenital heart disease. Pediatr Res 83 : 866-873, 2018.
PubMed
4) Waldow HC, Westhoff-Bleck M, Widera C, et al : Acquired von Willebrand syndrome in adult patients with congenital heart disease. Int J Cardiol 176 : 739-745, 2014.
 
5) Morgan C, Al-Aklabi M, Garcia Guerra G : Chronic kidney disease in congenital heart disease patients : a narrative review of evidence. Can J Kidney Health Dis 2 : 27, 2015.
 
P.533 掲載の参考文献
1) Laski ME, Vugrin D : Paraneoplastic syndromes in hypernephroma. Semin Nephrol 7 : 123-130, 1987.
PubMed
2) Osumi T, Awazu M, Fujimura E, et al : Leukemia kidney infiltration can cause secondary polycythemia by activating hypoxia-inducible factor (HIF) pathway. Eur J Pediatr 172 : 829-832, 2013.
PubMed
3) Friend DG, Hoskins RG, Kirkin MW : Relative erythrocythemia (polycythemia) and polycystic kidney disease, with uremia. Report of a case, with comments on frequency of occurrence. N Engl J Med 264 : 17-19, 1961.
PubMed
4) Cohen C, Coulon S, Bhukhai K, et al : Erythrocytosis associated with IgA nephropathy. EBioMedicine 75 : 103785, 2022.
PubMed
5) Sheqwara J, Alkhatib Y, Dabak V, et al : Idiopathic erythrocytosis in dialysis patients : a case report and literature review. Am J Nephrol 37 : 333-338, 2013.
PubMed
6) Nistico A, Iliescu EA, Fitzpatrick M, et al : Polycythemia due to obstructive sleep apnea in a patient on hemodialysis. Hemodial Int 14 : 333-336, 2010.
 
7) Obara N, Suzuki N, Kim K, et al : Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111 : 5223-5232, 2008.
PubMed
8) Asada N, Takase M, Nakamura J, et al : Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 121 : 3981-3990, 2011.
PubMed
9) Shiramizu M, Katsuoka Y, Grodberg J, et al : Constitutive secretion of erythropoietin by human renal adenocarcinoma cells in vivo and in vitro. Exp Cell Res 215 : 249-256, 1994.
PubMed
10) Wiesener MS, Munchenhagen PM, Berger I, et al : Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 61 : 5215-5222, 2001.
PubMed
11) Rad FH, Ulusakarya A, Gad S, et al : Novel somatic mutations of the VHL gene in an erythropoietin-producing renal carcinoma associated with secondary polycythemia and elevated circulating endothelial progenitor cells. Am J Hematol 83 : 155-158, 2008.
 
12) Turner KJ, Moore JW, Jones A, et al : Expression of hypoxia-inducible factors in human renal cancer : relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62 : 2957-2961, 2002.
 
13) Mitus WJ, Galbraith P, Gollerkeri M, et al : Experimental renal erythrocytosis. I. Effects of pressure and vascular interference. blood 24 : 343-355, 1964.
PubMed
14) Wickre CG, Norman DJ, Bennison A, et al : Postrenal transplant erythrocytosis : a review of 53 patients. Kidney Int 23 : 731-737, 1983.
PubMed
15) Martino R, Oliver A, Ballarin JM, et al : Postrenal transplant erythrocytosis : further evidence implicating erythropoietin production by the native kidneys. Ann Hematol 68 : 201-203, 1994.
PubMed
16) Kasuno K, Ono T, Kamata T, et al : IgA nephropathy associated with polycythaemia vera : accelerated course. Nephrol, Dial, Transplant 12 : 212-215, 1997.
PubMed
17) Wintrobe's Clinical Hematology, 14th Edition [Internet]. [cited 2023 Jun 19] [https://www.wolterskluwer.com/en/know/wintrobes-clinical-hematology]
 
P.536 掲載の参考文献
1) Burwell Cs, Robin ED, Whaleet RD, et al : Extreme obesity associated with alveolar hypoventilation-A Pickwickian syndrome. Am J Med 21 : 811-818, 1956.
 
2) 難病情報センター : 肺胞低換気症候群 (指定難病230). [https://www.nanbyou.or.jp/entry/316]
 
3) Obara N, Suzuki N, Kim K, et al : Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111 : 5223-5232, 2008.
PubMed
4) 増田詩織 : アクセスEPO試薬によるエリスロポエチン測定と血球算定検査値との比較検討. 医学と薬学 67 : 297-306, 2012.
 
5) Kakazu MT, Soghier I, Afshar M, et al : Weight Loss Interventions as Treatment of Obesity Hypoventilation Syndrome. A Systematic Review. Ann Am Thorac Soc 17, 492-502, 2020.
PubMed
6) Dixon JB, Schachter LM, O'Brien PE, et al : Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea : a randomized controlled trial. JAMA 308 : 1142-1149, 2012.
PubMed
7) Lyons HA, Huang CT : Therapeutic use of progesterone in alveolar hypoventilation associated with obesity. Am J Med 44 : 881-888, 1968.
PubMed
8) Sullivan CE, et al : Continuous positive airways pressure in sleep-disordered breathing. In : Principles and Practice of Sleep Medicine (ed by Kryger MH, et al), p559-570, WB Saunders, Philadelphia, 1989.
 
9) Berry RB, Chediak A, Brown LK, et al : Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes. J Clin Sleep Med 6 : 491-509, 2010.
PubMed
10) 中田誠一 : 成人の睡眠時無呼吸症候群と手術適応. 日本耳鼻咽喉科学会会報 119 : 1330-1331, 2016.
Medical*Online
11) Budweiser S, Riedl SG, Jorres RA, et al : Mortality and prognostic factors in patients with obesity-hypoventilation syndrome undergoing noninvasive ventilation. J Intern Med 261 : 375-383, 2007.
PubMed
12) Howard ME, Piper AJ, Stevens B, et al : A randomised controlled trial of CPAP versus non-invasive ventilation for initial treatment of obesity hypoventilation syndrome. Thorax 72 : 437-444, 2017.
 
13) Heinemann F, Budweiser S, Dobroschke J, et al : Non-invasive positive pressure ventilation improves lung volumes in the obesity hypoventilation syndrome. Respir Med 101 : 1229-1235, 2007.
PubMed
P.541 掲載の参考文献
1) 外山圭助 : エリスロポエチン産生腫瘍. 血液疾患最近の進歩 : あすへの内科展望. (高久史磨編), p32-39, 金原出版, 1978.
 
2) Bliss TL : Basal metabolism in polycythemia vera. Ann Intern Med 2 : 1155-1161, 1929.
 
3) Thomsen P, Marson W : Polycythemia with fibroids. Lancet 2 : 759-760, 1953.
 
4) 外山圭助, 中沢肇, 青木功, ほか : エリスロポエチン産生腫瘍. 臨床血液 26 : 685-693, 1985.
 
5) Luo JC, Hwang SJ, Wu JC, et al : Paraneoplastic syndromes in patients with hepatocellular carcinoma in Taiwan. Cancer 86 : 799-804, 1999.
PubMed
6) Lappin TR, Maxwell AP, Johnston PG : EPO's alter ego : erythropoietin has multiple actions. Stem Cells 20 : 485-492, 2002.
PubMed
7) Kew MC, Fisher JW : Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer 58 : 2485-2488, 1986.
PubMed
8) Ljungberg B, Rasmuson T, Grankvist K : Erythropoietin in renal cell carcinoma : evaluation of its usefulness as a tumor marker. Eur Urol 21 : 160-163, 1992.
PubMed
9) 鈴木光明, 高見澤聡, 榎本明美, ほか : エリスロポエチン産生腫瘍. 別冊日本臨牀内分泌症候群 (第2版) II, p283-286, 日本臨牀社, 2006.
 
10) Vlasveld LT, de Wit CW, Verweij RA, et al : Myomatous erythrocytosis syndrome : further proof for the pathogenic role of erythropoietin. Neth J Med 66 : 283-285, 2008.
PubMed
11) Jaquet K, Krause K, Kuck KH, et al : Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64 : 326-333, 2002.
PubMed
12) Pang JC, Chang Q, Chung YF, et al : Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor. Hum Pathol 36 : 36-43, 2005.
PubMed
13) 朝野晃, 島崇, 斉藤彩, ほか : 子宮筋腫からのエリスロポエチン産生によると思われた赤血球増多症の1例. 仙台医療センター医学雑誌 3 : 45-49, 2013.
Medical*Online
14) 下田和哉 : 多血症の診断と治療. 日本内科学会誌 95 : 2060-2066, 2006.
 
15) 伊禮俊充, 種村匡弘, 井上雅史ほか : 著明な赤血球増多症を合併したエリスロポエチン産生巨大肝細胞癌の1切除例. 日本消化器外科学会雑誌 47 : 18-25, 2014.
 
P.544 掲載の参考文献
1) Mallik N, Das R, Malhotra P, et al : Congenital erythrocytosis. Eur J Haematol 107 : 29-37, 2021.
PubMed
2) Gaspersic J, Kristan A, Kunej T, et al : Erythrocytosis : genes and pathways involved in disease development. Blood Transfus 19 : 518-532, 2021.
 
3) Poliakova LA : Familial erythrocytosis among the residents of the Chuvash ASSR. Probl Gematol Pereliv Krovi 19 : 30-33, 1974.
 
4) Ang SO, Chen H, Gordeuk VR, et al : Endemic polycythemia in Russia : mutation in the VHL gene. Blood Cells Mol Dis 28 : 57-62, 2002.
PubMed
5) Liu E, Percy MJ, Amos CI, et al : The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood 103 : 1937-1940, 2004.
PubMed
6) Lenglet M, Robriquet F, Schwarz K, et al : Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood 132 : 469-483, 2018.
PubMed
7) Oliveira JL, Coon LM, Frederick LA, et al : Genotype-phenotype correlation of hereditary erythrocytosis mutations, a single center experience. Am J Hematol 93 : 1029-1041, 2018.
 
8) Ivan M, Kondo K, Yang H, et al : HIFalpha targeted for VHL-mediated destruction by proline hydroxylation : implications for O2 sensing. Science 292 : 464-468, 2001.
PubMed
9) Jaakkola P, Mole DR, Tian YM, et al : Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 : 468-472, 2001.
 
10) Epstein AC, Gleadle JM, McNeill LA, et al : C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 : 43-54, 2001.
PubMed
11) Russell RC, Sufan RI, Zhou B, et al : Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med 17 : 845-853, 2011.
 
12) Bento C : Genetic basis of congenital erythrocytosis. Int J Lab Hematol 40 (Suppl 1) : 62-67, 2018.
 
13) Gordeuk VR, Sergueeva AI, Miasnikova GY, et al : Congenital disorder of oxygen sensing : association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 103 : 3924-3932, 2004.
 
14) Sergueeva AI, Miasnikova GY, Polyakova LA, et al : Complications in children and adolescents with Chuvash polycythemia. Blood 125 : 414-415, 2015.
PubMed
15) Zhou AW, Knoche EM, Engle EK, et al : Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia. N Engl J Med 375 : 494-496, 2016.
PubMed
P.547 掲載の参考文献
1) Barichard F, Joulin V, Henry I, et al : Chromosomal assignment of the human 2,3-bisphosphoglycerate mutase gene (BPGM) to region 7q34→7q22. Hum Genet 77 : 283-285, 1987.
 
2) Joulin V, Garel MC, Le Boulch P, et al : Isolation and characterization of the human 2,3-bisphosphoglycerate mutase gene. J Biol Chem 263 : 15785-15790, 1988.
 
3) Joulin V, Peduzzi J, Romeo PH, et al : Molecular cloning and sequencing of the human erythrocyte 2,3-bisphosphoglycerate mutase cDNA : revised amino acid sequence. EMBO J 5 : 2275-2283, 1986.
 
4) Rosa R, Prehu MO, Beuzard Y, et al : The first case of a complete deficiency of diphosphoglycerate mutase in human erythrocytes. J Clin Invest 62 : 907-915, 1978.
PubMed
5) Lemarchandel V, Joulin V, Valentin C, et al : Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency. Blood 80 : 2643-2649, 1992.
 
6) van Dijk MJ, van Oirschot BA, Stam-Slob MC, et al : Heterozygosity for bisphosphoglycerate mutase deficiency expressing clinically as congenital erythrocytosis : A case series and literature review. Br J Haematol 200 : 249-255, 2023.
PubMed
7) Wang Y, Wei Z, Bian Q, et al : Crystal structure of human bisphosphoglycerate mutase. J Biol Chem 279 : 39132-39138, 2004.
 
8) Dubart A, Romeo PH, Tsapis A, et al : Cell-free translation of messenger RNA for human bisphosphoglyceromutase. Biochem Biophys Res Commun 120 : 441-447, 1984.
PubMed
9) Travis SF, Martinez J, Garvin J Jr, et al : Study of a kindred with partial deficiency of red cell 2,3-diphosphoglycerate mutase (2,3-DPGM) and compensated hemolysis. Blood 51 : 1107-1116, 1978.
 
10) Oliveira JL, Coon LM, Frederick LA, et al : Genotype-phenotype correlation of hereditary erythrocytosis mutations, a single center experience. Am J Hematol 93 : 1029-1041, 2018.
 
11) Hong WJ, Gotlib J : Hereditary erythrocytosis, thrombocytosis and neutrophilia. Best Pract Res Clin Haematol 27 : 95-106, 2014.
PubMed
12) Beutler E, Blume KG, Kaplan JC, et al : International Committee for Standardization in Haematology : recommended methods for red-cell enzyme analysis. Br J Haematol 35 : 331-340, 1977.
PubMed

書評

最近チェックした商品履歴

Loading...